January | February | March | April | May | June | July | August | September | October | November | December |
| ||||||
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Corvidia Therapeutics to use Ablexis' Alivamab Mouse technology to discover and develop antibody candidates | Ablexis LLC | Corvidia Therapeutics | Payment unspecified | 1/3/19 |
| EIi Lilly to use Ablexis' AlivaMab Mouse platform for antibody drug candidates development | Ablexis LLC | Eli Lilly & Co. | Payment unspecified | 1/17/19 |
| Absci to apply SoluPro E.coli manufacturing platform and optimization assay system to Sanofi's biotherapeutic molecules | Absci LLC | Sanofi SA | Payment unspecified | 1/9/19 |
| Adaptive Biotechnologies and Genentech to develop, manufacture and commercialize neoantigen directed T-cell receptors for cancer, autoimmune conditions and infectious diseases worldwide | Adaptive Biotechnologies Corp. | Genentech Inc. | $2,300.00 | 1/4/19 |
| Adlai Nortye and Merck to evaluate AN-0025 in combination with Keytruda against solid tumors | Adlai Nortye Pharmaceutical Co. Ltd. | Merck & Co. Inc. | Payment unspecified | 1/3/19 |
| Cytomx acquired Agensys' technologies | Agensys Inc. | Cytomx Therapeutics Inc. | Payment unspecified | 1/7/19 |
| Circassia Pharmaceuticals to commercialize AIT Therapeutics' AirNOvent for PPHN in the U.S. and China | AIT Therapeutics Inc. | Circassia Pharmaceuticals plc | $32.55 | 1/24/19 |
| Aldevron to provide pALD Lenti product line, including Rev, VSV-G, GagPol and expression plasmids for Oxford's recombinant lentiviral vector production | Aldevron | Oxford Genetics Ltd. | Payment unspecified | 1/23/19 |
| Aldevron to supply plasmid DNA for Sarepta Therapeutics' gene therapy clinical trials and commercial supply | Aldevron LLC | Sarepta Therapeutics Inc. | Payment unspecified | 1/2/19 |
| Alivio and Purdue Pharma to develop ALV-107 for interstitial cystitis/bladder pain syndrome with option to collaborate on additional compounds | Alivio Therapeutics | Purdue Pharma LP | $274.75 | 1/28/19 |
| Kowa Pharmaceuticals to copromote Allergan's nebivolol in the U.S. | Allergan plc | Kowa Pharmaceuticals America Inc. | Payment unspecified | 1/28/19 |
| Merry Life Biomedical to develop Allianz’s compound for Alzheimer’s disease | Allianz Pharmascience Ltd | Merry Life Biomedical Co. Ltd. | Payment unspecified | 1/3/19 |
| Medison Pharma to commercialize Alnylam's RNAi therapeutics for rare diseases in Israel | Alnylam Pharmaceuticals Inc. | Medison Pharma Ltd. | Payment unspecified | 1/21/19 |
| Alphamab and HEC Pharm to develop KN-046 + Ningetinib for hepatocellular carcinoma in China | Alphamab Oncology | HEC Pharm Co. Ltd. | Payment unspecified | 1/25/19 |
| Five-year commercialization partnership with Idea for Amarantus' companies Elto Pharma Inc. and its Parkinson's disease levodopa-induced dyskinesia drug, regenerative medicine company Cutanogen Corp., and Manf Therapeutics Inc. with treatments for brain and ophthalmic disorders and Parkinson's disease | Amarantus Bioscience Holdings Inc. | Idea Pharma Ltd. | Payment unspecified | 1/14/19 |
| Merck to develop immuno-oncology therapeutics against an undisclosed target using Amunix’s ProTIA technology | Amunix Inc. | Merck & Co. Inc. | Payment unspecified | 1/3/19 |
| Celgene to use Aprinoia's APN-1607 to support patient selection and efficacy evaluation in clinical trials worldwide | Aprinoia Therapeutics Inc. | Celgene Corp. | Payment unspecified | 1/2/19 |
| Aptuit to manufacture and supply fenfluramine active pharmaceutical ingredient for Zogenix's Fintepla | Aptuit (Oxford) Ltd. | Zogenix Inc. | Payment unspecified | 1/31/19 |
| Vertex to discover and develop new gene editing therapies for cystic fibrosis and four other diseases using Arbor's protein biodiscovery platform | Arbor Biotechnologies Inc. | Vertex Pharmaceuticals Inc. | Payment unspecified | 1/3/19 |
| Cognate and Astero to sign letter-of-intent to advance the development of life-saving therapeutics using cell thawing platform | Astero Bio Corp. | Cognate Bioservices Inc. | Payment unspecified | 1/23/19 |
| Astrazeneca to promote Luye Pharma's Xuezhikang capsules for cardiovascular disease in mainland China | Astrazeneca plc | Luye Pharma Group Ltd. | Payment unspecified | 1/15/19 |
| Charles River Laboratories and Atomwise to provide integrated, artificial intelligence-driven drug discovery services | Atomwise | Charles River Laboratories International Inc. | Payment unspecified | 1/11/19 |
| Avalon Globocare and Arbele to establish joint venture to develop CAR-T and CAR-NK cellular therapies for cancer | Avalon Globocare Corp. | Arbele Ltd. | Unknown | 1/3/19 |
| Basilea Pharmaceutica and Roche to study the combination of derazantinib and atezolizumab against urothelial cancer and confirmed FGFR genomic aberrations | Basilea Pharmaceutica International Ltd. | Roche Holding AG | Payment unspecified | 1/24/19 |
| Lannett to distribute Bausch Health Companies' trientine hydrochloride capsules in the U.S. | Bausch Health Companies Inc. | Lannett Co. Inc. | Unknown | 1/22/19 |
| Be The Match Biotherapies to provide services to Gamida's bone marrow transplant, NiCord for hematologic malignancies and blood disorders | Be The Match Biotherapies | Gamida Cell Ltd. | Payment unspecified | 1/22/19 |
| Hikma to supply and distribute Beijing Sciecure Pharmaceutical's niche injectable antiviral medicines in the U.S. | Beijing Sciecure Pharmaceutical Co. Ltd. | Hikma Pharmaceuticals plc | Payment unspecified | 1/3/19 |
| Harbour Biomed acquires Berkeley's Beacon Optofluidic platform to accelerate single cell screening and analysis | Berkeley Lights Inc. | Harbour Biomed | Payment unspecified | 1/22/19 |
| Eli Lilly and Bigfoot to integrate the insulin products into the insulin delivery injection systems for diabetes | Bigfoot Biomedical | Eli Lilly and Co. | Payment unspecified | 1/7/19 |
| Bioasis Technologies and an undisclosed pharmaceutical company to evaluate delivery of therapeutics using xB3 peptide in central nervous system disorders | Bioasis Technologies Inc. | Undisclosed | $0.50 | 1/7/19 |
| Boehringer Ingelheim to develop Bioharmony's bacteriophage lysins against multidrug resistant Acinetobacter infections infections | Bioharmony Therapeutics Inc. | Boehringer Ingelheim International GmbH | Payment unspecified | 1/15/19 |
| Sanofi to use Biomunex's BiXAb technology for the development of bi- and multi-specific antibody therapeutics worldwide | Biomunex Pharmaceuticals | Sanofi SA | Payment unspecified | 1/16/19 |
| Cipla to distribute and market Bio-Thera Solutions's bevacizumab biosimilar for cancer in certain emerging markets | Bio-Thera Solutions Ltd. | Cipla Ltd. | Payment unspecified | 1/14/19 |
| Biogen and C4T to discover and develop treatments for neurological conditions, including Alzheimers disease and Parkinsons disease using C4T's protein degradation platform | C4 Therapeutics Inc. | Biogen Inc. | $415.00 | 1/4/19 |
| Alexion to develop Caelum's CAEL-101 for AL amyloidosis, with an option to acquire Caelum | Caelum Biosciences Inc. | Alexion Pharmaceuticals Inc. | $560.00 | 1/30/19 |
| Camp4 Therapeutics and Alnylam Pharmaceuticals to develop RNAi therapeutics against an undisclosed rare disease of the liver | Camp4 Therapeutics Corp. | Alnylam Pharmaceuticals Inc. | Payment Unspecified | 1/23/19 |
| GC Pharma to commercialize Canbridge's Hunterase against Hunter syndrome in greater China | Canbridge Life Sciences Ltd. | GC Pharma | Payment unspecified | 1/7/19 |
| Newcanna to enter into a non binding letter-of-intent with Cannabics Pharmaceuticals to form a joint venture for manufacturing and marketing Cannabics SR capsules in Colombia | Cannabics Pharmaceuticals Inc. | Newcanna Hub | Unknown | 1/24/19 |
| Cartherics and Toolgen to develop CAR-T therapy for ovarian and bowel cancers | Cartherics Pty. Ltd. | Toolgen Inc. | Unknown | 1/24/19 |
| Xell to distribute Cevec's CAP-CDM Medium and CAP-CDM Feed | Cevec Pharmaceuticals GmbH | Xell AG | Payment unspecified | 1/29/19 |
| Charles River to evaluate Orion's OB-002O in colorectal cancer | Charles River Laboratories International Inc. | Orion Biotechnology Canada Ltd. | Payment Unspecified | 1/15/19 |
| CJ Healthcare and Chong Kun Dang to form joint venture for sale of K-CAB against gastro esophageal reflux disease | CJ Healthcare Corp. | Chong Kun Dang Pharmaceutical Corp. | Payment unspecified | 1/22/19 |
| Otsuka and Click Therapeutics to develop and commercialize digital therapeutic, CT-152, for major depressive disorder worldwide | Click Therapeutics Inc. | Otsuka America Pharmaceutical Inc. | $302.00 | 1/3/19 |
| Decibel to develop Cocoon's drug formulations for transtympanic delivery to the inner ear | Cocoon Biotech Inc. | Decibel Therapeutics | Payment unspecified | 1/7/19 |
| Cocrystal Pharma and Merck to discover and develop certain influenza A/B antiviral agents worldwide | Cocrystal Pharma Inc. | Merck & Co. Inc. | $156.00 | 1/3/19 |
| Jazz to develop and commercialize exosome therapeutics against five targets for cancer using Codiak's engEx technology, worldwide | Codiak BioSciences Inc. | Jazz Pharmaceuticals Inc. | $1,076.00 | 1/3/19 |
| Coherus to commercialize its CHS-1420, a Humira biosimilar for treatment of psoriasis in the U.S. in litigation settlement with Abbvie | Coherus Biosciences Inc. | Abbvie Inc. | Unknown | 1/25/19 |
| Kaken to develop and commercialize Corbus' Lenabasum for systemic sclerosis and dermatomyositis in Japan | Corbus Pharmaceuticals Holdings Inc. | Kaken Pharmaceutical Co. Ltd. | $200.00 | 1/3/19 |
| Covance to provide Olix with GLP toxicology study services for OLX-10020 against geographic atrophy and OLX-101 for scarring | Covance Inc. | Olix Pharmaceuticals Inc. | Payment unspecified | 1/18/19 |
| Ceyoka to market Creso Pharma's medicinal cannabis products in Sri Lanka | Creso Pharma | Ceyoka Pvt. Ltd. | Payment unspecified | 1/7/19 |
| Creso Pharma to supply TerrAscend with premium cannabis product | Creso Pharma | Terrascend Corp. | Payment unspecified | 1/21/19 |
| Crispr and Probiogen to develop in vivo delivery technologies for CRISPR/Cas9 | Crispr Therapeutics AG | Probiogen AG | Payment unspecified | 1/22/19 |
| Pfizer to use Cytoreason's machine learning model of the immune system for drug discovery | Cytoreason Ltd. | Pfizer Inc. | Payment unspecified | 1/7/19 |
| B-Mogen and Cytosen to develop next generation of gene-modified natural killer cell therapies for cancer | Cytosen Therapeutics Inc. | B-MoGen Biotechnologies Inc. | Payment unspecified | 1/23/19 |
| Medicinal Genomics to use Eiken Chemicals' patents related to Loop-mediated Isothermal Amplification technology | Eiken Chemical Co. Ltd. | Medicinal Genomics Corp. | Payment unspecified | 1/3/19 |
| Immunoforge to use Elasmogen's NDure half-life extension technology for use in two non-disclosed targets | Elasmogen Ltd | Immunoforge Co. Ltd. | Payment unspecified | 1/7/19 |
| Daiichi Sankyo Europe to distribute Esperion Therapeutics' bempedoic acid and the bempedoic acid/ezetimibe in the European Economic Area and Switzerland | Esperion Therapeutics Inc. | Daiichi Sankyo Europe GmbH | $1,200.00 | 1/2/19 |
| Exscientia and Roche to discover preclinical drug candidates using Exscientia's AI enabled platform | Exscientia Ltd. | Roche Holding AG | $67.27 | 1/7/19 |
| Fedora and Meiji Seika to a form a joint venture, Nacugen Therapeutics, to develop and commercialize anti-infectives, including nacubactam in Canada | Fedora Pharmaceuticals Inc. | Meiji Seika Pharma Co. Ltd. | Unknown | 1/7/19 |
| Galapagos to develop and commercialize Fibrocor's small molecule inhibitor for idiopathic fibrotic diseases of the lung and other organs, worldwide | Fibrocor Therapeutics LP | Galapagos NV | Payment unspecified | 1/4/19 |
| Stellapharma to acquire assets of G2B Pharma's dry powder nasal formulation of epinephrine, including intellectual property, for anaphylaxis | G2B Pharma Inc. | Stella Pharma Corp. | Payment unspecified | 1/15/19 |
| Ocumension to develop GTS' biosimilars in ophthalmologic field in China and Taiwan | Gene Techno Science Co. Ltd. | Ocumension Therapeutics | Payment unspecified | 1/31/19 |
| Covance to advance the access to Genfit's nonalcoholic steatohepatitis assay in the clinical research market | Genfit SA | Covance Inc. | Payment unspecified | 1/3/19 |
| GenScript and Amgen to develop protein and antibody purification technology AmMag | Genscript Corp. | Amgen Inc. | Unknown | 1/14/19 |
| Yuhan to commercialize Glenmark Pharmaceuticals’ Ryaltris for seasonal allergic rhinitis in South Korea | Glenmark Pharmaceuticals Ltd. | Yuhan Corp. | Payment unspecified | 1/10/19 |
| CSPC Ouyi to develop and commercialize Hangzhou's five small molecules for cancer in China, including Hong Kong, Macau and Taiwan, and the U.S. | Hangzhou Innogate Pharma Co. Ltd. | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. | $32.52 | 1/4/19 |
| Horizon Pharma and Hemoshear Therapeutics to discover and develop novel therapeutics for gout | Hemoshear Therapeutics LLC | Horizon Pharma plc | $500.00 | 1/3/19 |
| Medunik Canada to commercialize HRA Pharma's Lysodren (mitotane) for inoperable functional and non-functional adrenal cortical carcinoma in Canada | HRA Pharma | Medunik Canada | Payment unspecified | 1/15/19 |
| Servier and Iktos to evaluate artificial intelligence technology for discovery of new compounds | Iktos | Servier SA | Payment unspecified | 1/29/19 |
| Nektar to use Imaginab's CD8 Immuno-PET technology to fasten the development of its investigational immuno-oncology therapeutics | Imaginab Inc. | Nektar Therapeutics | Payment unspecified | 1/3/19 |
| Cytlimic to evaluate its CYT-001 peptide vaccine incorporating Immutep's eftilagimod alpha for cancer | Immutep Ltd. | Cytlimic Inc. | $5.00 | 1/7/19 |
| Bluebird Bio and Inhibrx to develop and commercialize CAR-T therapies for cancers worldwide | Inhibrx LLC | Bluebird Bio Inc. | $7.00 | 1/7/19 |
| Elevian and Insilico Medicine to discover and develop oral small molecule GDF11 modulators against age-related diseases | Insilico Medicine Inc. | Elevian Inc. | Payment unspecified | 1/9/19 |
| Integral Molecular and Ono Pharmaceutical to discover monoclonal antibodies against an undisclosed target | Integral Molecular Inc. | Ono Pharmaceutical Co. Ltd. | Payment unspecified | 1/3/19 |
| Integral Molecular and Daiichi Sankyo to discover new therapeutic targets in immuno-oncology using Membrane Proteome Array (MPA) platform | Integral Molecular Inc. | Daiichi Sankyo Co. Ltd. | Payment unspecified | 1/7/19 |
| Invictus and Cannamerica to sign a binding letter of intent to establish a joint venture to extract and supply CBD to the U.S. market | Invictus MD | Cannamerica Brands Corp. | Unknown | 1/7/19 |
| Thyas to acquire IP rights related to iPS' cell-derived T cells for autologous immunotherapy of cancer and infectious disease worldwide | iPS Academia Japan Inc. | Thyas Co. Ltd. | Payment unspecified | 1/18/19 |
| Tiburio Therapeutics to develop and commercialize Ipsen's TBR-760 for non-functioning pituitary adenoma and TBR-065 for additional rare endocrine diseases worldwide | Ipsen | Tiburio Therapeutics Inc. | Payment unspecified | 1/3/19 |
| Iqvia to provide services in support of phase III clinical study of Oncoquest's oregovomab against ovarian cancer | Iqvia Holdings Inc. | Oncoquest Inc. | Payment unspecified | 1/25/19 |
| Nippon and Janssen to co-promote apalutamide against prostate cancer in Japan | Janssen Pharmaceutical KK | Nippon Shinyaku Co. Ltd. | Payment unspecified | 1/21/19 |
| Veracyte and Johnson and Johnson Innovation to develop and commercialization lung cancer diagnostics | Johnson and Johnson Innovation, JLABS | Veracyte Inc. | Payment unspecified | 1/3/19 |
| Searle to commercialize Julphar's human insulin formulations against diabetes in Pakistan | Julphar Gulf Pharmaceutical Industries | Searle Pakistan Ltd. | Payment unspecified | 1/6/19 |
| Kingmed and PGDx to provide PGDx elio tissue complete assay for cancer clinical trials in China and Hong Kong | Kingmed Diagnostics | Personal Genome Diagnostics Inc. | Payment unspecified | 1/3/19 |
| Coeptis Pharmaceuticals to market and distribute Kitov Pharmaceutical’s Consensi in the U.S. for osteoarthritis pain and hypertension | Kitov Pharmaceuticals Ltd. | Coeptis Pharmaceuticals Inc. | $3.50 | 1/3/19 |
| Purdue to develop and supply Klaria's KL-01401 for anaphylactic reactions worldwide | Klaria Pharma Holding AB | Purdue Pharma Canada | $55.20 | 1/22/19 |
| Korea Pharma to commercialize Norgine's Plenvu in the Republic of Korea | Korea Pharma Co. Ltd. | Norgine BV | Payment unspecified | 1/3/19 |
| Celgene to obtain option to develop and commercialize Kyn's AHR antagonist program and Kynase program for cancer, worldwide | Kyn Therapeutics | Celgene Corp. | $80.00 | 1/18/19 |
| Eton to develop and supply Liqmeds' ET-104 for neurological condition | Liqmeds Worldwide Ltd. | Eton Pharmaceuticals Inc. | $2.50 | 1/23/19 |
| Janssen and Locus to develop, manufacture and commercialize crPhage products for respiratory and other organ systems infections | Locus Biosciences | Janssen Pharmaceuticals Inc. | $818.00 | 1/3/19 |
| Aligos to develop and commercialize therapies using Luxiana's nucleic acid technology against multiple gene targets worldwide | Luxiana Biotech Co. Ltd. | Aligos Therapeutics | Payment unspecified | 1/22/19 |
| Biontech to acquire Mab Discovery’s operational antibody generation unit along with all assets, employees and know-how for mAb generation | Mab Discovery GmbH | Biontech SE | Payment unspecified | 1/23/19 |
| Maruho and Kose to form skin care products joint venture | Maruho Co. Ltd. | Kose Corp. | Payment unspecified | 1/31/19 |
| Matinas to evaluate the combined effect of its lipid-nano-crystal technology with an undisclosed worldwide pharmaceutical company's nucleic acid polymer technology to formulate oligosaccharides | Matinas BioPharma Holdings Inc | Undisclosed | Payment unspecified | 1/10/19 |
| Emmac Life Sciences acquires a majority interest in Medalchemy | Medalchemy | Emmac Life Sciences plc | Payment unspecified | 1/22/19 |
| Medochemie to manufacture Pfizer's products in the therapeutic areas of anti-infective, cardiovascular, and pain | Medochemie Ltd. | Pfizer Inc. | Payment unspecified | 1/11/19 |
| Medpace to conduct phase II of Deinove's DNV-3837 for Clostridium difficile infections | Medpace Inc. | Deinove | Payment unspecified | 1/31/19 |
| Meiragtx and Janssen Pharmaceuticals in researach deal for preclinical gene therapy candidates for inherited retinal diseases | Meiragtx | Janssen Pharmaceuticals Inc. | Payment unspecified | 1/31/19 |
| Janssen to develop and commercialize Meiragtx's clinical-stage gene therapies against inherited retinal diseases worldwide | Meiragtx | Janssen Pharmaceuticals Inc. | $440.00 | 1/31/19 |
| Vertex to develop Merck KGaA's DNA-PK inhibitors, including M-9831 and a gene editing preclinical compound for six specific genetic disease indications | Merck KGaA | Vertex Pharmaceuticals Inc. | Payment unspecified | 1/24/19 |
| Betta Pharmaceuticals to develop and commercialize Merus's MCLA-129 against solid tumors in China | Merus BV | Betta Pharmaceuticals Co. Ltd. | Payment unspecified | 1/2/19 |
| Paragon Genomics to distribute MGI's automated workstation systems in the U.S. and Canada | MGI Tech Co. Ltd. | Paragon Genomics Inc. | Payment unspecified | 1/6/19 |
| China Medical System Holdings to develop and commercialize Midatech's products in greater China and certain southeast Asian countries | Midatech Pharma plc | China Medical System Holdings Ltd. | Payment unspecified | 1/29/19 |
| Mirati Therapeutics and BMS to evaluate the combination of sitravatinib and nivolumab in phase III trial in non-small cell lung cancer patients | Mirati Therapeutics Inc. | Bristol-Myers Squibb Co. | Unknown | 1/7/19 |
| MTTI and Johnson & Johnson to develop human anti-rabies monoclonal antibody in China | Molecular Targeting Technologies Inc. | Johnson & Johnson | Payment unspecified | 1/23/19 |
| Morphosys and Janssen to settle monoclonal antibody-related, including daratumumab, patent litigation in the U.S. | Morphosys AG | Janssen Biotech Inc. | Payment unspecified | 1/31/19 |
| Mundipharma and Baxter Oncology to develop pralatrexate for peripheral T-cell lymphoma | Mundipharma International Corp. Ltd. | Baxter Oncology GmbH | Unknown | 1/2/19 |
| Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the ?-Klotho/FGFR1c receptor complex for nonalcoholic steatohepatitis and type 2 diabetes | NGM Biopharmaceuticals Inc. | Merck & Co. Inc. | $20.00 | 1/3/19 |
| Linde to support research study of a Nobilis' xenon inhalation using portable device administration for post-traumatic stress disorder | Nobilis Therapeutics LLC | The Linde Group | Payment unspecified | 1/10/19 |
| Oculis to develop Novartis's LME 636 against dry eye disease | Novartis AG | Oculis ehf | Payment unspecified | 1/4/19 |
| NGP to commercialize Evoke's Gimoti for acute and recurrent diabetic gastroparesis | Novos Growth Partners | Evoke Pharma Inc. | $5.00 | 1/7/19 |
| Numerate to apply its Artificial Intelligence platform to identify clinical candidates for Lundbeck's central nervous system disorders, depression, psychosis, seizure and neurodegenerative disorders | Numerate Inc. | Lundbeck Pharmaceuticals Ltd. | Payment unspecified | 1/7/19 |
| Obsidian Therapeutics and Celgene to discover and develop cell therapies for cancer using DD technology, with an option for worldwide inlicense rights | Obsidian Therapeutics Inc. | Celgene Corp. | Payment unspecified | 1/18/19 |
| Purdue Pharma and Ocular Therapeutix to develop therapies against pain using bioresorbable hydrogel-based technology | Ocular Therapeutix Inc. | Purdue Pharma LP | Payment unspecified | 1/7/19 |
| Generex Biotechnology acquires majority stake in Olaregen Therapeutix | Olaregen Therapeutix Inc. | Generex Biotechnology Corp. | $12.00 | 1/8/19 |
| Oncoimmunity and European cancer vaccine company to use ImmuneProfiler to identify immunogenic neoantigens in sarcoma | Oncoimmunity AS | Undisclosed | Payment unspecified | 1/24/19 |
| Oncovir to supply Hiltonol to Cytlimic to develop CYT-001 cancer vaccine | Oncovir Inc. | Cytlimic Inc. | Payment unspecified | 1/7/19 |
| Zeon Lifesciences to market Optibiotix's Slimbiome for weight loss in India | Optibiotix Health plc | Zeon Lifesciences Ltd. | Unknown | 1/7/19 |
| Inexia to use Optinose's exhalation delivery system to develop positive modulators of Orexin OX1 and OX2 for neurological diseases worldwide | Optinose AS | Inexia Ltd. | $45.50 | 1/31/19 |
| Biotime to evaluate Orbit Biomedical's injection technology to deliver Opregen for the treatment of dry-age-related macular degeneration | Orbit Biomedical Ltd. | Biotime Inc. | Payment unspecified | 1/7/19 |
| Origenis and Expansion Therapeutics to research and discover small molecule compounds targeting RNA-mediated diseases worldwide | Origenis GmbH | Expansion Therapeutics Inc. | Payment unspecified | 1/24/19 |
| Orion to conduct phase I study for Acticor's ACT-017 against acute ischemic stroke | Orion Corp. | Acticor Biotech | Unknown | 1/23/19 |
| MGI Tech to distribute Paragon Genomics' CleanPlexNGS Panels with MGI's sequencing platforms worldwide except the U.S. | Paragon Genomics Inc. | MGI Tech Co. Ltd. | Payment unspecified | 1/6/19 |
| Parexel to provide contract research services related to Geron's clinical trials, including imetelstat for myelodysplastic syndrome | Parexel International (IRL) Ltd. | Geron Corp. | $33.00 | 1/30/19 |
| 1Cellbio to use inDrop System with Partek's Flow bioinformatics software for single cell analysis | Partek Inc. | 1Cellbio Inc. | Payment unspecified | 1/24/19 |
| Peptidream to discover PDCs for Shionogi's targets against central nervous system diseases using PDPS technology | Peptidream Inc. | Shionogi & Co. Ltd. | Payment unspecified | 1/23/19 |
| Atai Life acquires majority stake in Perception Neuroscience | Perception Neuroscience LLC | Atai Life Sciences AG | Payment unspecified | 1/3/19 |
| Merck to use PGDx' genomic solutions to support phase II KeyImpact study of pembrolizumab in combination with MK-4280 or lenvatinib for non-small-cell lung cancer | Personal Genome Diagnostics Inc. | Merck & Co. Inc. | Payment unspecified | 1/3/19 |
| PGDx and Pathgroup to co-develop PGDx elio tissue complete assay for cancer | Personal Genome Diagnostics Inc. | Pathgroup | Payment unspecified | 1/7/19 |
| Philochem and Janssen Biotech to discover small molecule-based therapeutics using lead-generation technologies | Philochem AG | Janssen Biotech Inc. | Payment unspecified | 1/23/19 |
| Philogen and Celgene to discover and develop immunomodulator therapeutics | Philogen SpA | Celgene Corp. | Payment unspecified | 1/23/19 |
| Philogen and Novartis to discover and develop immunomodulatory therapeutics for cancer | Philogen SpA | Novartis AG | Payment unspecified | 1/23/19 |
| Agenus to develop an alternative manufacturing process for Phyton's QS-21 | Phyton Biotech Inc. | Agenus Inc. | Payment unspecified | 1/3/19 |
| Phyton and PellePharm to develop plant cell culture based production process for patidegib in the treatment of gorlin syndrome and basal cell carcinoma | Phyton Biotech Inc. | Pellepharm Inc. | Payment unspecified | 1/31/19 |
| Illumina and PierianDx to combine pan-cancer tumor profiling assays with clinical informatics platform | PierianDx | Illumina Inc. | Payment unspecified | 1/4/19 |
| Curium to develop and commercialize Progenics' PyL for prostate cancer in Europe | Progenics Pharmaceuticals Inc. | Curium | Payment unspecified | 1/3/19 |
| Itochu to support Promethera's Hepastem against acute chronic liver failure, nonalcoholic steatohepatitis and urea cycle disorder | Promethera Biosciences SA/NV | Itochu Corp. | Payment unspecified | 1/2/19 |
| Prometheus to use RexRegistry data platform to create clinical data registry of patients with SCN2A mutations for Rogcon against neurological disorders | Prometheus Research | Rogcon Biosciences | Payment unspecified | 1/14/19 |
| Puma Biotechnology to commercialize Knight Therapeutics' Nerlynx for breast cancer in Canada | Puma Biotechnology Inc. | Knight Therapeutics Inc. | $7.30 | 1/9/19 |
| Rafael Holdings acquires majority stake in Rafael Pharmaceuticals | Rafael Pharmaceuticals Inc. | Rafael Holdings Inc. | Payment unspecified | 1/23/19 |
| Recro Gainesville to manufacture and supply Novartis' Ritalin LA and Focalin XR for attention deficit hyperactivity disorder | Recro Gainesville LLC | Novartis AG | Payment unspecified | 1/1/19 |
| Sanofi and Regeneron to discover, develop and commercialize antibodies, including REGN-2810 against cancer and immune disorder worldwide; deal was restructured in Jan. 2019 to add $462M to cover remaining share of Sanofi's obligations, and $120M to develop two bispecifics, BCMAxCD3 and MUC16xCD3 | Regeneron Pharmaceuticals Inc | Sanofi SA | $582.00 | 1/7/19 |
| Generex to sign binding letter of intent to acquire majority stake in Regentys | Regentys | Generex Biotechnology Corp. | $0.40 | 1/7/19 |
| Reneuron and U.S.-based undisclosed company to explore the use of exosome technology platform for synthetic oligonucleotides delivery | Reneuron Group plc | Undisclosed | Unknown | 1/4/19 |
| Ono and Repare to develop and commercialize Pol? inhibitor program for cancer in Japan and selected Asian territories ex-China | Repare Therapeutics Inc. | Ono Pharmaceutical Co. Ltd. | $175.00 | 1/31/19 |
| Grifols to commercialize Rigel's fostamatinib for palliation and human diseases, including immune thrombocytopenia, autoimmune hemolytic anemia, and IgA nephropathy in Europe and Turkey | Rigel Pharmaceuticals Inc. | Grifols SA | $327.50 | 1/22/19 |
| Phoenix and Roche to develop a companion diagnostic for PMD-026 against triple-negative breast cancer | Roche Holding AG | Phoenix Molecular Designs | Payment unspecified | 1/15/19 |
| 3Sbio to develop and commercialize Samsung Bioepis' biosimilar candidates, including SB-8, in Mainland China, excluding Hong Kong, Macau and Taiwan | Samsung Bioepis | 3Sbio Inc. | Payment unspecified | 1/6/19 |
| Acer to develop Sanofi's osanetant against neuroendocrine-related disorders worldwide | Sanofi SA | Acer Therapeutics Inc. | Payment unspecified | 1/2/19 |
| Agenus to use Selexis' SUREtechnology platform for the production of next-generation antibody programs for cancer | Selexis SA | Agenus Inc. | Payment unspecified | 1/9/19 |
| Sirion and Denali Therapeutics to discover AAV vectors gene therapies for the delivery of drugs across the blood brain barrier in neurodegenerative diseases | Sirion Gmbh | Denali Therapeutics Inc. | Payment unspecified | 1/9/19 |
| Skyhawk and Biogen to discover RNA Splicing Modifiers for neurological diseases using Skystar technology with worldwide license option | Skyhawk Therapeutics | Biogen Inc. | $74.00 | 1/4/19 |
| Solentim and ATUM to integrate technologies for rapid high expression cell line development | Solentim | ATUM | Unknown | 1/14/19 |
| Acrotech to purchase Spectrum's portfolio of seven FDA-approved hematology/oncology products | Spectrum Pharmaceuticals Inc. | Acrotech Biopharma LLC | $300.00 | 1/17/19 |
| Everest Medicine to develop, manufacture and commercialize Spero Therapeutics' SPR-206 in China, South Korea and Southeast Asia, with an option to rights to SPR-741 | Spero Therapeutics Inc. | Everest Medicines | $62.50 | 1/4/19 |
| Eurofarma acquires Stein's prescription drug line | Stein Lab | Eurofarma | Payment unspecified | 1/31/19 |
| Ascletis to develop and commercialize Suzhou Alphamab's KN-035 against hepatitis B and other viral diseases in China | Suzhou Alphamab Co. Ltd. | Ascletis Pharma Inc. | Payment unspecified | 1/14/19 |
| Mersana to incorporate Synaffix's Glycoconnect ADC technology into one of its ADC development candidates | Synaffix BV | Mersana Therapeutics Inc. | $295.00 | 1/4/19 |
| Lotus Pharmaceutical to acquire Takeda's Evista for osteoporosis in seven Asia-Pacific countries | Takeda Pharmaceutical Co. Ltd. | Lotus Pharmaceutical Co. Ltd. | $22.00 | 1/28/19 |
| Tara Biosystems and Insilico Medicine to discover and develop novel therapies for cardiac disease | Tara Biosystems Inc. | Insilico Medicine Inc. | Payment unspecified | 1/7/19 |
| Zeclinics and Taros Chemicals to discover therapeutics for ischemic heart disease | Taros Chemicals GmbH | Zeclinics SL | Payment unspecified | 1/30/19 |
| Chiesi Farmaceutici to develop and commercialize Tiumbio's NCE-401 for respiratory disease worldwide | Tiumbio Co. Ltd. | Chiesi Farmaceutici SpA | $74.00 | 1/10/19 |
| Abbvie and Tizona Therapeutics to develop and commercialize CD39-targeted therapeutics, including TTX-030, for the treatment of cancer worldwide | Tizona Therapeutics Inc. | Abbvie Inc. | $105.00 | 1/3/19 |
| Meiji Seika to develop and commercialize Toray's TRK-820 for the treatment of pruritus in Thailand and Indonesia | Toray Industries Inc. | Meiji Seika Pharma Co. Ltd. | Payment unspecified | 1/18/19 |
| Applied Biosciences acquires majority stake in Trace Analytics | Trace Analytics Gmbh | Applied Biosciences Corp. | Payment unspecified | 1/9/19 |
| Celgene to obtain option rights for development of Triphase Accelerator's WDR5 protein, TRPH-395, against blood cancers, including leukemia | Triphase Accelerator Corp. | Celgene Corp. | $980.00 | 1/29/19 |
| 1st Bio Therapeutics and Twoxar to discover and co-develop novel treatments for glioblastoma multiforme using AI technology | Twoxar Inc. | 1st Bio Therapeutics Inc. | Payment unspecified | 1/3/19 |
| Dong-A ST and Ty Bio to form joint venture TY RED to reposition evogliptin for calcific aortic valve disease | Ty Bio | Dong-A ST Co. Ltd. | $3.55 | 1/16/19 |
| Nuance Biotech to develop TYG Oncology's OQR-200 for the treatment of breast and prostate cancers in China and South Africa | TYG Oncology Ltd. | Nuance Biotech Inc. | Payment unspecified | 1/25/19 |
| Biomed X to use Velabs Therapeutics' microfluidics-based technology for T-cell screening in autoimmune diseases | Velabs Therapeutics GmbH | Biomed X GmbH | Payment unspecified | 1/7/19 |
| Veritas Pharma and Santa Marta to sign MOU for the development and commercialization of medical cannabis products | Veritas Pharma Inc. | Santa Marta Gold Holdings Ltd. | Payment unspecified | 1/15/19 |
| Neurocrine and Voyager to develop and commercialize VY-AADC for PD, two discovery programs worldwide and VY-FXN01 for Friedreich’s ataxia in the U.S. | Voyager Therapeutics | Neurocrine Biosciences Inc. | $1,895.00 | 1/28/19 |
| Scpharmaceuticals to use West Pharmaceutical Services' SmartDose Drug Delivery System with Furoscix | West Pharmaceutical Services Inc. | Scpharmaceuticals Inc. | Payment unspecified | 1/29/19 |
| Janssen collaboration to focus on developing a sensitive digital biomarker that can distinguish patients with mild cognitive impairment, an early stage of Alzheimer's disease, from healthy elderly subjects | Winterlight Labs | Johnson & Johnson | Payment unspecified | 1/7/19 |
| Biocure and Y-Biologics to conduct preclinical studies for anti-CD19 chimeric antigen receptor T-cell therapy in combination with YBL-006 against solid tumors | Y-Biologics Inc. | Biocure Technology Inc. | Payment unspecified | 1/14/19 |
| Gilead and Yuhan to develop and commercialize therapeutic candidates for advanced fibrosis due to nonalcoholic steatohepatitis worldwide, ex-Republic of Korea | Yuhan Corp. | Gilead Sciences Inc. | $785.00 | 1/6/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Boehringer to discover therapeutics using 3BP's peptide library and hit identification technology | 3B Pharmaceuticals GmbH | Boehringer Ingelheim International GmbH | Payment unspecified | 2/21/19 |
| Ascletis to develop and commercialize 3V Biosciences' ASC-40 and related compounds for nonalcoholic steatohepatitis in greater China | 3V Biosciences Inc. | Ascletis Pharma Inc. | Payment unspecified | 2/12/19 |
| Abcellera and Novartis to develop therapies against 10 targets using antibody discovery and single-cell screening technology | Abcellera Biologics Inc. | Novartis AG | Payment unspecified | 2/14/19 |
| NJCTTQ and Abpro to develop seven new bispecific antibody therapies, including T-cell engagers using diversimmune and multimab platform worldwide | Abpro Inc. | Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. | $4,000.00 | 2/28/19 |
| Excellerate Biosciences and Adalta to develop new i-bodies targeting G protein-coupled receptors for treatment of diseases | Adalta Pty Ltd. | Excellerate Biosciences | Payment unspecified | 2/28/19 |
| Alyvant to copromote Adhera Therapeutics’ Prestalia for hypertension in five specific geographic areas within the U.S. | Adhera Therapeutics Inc. | Alyvant | Payment unspecified | 2/28/19 |
| Medcdx and Admera to develop companion diagnostics using genomics and bioinformatics | Admera Health | Qiagen (Suzhou) Translational Medicine Co. | Payment unspecified | 2/26/19 |
| Adorx Therapeutics and Johnson & Johnson to develop therapeutics against lung cancer | Adorx Therapeutics Ltd. | Johnson & Johnson Innovation, JLABS | Payment unspecified | 2/28/19 |
| Recordati to manufacture and commercialize Aegerion's Juxtapid for homozygous familial hypercholesterolemia in Japan | Aegerion Pharmaceuticals Inc. | Recordati Rare Diseases | $110.00 | 2/5/19 |
| AGC Biologics to manufacture Calypso Biotech’s humanized monoclonal antibody CALY-002 for clinical trials | AGC Biologics | Calypso Biotech | Payment unspecified | 2/19/19 |
| Alkermes and Clovis Oncology to evaluate ALKS-4230 in combination with rucaparib and lucitanib for cancer | Alkermes plc | Clovis Oncology Inc. | Unknown | 2/19/19 |
| Abilita to identify Amgen's integral membrane protein targets using Enabled Membrane Protein technology platform | Amgen Inc. | Abilita Bio Inc. | Payment unspecified | 2/13/19 |
| Andrew and Valitacell to integrate cell line development with Onelab software for manufacture of biologic drugs | Andrew Alliance SA | Valitacell Ltd. | Payment unspecified | 2/5/19 |
| Apellis and SFJ to develop APL-2 for hematologic indications, including paroxysmal nocturnal hemoglobinuria, cold agglutinin disease and warm antibody hemolytic anemia | Apellis Pharmaceuticals Inc. | SFJ Pharmaceuticals Inc. | $640.00 | 2/28/19 |
| Apexigen and undisclosed pharma company to develop humanized monoclonal antibody for ocular disease | Apexigen Inc. | Undisclosed | Payment unspecified | 2/8/19 |
| Kaken to develop and commercialize Arbor's Sklice lotion for the treatment of head lice in Japan | Arbor Pharmaceuticals Inc. | Kaken Pharmaceutical Co. Ltd. | Payment unspecified | 2/27/19 |
| Arbor Pharmaceuticals and an undisclosed company for the development of AR-30 against psychiatric disorders | Arbor Pharmaceuticals Inc. | Undisclosed | Payment unspecified | 2/16/19 |
| Moderna to use Avacta's Affimer technology against certain targets; exercised option for exclusive licensing agreement | Avacta Ltd. | Moderna Therapeutics | $0.50 | 2/4/19 |
| Beactica, VIB and KU Leuven's Centre for Drug Design and Discovery to discover drugs targeting inflammatory diseases | Beactica AB | VIB Discovery Sciences | Payment unspecified | 2/27/19 |
| Seelos acquires Bioblast's trehalose | Bioblast Pharma Ltd. | Seelos Therapeutics Inc. | $20.50 | 2/15/19 |
| Imab and BCT to enter into a memorandum-of-understanding to develop therapeutics, including PEG-BCT-100 for arginine depletion therapy in autoimmune diseases and cancers | Bio-Cancer Treatment International Ltd. | Imab Biopharma | Payment unspecified | 2/1/19 |
| Biogenetics to commercialize Aslan's varlitinib in all the indications in South Korea | Biogenetics Co. Ltd. | Aslan Pharmaceuticals Pte. Ltd. | $13.00 | 2/27/19 |
| STA to use Biolingus' sublingual and buccal delivery technology | Biolingus AG | STA Pharmaceutical Co. Ltd. | Payment unspecified | 2/18/19 |
| Shire to use Biomarin's enabling technology to develop iduronate-2-sulfatase for hunter syndrome in U.S. | Biomarin Pharmaceutical Inc. | Shire Human Genetic Therapies Inc. | Payment unspecified | 2/1/19 |
| Biomérieux to provide Biofire Filmarray instruments and Biofire Filmarray pneumonia panels to Entasis for ETX-2514SUL clinical trial | Biomerieux SA | Entasis Therapeutics | Payment unspecified | 2/5/19 |
| Cannabics and Wize Pharma to form joint venture for development of cannabinoid therapies for ophthalmic disorders | Cannabics Pharmaceuticals Inc. | Wize Pharma Inc. | Unknown | 2/7/19 |
| Catalent to provide clinical packaging and distribution services for Adial Pharmaceuticals' AD-04 | Catalent Inc. | Adial Pharmaceuticals LLC | Payment unspecified | 2/20/19 |
| Cato Research to provide clinical development services for Oncbiomune's PGT chemotherapy (a complex of paclitaxel, gallium and transferrin) against refractory cancers | Cato Research Ltd. | Oncbiomune Pharmaceuticals Inc. | Payment unspecified | 2/28/19 |
| Rockland to distribute Cellaria's in-vitro disease models and cell culture media for cancer research worldwide | Cellaria Biosciences | Rockland Immunochemicals Inc. | Payment unspecified | 2/25/19 |
| Centogene to provide Sarepta diagnostic services to identify patients with Duchenne muscular dystrophy | Centogene GmbH | Sarepta Therapeutics Inc. | Payment unspecified | 2/28/19 |
| Carnot Laboratorios to distribute CJ Healthcare’s gastro K-Cab for the treatment of gastroesophageal reflux disease in South America | CJ Healthcare Corp. | Carnot Laboratorios | $84.00 | 2/13/19 |
| Codexis to supply enzyme to Kyorin for the manufacturing of vibegron for overactive bladder | Codexis Inc. | Kyorin Pharmaceutical Co. Ltd. | Payment unspecified | 2/6/19 |
| Cipla to develop and commercialize Concert's CTP-354 for spasticity, worldwide | Concert Pharmaceuticals Inc. | Cipla Ltd. | Payment unspecified | 2/28/19 |
| Crescita and Tetra Natural to enhance dermatology portfolio using patented transdermal delivery technologies | Crescita Therapeutics Inc. | Tetra Biopharma Inc. | Payment unspecified | 2/4/19 |
| Creso and Hempate to develop cannabinoids hemp products for anxiety, pain and sleep in Europe | Creso Pharma Switzerland GmbH | Hempmate AG | Payment unspecified | 2/13/19 |
| Dendreon to use Decipher's genomic tumor profiling to identify prostate cancer patients for sipuleucel-T treatment | Decipher Biosciences | Dendreon Corp. | Payment unspecified | 2/15/19 |
| Almirall to acquire an option to develop and commercialize Dermira's lebrikizumab for atopic dermatitis and certain other indications in Europe | Dermira Inc. | Almirall Prodesfarma SA | $1,445.00 | 2/12/19 |
| Ligand Pharmaceuticals to invest in Dianomi Therapeutics | Dianomi Therapeutics | Ligand Pharmaceuticals Inc. | $4.00 | 2/4/19 |
| EA Pharma to develop and commercialize Dr Falk Pharma's nor-Ursodeoxycholic Acid for primary sclerosing cholangitis and nonalcoholic steatohepatitis in Japan | Dr Falk Pharma GmbH | EA Pharma Co. Ltd. | Payment unspecified | 2/19/19 |
| Editas and Allergan to jointly codevelop and commercialize the products, including the LCA-10 for leber congenital amaurosis | Editas Medicine Inc | Allergan Sales LLC | Payment unspecified | 2/22/19 |
| Gamida to evaluate NAM-NK cells with undisclosed targets using Editas Medicine’s CRISPR technology for blood cancer and solid tumor | Editas Medicine Inc. | Gamida Cell Ltd. | Payment unspecified | 2/19/19 |
| Mayfield acquires Elle's MAY-44 formulation assets and intellectual property for dyspareunia | Elle Pharmaceutical LLC | Mayfield Pharmaceuticals | $0.20 | 2/1/19 |
| Taiba to commercialize Emmaus' Endari for sickle cell disease in Middle East and North African countries | Emmaus Medical Inc. | Taiba Pharma LLC | Payment unspecified | 2/4/19 |
| ENB Therapeutics and Merck to evaluate the combination of ENB-003 with Keytruda in a phase I/II study for advanced solid tumors | ENB Therapeutics Inc. | Merck & Co. Inc. | Payment unspecified | 2/4/19 |
| Bausch & Lomb acquires U.S. rights of Eton's EM-100 for ocular itching associated with allergic conjunctivitis | Eton Pharmaceuticals Inc. | Bausch & Lomb Inc. | Payment unspecified | 2/19/19 |
| Evotec and Galapagos to develop small molecule program for fibrosis and other indications worldwide | Evotec AG | Galapagos NV | Payment unspecified | 2/7/19 |
| Dermelix to develop and commercialize spherical nucleic acid (SNA) therapeutics, including DMX-102 using Exicure's SNA technology for Netherton Syndrome and skin indications worldwide | Exicure Inc. | Dermelix LLC | $1,002.00 | 2/19/19 |
| Accord Healthcare to commercialize Foresee Pharmaceuticals' FP-001 program worldwide excluding the U.S., China, Japan, Taiwan, Israel, Turkey and certain Middle East countries | Foresee Pharmaceuticals Co. Ltd. | Accord Healthcare Inc. | $86.00 | 2/11/19 |
| FSD Pharma to sign letter-of-intent with Solarvest to develop and test pharma-grade cannabinoids using algal expression technology worldwide | FSD Pharma Inc. | Solarvest Bioenergy Inc. | Payment unspecified | 2/5/19 |
| Recida to develop and commercialize Fujifilm's RC-01 for multidrug-resistant gram-negative infections, worldwide ex-Japan | Fujifilm Toyama Chemical Co. Ltd. | Recida Therapeutics Inc. | Payment unspecified | 2/6/19 |
| Shionogi and Funpep to develop antibody-inducing peptides for pain | Funpep Co. Ltd. | Shionogi & Co. Ltd. | Payment unspecified | 2/18/19 |
| Stembiosys to consign entire selection of matrices and cells into Gemini Bio Products’ portfolio | Gemini Bio Products Inc. | Stembiosys Inc. | Payment unspecified | 2/11/19 |
| Huasin to develop and produce DiBao using Genomica's CLART test technology platform to fight against cervical cancer in the China | Genomica SAU | Huasin Science Co. Ltd. | Payment unspecified | 2/18/19 |
| Grand Pharma to commercialize Glenmark Pharmaceuticals’ Ryaltris for seasonal allergic rhinitis in China | Glenmark Pharmaceuticals Ltd. | Grandpharma | Payment unspecified | 2/6/19 |
| Shanghai Haihe and China Shijiazhuang to form joint venture to co-develop RMX-1001, RMX-1002, RMX-2001, HH-185 and CDK4/6i | Haihe Biopharma Co. Ltd. | CSPC Pharmaceuticals Group Ltd. | Unknown | 2/18/19 |
| Hairmore to develop Applied Biology's AB-105 for the treatment of ponytail induced alopecia in the Chinese market | Hairmore Group | Applied Biology Inc. | Payment unspecified | 2/12/19 |
| Argenx to use Halozyme's Enhanze technology to develop multiple subcutaneous formulations, including ARGX-113 and two additional targets for autoimmune diseases worldwide | Halozyme Therapeutics Inc. | Argenx NV | $530.00 | 2/4/19 |
| Undisclosed company to develop and commercialize Handa' HND-026 for gastrointestinal diseases | Handa Pharmaceuticals Inc | Undisclosed | Payment unspecified | 2/11/19 |
| Hertz and Yuzheng to develop HZ-A-018 against lymphoma | Hangzhou Hertz Pharmaceutical Co. Ltd. | Hangzhou Yuzheng Pharmaceutical Biotechnology Co. Ltd. | Unknown | 2/2/19 |
| Kyowa Hakko Kirin to commercialize Hisamitsu Pharmaceutical's HP-3000 for Parkinson's disease in Japan | Hisamitsu Pharmaceutical Co. Inc. | Kyowa Hakko Kirin Co. Ltd. | Payment unspecified | 2/5/19 |
| Nacalai Tesque to use ID Pharma's CytoTune-iPS technology | ID Pharma Co. Ltd. | Nacalai Tesque Inc. | Payment unspecified | 2/20/19 |
| Roche to evaluate Immatics' IMA-101 in combination with atezolizumab against solid tumors | Immatics U.S. Inc. | Roche Holding AG | Payment unspecified | 2/26/19 |
| Leidos Biomedical Research to award subcontract to Immunoprecise Antibodies to produce rabbit monoclonal antibodies using B-cell select platform | Immunoprecise Antibodies Ltd. | Leidos Biomedical Research Inc. | Payment unspecified | 2/21/19 |
| Zhejiang Pukang to acquire Indivior's Sai Bo Song (buprenorphine, naloxone) tablet for opiate dependence in China | Indivior plc | Zhejiang Pukang Biotechnology Co. Ltd. | $122.50 | 2/4/19 |
| Teva to apply Insilico’s predictive digital twins technology for biopharmaceutical production | Insilico Biotechnology GmbH | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 2/21/19 |
| Horizon to use iPS Academia's in vitro diagnostic reference standards related to iPS cell related technologies | iPS Academia Japan Inc. | Horizon Discovery Group plc | Payment unspecified | 2/8/19 |
| Irisys to manufacture Biocorrx's BICX-102 for opioid use disorder | Irisys LLC | Biocorrx Inc. | Payment unspecified | 2/26/19 |
| SK chemicals to distribute Janssen Korea's Reminyl in Korea | Janssen Korea Ltd. | SK Chemicals Co. Ltd. | Payment unspecified | 2/12/19 |
| Jubilant and Sanofi to discover and develop small molecule therapeutics for neurological diseases | Jubilant Biosys Ltd. | Sanofi SA | Payment unspecified | 2/13/19 |
| TIPR-HUYA Advancing Innovative Medicines to distribute Kaken Pharmaceutical's efinaconazole for onychomycosis in China | Kaken Pharmaceutical Co. Ltd. | Tianjin Institute of Pharmaceutical Research - Huya Bioscience International (TIPR-HUYA) Advancing Innovative Medicines | Payment unspecified | 2/1/19 |
| Kamada to distribute Anges' beperminogene perplasmid for critical limb ischemia in Israel | Kamada Ltd. | Anges MG Inc. | $4.10 | 2/12/19 |
| Genagon to use Ligand’s full Omniab transgenic animal technology platform to discover antibody-based therapeutics for immuno-oncology worldwide | Ligand Pharmaceuticals Inc. | Genagon Therapeutics AB | Payment unspecified | 2/4/19 |
| Mallinckrodt Pharmaceuticals and Transimmune to develop photopheresis technology | Mallinckrodt plc | Transimmune AG | Payment unspecified | 2/25/19 |
| Neotx and Medimmune to evaluate Anyara in combination with Imfinzi against solid tumor | Medimmune LLC | Neotx Therapeutics Ltd. | Payment unspecified | 2/11/19 |
| Arrevus acquires fusidic acid from Melinta Therapeutics | Melinta Therapeutics Inc. | Arrevus Inc. | Payment unspecified | 2/5/19 |
| Hikma Pharmaceuticals to distribute Melinta Therapeutics' intravenous and oral formulations of Baxdela in the Middle East and North Africa (MENA) region | Melinta Therapeutics Inc. | Hikma Pharmaceuticals plc | Payment unspecified | 2/28/19 |
| Glaxosmithkline and Merck to co-develop M-7824 against cancers worldwide | Merck KGaA | Glaxosmithkline plc | $4,221.64 | 2/5/19 |
| Itrom to commercialize Mithra's Myring for contraception in Middle East | Mithra Pharmaceuticals | Itrom Pharmaceutical Group | Payment unspecified | 2/12/19 |
| Itrom to commercialize Mithra Pharmaceuticals' Estelle for contraception in the Middle-East and North-Africa (MENA) region | Mithra Pharmaceuticals | Itrom Pharmaceutical Group | $62.75 | 2/28/19 |
| Bayer to commercialize Moberg MOB-015 against onychomycosis in Europe | Moberg Pharma AB | Bayer AG | $58.76 | 2/11/19 |
| Leiters to market Mobius' Mitosol for use in glaucoma surgical procedures in the U.S. | Mobius Therapeutics Inc. | Leiters | Payment unspecified | 2/14/19 |
| WPD to develop and market Moleculin's technologies in certain European countries excluding the U.K., France, Italy and Spain | Moleculin Biotech Inc. | WPD Pharmaceuticals | $4.00 | 2/20/19 |
| Janssen and Morphic Therapeutic to discover and develop integrin therapeutics for undisclosed indications worldwide | Morphic Therapeutic Inc. | Janssen Biotech Inc. | $725.00 | 2/21/19 |
| Mundipharma and Imbrium to develop etoposide toniribate against relapsed refractory biliary tract cancer | Mundipharma EDO GmbH | Imbrium Therapeutics LP | Payment unspecified | 2/26/19 |
| Cascade Pure to distribute Nanosphere's Evolve Formulas products in Oregon | Nanossphere Health Sciences LLC | Cascade Pure LLC | Unknown | 2/20/19 |
| ARS Pharmaceuticals to use Neurelis' Intravail drug delivery technology to develop ARS-1 for hypersensitivity | Neurelis Inc. | ARS Pharmaceuticals Inc. | Payment unspecified | 2/19/19 |
| Neurovive Pharmaceutical to supply mitochondrial medicine research compounds as research tool to Oroboros Instruments | Neurovive Pharmaceutical AB | Oroboros Instruments | Payment unspecified | 2/21/19 |
| Nordic to manufacture Aventis' mifepristone for abortion in the Netherlands | Nordic Pharma | Aventis Pharma AG | Payment unspecified | 2/12/19 |
| Recordati to commercialize Novabiotics's Lynovex for acute infectious exacerbations associated with cystic fibrosis worldwide | Novabiotics Ltd. | Finanziaria Industriale Mobiliare ed Immobiliare SPA | Payment unspecified | 2/28/19 |
| Anthos to develop Novartis' MAA-868 against thrombosis | Novartis AG | Anthos Therapeutics Inc. | Payment unspecified | 2/27/19 |
| Enzene to use Novasep's BioSC Pilot for purification of biopharmaceuticals | Novasep | Enzene Biosciences Ltd. | Payment unspecified | 2/5/19 |
| Aucta and Oakrum to develop and manufacture four prescription generic pharmaceutical product to be marketed in the U.S. | Oakrum Pharma LLC | Aucta Pharmaceuticals Inc. | Payment unspecified | 2/19/19 |
| Ohara to develop Oncoceutics' ONC-201 for glioma in Japan with a right of first refusal to ONC-201 and ONC-206 in Asia and West Africa | Oncoceutics Inc. | Ohara Pharmaceutical Co. Ltd. | Payment unspecified | 2/15/19 |
| Biolat to package and commercialize Optibiotix's cholesterol and blood pressure reducing Lactobacillus plantarum strain in Estonia, Latvia and Lithuania | Optibiotix Health plc | Biolat JSC | Payment unspecified | 2/7/19 |
| Oxford Genetics and Sphere Fluidics to develop next-generation, microfluidic enabled gene editing workflows | Oxford Genetics Ltd. | Sphere Fluidics Ltd. | Payment unspecified | 2/18/19 |
| Pancella and Cartherics to develop and commercialize pluripotent cell lines against cancer and other diseases using cell therapy | Pancella Inc. | Cartherics Pty. Ltd. | Payment unspecified | 2/12/19 |
| Gedeon Richter to commercialize Pantarhei Bioscience’s combined oral contraceptive in Europe, Russia, Latin America and Australia | Pantarhei Bioscience BV | Gedeon Richter Ltd. | Payment unspecified | 2/4/19 |
| Theramex to commercialize Pfenex's PF-708 for osteoporosis in Europe and Switzerland | Pfenex Inc. | Theramex | Payment unspecified | 2/28/19 |
| SAJA to commercialize Pfenex's PF-708 for osteoporosis in Middle East and North Africa | Pfenex Inc. | Saudi-Arabian Japanese Pharmaceutical Co. | Payment unspecified | 2/28/19 |
| Pivot Pharmaceuticals to sign letter of intent with Pharmascience to conduct analytical testing, development and research of medicinal products containing cannabis or cannabis derivatives | Pharmascience Inc. | Pivot Pharmaceuticals Inc. | Payment unspecified | 2/26/19 |
| POA Pharma to commercialize Primex's ADV-6209 as sedative and anesthetic premedication in Denmark, Finland, Norway and Sweden | Primex Pharmaceuticals AG | POA Pharma Scandinavia AB | Payment unspecified | 2/21/19 |
| Eli Lilly to apply Proteonic's 2G Unic technology for recombinant protein production | Proteonic | Eli Lilly and Co. | Payment unspecified | 2/5/19 |
| Recida and Micurx to develop and commercialize RC-01 for multidrug-resistant gram-negative infections in greater China | Recida Therapeutics Inc. | Micurx Pharmaceuticals Inc. | Payment unspecified | 2/6/19 |
| RPDC to establish a memorandum-of-understanding to support the commercialization of Celltex Therapeutics' stem cell therapy technology in Riyadh, Saudi Arabia | Research Products Development Co. | Celltex Therapeutics Corp. | Payment unspecified | 2/21/19 |
| Impression to sign non-binding memorandum of understanding to commercialize Respirerx's dronabinol for obstructive sleep apnea in Australia, New Zealand and Southeast Asia | Respirerx Pharmaceuticals Inc. | Impression Healthcare Ltd. | Payment unspecified | 2/19/19 |
| Rose Pharma and Transparency Life Sciences to develop ROSE-010 for the treatment of irritable bowel syndrome | Rose Pharma A/S | Transparency Life Sciences LLC | Payment unspecified | 2/27/19 |
| Samsung Bioepis and Affamed to develop and commercialize biosimilars, including SB-11, SB-12 and SB-3 in China | Samsung Bioepis | Affamed Therapeutics | Payment unspecified | 2/10/19 |
| Seaspine to market Kuros Biosciences' advanced bone graft for spinal disorders in the U.S., Europe, South America and the Middle East | Seapine Holdings Corp. | Kuros Biosciences Ltd. | Payment unspecified | 2/11/19 |
| Turgut to utilize Selexis' Suretechnolgy platform and Sure CHO-M Cell Line for the development of two biosimilar antibodies – a checkpoint inhibitor for the treatment of certain cancers and a monoclonal antibody for the treatment of metastatic HER2-positive breast cancer | Selexis SA | Turgut ?laclari AS | Payment unspecified | 2/26/19 |
| Servier to promote Tianjin Tanabe's Tenelia against type 2 diabetes in mainland China | Servier Pharmaceuticals LLC | Tianjin Tanabe Seiyaku Co. Ltd. | Payment unspecified | 2/28/19 |
| BGI Americas to provide sequencing services for Flow Pharma's FlowVax neoantigen-based personalized therapeutic cancer vaccines | Shenzhen BGI Genomics Techonology Co. Ltd. | Flow Pharma Inc. | Payment unspecified | 2/28/19 |
| Chipscreen and Innovent to evaluate safety and tolerability of Chidamide and Sintilimab in combination with IBI-305 for colorectal carcinoma | Shenzhen Chipscreen Biosciences Ltd. | Innovent Biologics Inc. | Unknown | 2/17/19 |
| CBPE Capital acquires Simbec-Orion Group | Simbec-Orion Group Ltd. | CBPE Capital LLP | Payment unspecified | 2/4/19 |
| Eton Pharmaceuticals to market Sintetica's ET-202 and ET-203 in the U.S. | Sintetica SA | Eton Pharmaceuticals Inc. | $5.50 | 2/8/19 |
| Arvelle Therapeutics to develop and commercialize SK Biopharmaceuticals' cenobamate for epilepsy, specifically partial-onset seizures in Europe | SK Biopharmaceuticals | Arvelle Therapeutics GmbH | $530.00 | 2/14/19 |
| Valitacell and Solentim to collaborate on the discovery and development of biologic drugs and advanced cell therapies | Solentim | Valitacell Ltd. | Payment unspecified | 2/21/19 |
| Pathios and Sygnature to develop therapies against GPR65 for autoimmune disease and immuno-oncology | Sygnature Discovery Ltd. | Pathios Therapeutics | Payment unspecified | 2/6/19 |
| Cullinan to develop and commercialize Taiho's TAS-6417 against cancer worldwide excluding Japan | Taiho Pharmaceutical Co. Ltd. | Cullinan Oncology LLC | Payment unspecified | 2/5/19 |
| Abbvie to have option rights to acquire Teneoone and subsequently develop and commercialize TNB-383B against multiple myeloma worldwide | Teneoone Inc. | Abbvie Inc. | $90.00 | 2/11/19 |
| Imbrium and Tetragenetics to discover and develop non-opioid monoclonal antibodies against ion channels using Tetraexpress technology for chronic pain, with an option to further develop | Tetragenetics Inc. | Imbrium Therapeutics LP | $273.00 | 2/26/19 |
| Nanoviricides to use Theracour's nanotechnology on varicella-zoster virus, the virus that causes chickenpox and shingles | Theracour Pharma Inc. | Nanoviricides Inc. | $4.00 | 2/26/19 |
| Therapeutics to conduct phase II clinical study of Durect's DUR-928 for plaque psoriasis | Therapeutics Inc. | Durect Corp. | Payment unspecified | 2/12/19 |
| Thermo Fisher to supply nucleotides, enzymes and other critical raw materials for Biontech's messenger RNA (mRNA) manufacturing platform | Thermo Fisher Scientific Inc. | Biontech SE | Payment unspecified | 2/26/19 |
| Daewon to develop Tium Bio's TU-2670 in Korea | Tium Bio Co. Ltd. | Daewon Pharm Co. Ltd. | Payment unspecified | 2/25/19 |
| Torque and Merck to evaluate Torque's TRQ-1501 in combination with Merck's Keytruda against multiple solid tumor indications | Torque Therapeutics Inc. | Merck & Co. Inc. | Payment unspecified | 2/20/19 |
| Knight to award Triumvira loan for development of novel platform for engineering T cells against cancer and commercialize future approved products for Canada, Israel, Mexico, Colombia | Triumvira Immunologics Inc. | Knight Therapeutics Inc. | $5.00 | 2/20/19 |
| Up Cannabis to supply dried bulk medical cannabis to Zyus Life Sciences | Up Cannabis Inc. | Zyus Life Sciences Inc. | Payment unspecified | 2/7/19 |
| Vaccibody to study the combination of VB-10.16 in a phase II study with Roche's Tecentriq for advanced cervical cancer | Vaccibody AS | Roche Holding AG | Payment unspecified | 2/13/19 |
| 3sbio to develop and commercialize macrophage checkpoint modulator antibodies against cancer using Verseau's technology worldwide, including mainland China, Taiwan, Hong Kong and Macau | Verseau Therapeutics Inc. | 3sbio Inc. | Payment unspecified | 2/11/19 |
| Autolus to use Vineti's software platform to support delivery of T-cell therapies | Vineti Inc. | Autolus Therapeutics Ltd. | Payment unspecified | 2/25/19 |
| Vitruvias and Bright Future to develop semi-solids to be marketed in the U.S. and China | Vitruvias Therapeutics | Bright Future Pharmaceutical Laboratories Ltd. | Payment unspecified | 2/11/19 |
| Abbvie and Voyager to develop and commercialize vectorized antibodies against alpha-synuclein for Parkinson's disease and other diseases, worldwide | Voyager Therapeutics | Abbvie Inc. | $1,537.50 | 2/21/19 |
| Wellmarker and Biogenetics to develop WM-S1-001 for Erbitux-resistant colon cancer | Wellmarker Bio Co. Ltd. | Biogenetics Co. Ltd. | Payment unspecified | 2/27/19 |
| Wuxi to manufacture Amicus' Pompe biologic ATB-200 | Wuxi Biologics | Amicus Therapeutics Inc. | Payment unspecified | 2/11/19 |
| Genentech to develop and commercialize Xencor's IL-15 cytokine therapeutics, including XmAb-24306 and other IL-15 programs worldwide | Xencor Inc. | Genentech Inc. | $460.00 | 2/4/19 |
| Zylo to develop and supply Z-pods to Ferndale to incorporate into other two products in the U.S. and Canada | Zylo Therapeutics | Ferndale Pharma Group Inc. | Payment unspecified | 2/12/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Abzena to manufacture and produce Lipum's BSSL antibody IND program for autoimmune inflammatory diseases, including juvenile idiopathic arthritis | Abzena plc | Lipum AB | Payment unspecified | 3/19/19 |
| Adagene to evaluate its precision library to discover antibodies against Celgene's targets | Adagene Suzhou Ltd. | Celgene Corp. | Payment unspecified | 3/4/19 |
| Alexion and Affibody to develop ABY-039 for IgG mediated autoimmune diseases with an option to co-promote in the U.S. | Affibody AB | Alexion Pharmaceuticals Inc. | $650.00 | 3/20/19 |
| Shionogi to develop and commercialize Akili Interactive's AKL-T01 and AKL-T02 against attention deficit hyperactivity disorder and autism spectrum disorder in Japan and Taiwan | Akili Interactive Labs Inc. | Shionogi & Co. Ltd. | $125.00 | 3/7/19 |
| Ambrx and Beigene to discover and develop biologic drug candidates using Expanded Genetic Code platforms worldwide | Ambrx Inc. | Beigene Co. Ltd. | $475.00 | 3/6/19 |
| Anthrop to distribute Diurnal's Alkindi in the Nordic region, including Sweden, Norway, Denmark, Finland and Iceland | Anthrop Pharmaceuticals AB | Diurnal Ltd. | Payment unspecified | 3/28/19 |
| Pfizer to gain a license option to develop Antolrx's antigen-specific targeted nanoparticle tolerance therapeutics for type 1 diabetes | Antolrx Inc. | Pfizer Inc. | $51.00 | 3/5/19 |
| Appianrx to provide HUB and patient services to Titan Pharmaceuticals' probuphine for opioid use disorder | Appianrx | Titan Pharmaceuticals Inc. | Payment unspecified | 3/28/19 |
| Applied DNA Sciences and Takis to develop linear-DNA based anticancer vaccines | Applied DNA Sciences Inc. | Takis Biotech | Payment unspecified | 3/1/19 |
| Biogenetics to commercialize Aslan's ASLAN-003 in all indications in South Korea | Aslan Pharmaceuticals Pte Ltd. | Biogenetics Co. Ltd. | $9.00 | 3/11/19 |
| Gesynta to acquire Astrazeneca's late-stage drug discovery project asset including several molecules targeting microsomal Prostaglandin E synthase in the inflammatory processes of cardiovascular diseases and cancer | Astrazeneca plc | Gesynta Pharma AB | Payment unspecified | 3/19/19 |
| HLS Therapeutics to use Athelas' One device for Clozaril against treatment-resistant schizophrenia in Canada | Athelas Inc. | HLS Therapeutics Inc. | Payment unspecified | 3/14/19 |
| Atyr Pharma and CSL Behring to develop IND immunological therapies derived from up to four tRNA synthetases with an option for worldwide rights | Atyr Pharma Inc. | CSL Ltd. | $17.00 | 3/11/19 |
| Suda Pharmaceuticals to commercialize Aytu Bioscience's ZolpiMist worldwide outside the U.S. and Canada, including Europe, Asia, and Latin America | Aytu Bioscience Inc. | Suda Pharmaceuticals Ltd. | Payment unspecified | 3/6/19 |
| Barc Lab and OWL to provide clinical support solutions to biopharmaceutical companies for liver diseases worldwide | Barc Lab | OWL Metabolomics | Payment unspecified | 3/28/19 |
| Bristol-Myers to use Biocartis' Idylla Microsatellite Instability test for Opdivo and Yervoy against metastatic colorectal cancer | Biocartis | Bristol-Myers Squibb Co. | Payment unspecified | 3/12/19 |
| Fujifilm to acquire large-scale biologics manufacturing site from Biogen | Biogen Inc. | Fujifilm Holdings Corp. | $890.00 | 3/12/19 |
| Baxter and Biomerieux to develop biomarkers for identification and treatment of acute kidney injury | Biomerieux SA | Baxter International Inc. | Payment unspecified | 3/19/19 |
| Bioxcel and Nektar to evaluate NKTR-214 and BXCL-701 combination against multiple oncology indications, including pancreatic and prostate cancer | Bioxcel Therapeutics Inc. | Nektar Therapeutics | Payment unspecified | 3/4/19 |
| Sunstar acquires BMG Pharma's GelX for the treatment and prevention of oral mucositis | BMG Pharma Srl | Sunstar Suisse SA | Payment unspecified | 2/25/19 |
| Eisai to use Cerveau's 18F-MK-6240, an imaging agent, to assess the progression of neurofibrillary tangles in the brain | Cerveau Technologies Inc. | Eisai Co. Ltd. | Payment unspecified | 3/22/19 |
| China Resources Guokang to distribute Casi Pharmaceuticals' Evomela for multiple myeloma in China | China Resources Guokang Pharmaceuticals Co. Ltd. | Casi Pharmaceuticals Inc. | Payment unspecified | 3/13/19 |
| Marizyme to enter into an letter of intent to acquire Chromocell's certain non-opiate pain relief and rare disease assets | Chromocell Corp. | Marizyme Inc. | Payment Unspecified | 3/18/19 |
| Clinigen and Eiger Biopharmaceuticals to launch a worldwide lonafarnib managed access program for patients with Progeria and Progeroid laminopathies | Clinigen Group plc | Eiger Biopharmaceuticals Inc. | Payment unspecified | 3/4/19 |
| Charles River Laboratories to distribute Crown Bioscience's Zucker Diabetic Sprague-Dawley rat for various indications worldwide | Crown Bioscience Inc. | Charles River Laboratories International Inc. | Payment unspecified | 3/12/19 |
| Cryoport to provide temperature-controlled logistics to Biokin to support phase I and II clinical trials of bispecific and multi-specific antibody, antibody drug conjugate and T-cell therapies in immuno-oncology | Cryoport Inc. | Sichuan Biokin Pharmaceutical Co. Ltd. | Payment unspecified | 3/28/19 |
| Winhealth Pharma to distribute Cumberland’s Acetadote and Caldolor to treat paracetamol overdose, pain and fever respectively in China | Cumberland Pharmaceuticals Inc. | Winhealth Pharma Group | $2.00 | 3/29/19 |
| Pharmabcine and Curocell to develop PMC-005BL for treating PD-L1 positive solid tumor | Curocell Inc. | Pharmabcine | Payment unspecified | 3/26/19 |
| Lorem Vascular to acquire Cytori's cell therapy assets worlwide except Japan | Cytori Therapeutics Inc. | Lorem Vascular Co. Ltd. | $4.00 | 3/29/19 |
| Astrazeneca to develop and commercialize Daiichi's antibody-drug conjugate, DS-8201 against HER2-expressing cancers worldwide | Daiichi Sankyo Co. Ltd. | Astrazeneca plc | $6,900.00 | 3/28/19 |
| Transcenta's HJB to develop and commercialize Eli Lilly's biotherapeutics including blosozumab against bone diseases, including osteoporosis in greater China | Eli Lilly and Co. | Transcenta Holding Inc. | Payment unspecified | 3/28/19 |
| Lannett to market Elite Pharmaceuticals' generic version of Adderall and extended-release central nervous system stimulant in the U.S. | Elite Pharmaceuticals Inc. | Lannett Co. Inc. | Unknown | 3/7/19 |
| Cereno to acquire Emeriti's EB-014 | Emeriti Bio | Cereno Scientific AB | Payment unspecified | 3/13/19 |
| Express Scripts to distribute Emmaus' Endari against sickle cell disease | Emmaus Medical Inc. | Express Scripts Inc. | Payment unspecified | 3/11/19 |
| Eurofarma to develop and commercialize NLS Pharma's treatment against attention deficit hyperactivity disorder in Latin America | Eurofarma | NLS Pharma AG | Payment unspecified | 3/18/19 |
| Exscientia and Celgene to discover small molecule therapeutic drug candidates in oncology and autoimmunity using Centaur Chemist AI drug discovery platform | Exscientia Ltd. | Celgene Corp. | $25.00 | 3/21/19 |
| Iksuda to use Femtogenix's sequence selective DNA interactive payload molecules to advance lead antibody-drug conjugate towards the clinic against solid tumors | Femtogenix Ltd. | Iksuda Therapeutics | Payment unspecified | 3/5/19 |
| Teva Pharmaceutical to use Genedata's workflow platform for the identification, engineering, and characterization of novel biopharmaceuticals drugs | Genedata AG | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 3/21/19 |
| Nemus to conduct research for NB-1111 using 3D HTM model against glaucoma | Glauconix Biosciences Inc. | Nemus Bioscience Inc. | $0.18 | 3/13/19 |
| Biohaven to purchase PRV from GW Research to accelerate the rimegepant Zydis NDA | GW Research Ltd. | Biohaven Pharmaceutical Holding Co. Ltd. | $105.00 | 3/15/19 |
| H. Lundbeck and Enamine to identify and develop hit series in multiple research programs using in-house discovery chemistry diverse library | H Lundbeck A/S | Enamine Ltd. | Payment unspecified | 3/25/19 |
| Health House to distribute Satipharm's Gelpell for epilepsy in Australia, New Zealand and Asia | Health House International Pty Ltd. | Satipharm | Payment unspecified | 3/28/19 |
| Helomics and Viome to study link between the gut microbiome and ovarian cancer to identify the personalized treatments for ovarian cancer | Helomics Corp. | Viome | Payment unspecified | 3/21/19 |
| Hitgen to discover small molecule leads for SPARC's targets | Hitgen Ltd. | Sun Pharmaceutical Advanced Research Co. Ltd. | Payment unspecified | 3/12/19 |
| Hitgen and Almirall to discover small molecule leads against atopic dermatitis | Hitgen Ltd. | Almirall Prodesfarma SA | Payment unspecified | 3/25/19 |
| Echelon to distribute Hyalose's Select-hyaluronic acid products worldwide | Hyalose LLC | Echelon Biosciences Inc. | Payment unspecified | 3/26/19 |
| Iktos to provide AI technology access for Merck to advance drug discovery across three drug discovery projects | Iktos | Merck KGaA | Payment unspecified | 3/14/19 |
| Boai NKY and Illumina to co-develop NGS technology to use in IVD assays for genetic kidney disease testing | Illumina Inc. | Boai Nky Pharmaceuticals Ltd. | Payment unspecified | 3/5/19 |
| Eli Lilly and Immunext to develop an antibody for autoimmune diseases by regulating metabolism of lymphocytes worldwide | Immunext Inc. | Eli Lilly and Co. | $605.00 | 3/26/19 |
| HCR to purchase Infinity's royalty stream for Copiktra | Infinity Pharmaceuticals Inc. | Healthcare Royalty Partners | $50.00 | 3/5/19 |
| F-star to develop Kymab's KY-1055 for the treatment of cancer | Kymab Ltd. | F-star Biotechnologische Forschungs-und Entwicklungs GmbH | Unknown | 3/22/19 |
| Tillotts and Labgenius to identify and develop new drug candidates for the treatment of inflammatory bowel diseases | Labgenius Ltd. | Tillotts Pharma AG | Payment unspecified | 3/14/19 |
| Azurrx to purchase Laboratoires Mayoly's MS-1819-SD along with related patents for exocrine pancreatic insufficiency | Laboratoires Mayoly Spindler SAS | Azurrx Biopharma Inc. | $2.62 | 3/27/19 |
| Immunobiology and LIBP to co-develop Pnubiovax vaccine for pneumococcal disease in greater China | Lanzhou Institute of Biological Products | Immunobiology Ltd. | Payment unspecified | 3/18/19 |
| Takeda and LCB to develop antibody drug conjugates for cancer using ConjuAll technology | Legochem Bioscience Inc. | Takeda Pharmaceutical Co. Ltd. | $411.25 | 3/22/19 |
| Royalty Pharma acquires rights to intellectual property and royalties from Ligand Pharmaceuticals for Promacta | Ligand Pharmaceuticals Inc. | Royalty Pharma | $827.00 | 3/5/19 |
| Kite Pharma to use Maxcyte's Flow Electroporation technology to develop multiple CAR-T drug candidates for up to 10 targets | Maxcyte Inc. | Kite Pharma Inc. | Payment unspecified | 3/1/19 |
| MVC and Taiwan Bio to co-develop cell therapy technologies for Taiwan | Medigen Vaccine Biologics Corp. | Taiwan Bio Therapeutics Co. Ltd | Payment unspecified | 3/5/19 |
| Pharmascience to develop and commercialize Medlab's Nanabis for cancer pain worldwide | Medlab Clinical Ltd. | Pharmascience Inc. | Payment unspecified | 3/5/19 |
| Medpharm to provide development services to Destiny Pharma for XF-platform compounds against dermal and ocular infections | Medpharm Ltd. | Destiny Pharma Ltd. | Payment unspecified | 3/27/19 |
| Megapharm to distribute IBT's IBP-9414 for necrotizing enterocolitis in Israel and Palestinian Authority’s territories | Megapharm Ltd. | Infant Bacterial Therapeutics AB | Payment unspecified | 3/5/19 |
| Enigma Biomedical to develop and commercialize Merck’s MK-688 worldwide to measure cholinergic tone change in vivo | Merck & Co. Inc. | Enigma Biomedical Group Inc. | Payment unspecified | 3/15/19 |
| Merck to sign memorandum of understanding with Genscript for the study of cell and gene therapy industrialization in China | Merck KGaA | Genscript Biotech Co. | Payment unspecified | 3/19/19 |
| Baxter Oncology and Merck to develop bintrafusp alfa for non-small-cell lung cancer in China | Merck KGaA | Baxter Oncology GmbH | Payment unspecified | 3/4/19 |
| Miltenyi to supply products related to genetically modified, cell-based therapeutics to Bellicum for human diseases including solid tumors and hematological cancers worldwide | Miltenyi Biotec GmbH | Bellicum Pharmaceuticals Inc. | $2.85 | 3/27/19 |
| Saval Pharmaceuticals to commercialize Mithra Pharmaceuticals' Tibelia for hormone replacement therapy in Chile | Mithra Pharmaceuticals | Laboratorios Saval S.A. | Payment unspecified | 3/5/19 |
| Molecular Partners and Gilead Sciences to research on Darpin molecules against oncology | Molecular Partners AG | Gilead Sciences Inc. | Payment unspecified | 3/31/19 |
| MRI Interventions to supply V-TAG device for use in Voyager's RESTORE-1 trial of VY-AADC gene therapy program for Parkinson's disease | MRI Interventions Inc. | Voyager Therapeutics | Payment unspecified | 3/11/19 |
| Sunovion to commercialize Nabriva's lefamulin for community-acquired bacterial pneumonia and in other approved indication in Canada | Nabriva Therapeutics AG | Sunovion Pharmaceuticals Canada Inc. | Payment unspecified | 3/28/19 |
| Napajen Pharma and Astellas Pharma to use Napajen’s delivery technology to discover and develop oligonucleotide therapeutics for immune diseases | Napajen Pharma Inc. | Astellas Pharma Inc. | Payment unspecified | 3/18/19 |
| Natera to offer Signatera MRD assay services to assess clinical trial response of Amal's ATP-128 on stage IV colorectal | Natera Inc. | Amal Therapeutics SA | Payment unspecified | 3/26/19 |
| BGI Genomics to commercialize Natera's Signatera MRD test in China and to develop reproductive health tests using DNBseq NGS technology platform | Natera Inc. | Shenzhen BGI Genomics Techonology Co. Ltd. | $56.00 | 3/11/19 |
| NHC and Canopy Growth to conduct research on cannabinoids for post-concussion neurological diseases | Neeka Health Canada | Canopy Growth Corp. | Payment unspecified | 3/2/19 |
| Ocumension to develop and commercialize Nicox's Zerviate against allergic conjunctivitis in mainland China, Hong Kong, Macau and Taiwan | Nicox SA | Ocumension Therapeutics | $19.40 | 3/15/19 |
| Neurimmune and Novago to discover human antibodies targeting Nogo-A for stroke | Novago Therapeutics AG | Neurimmune Holding AG | Payment unspecified | 3/4/19 |
| Secura Bio acquires worldwide rights to Novartis' Farydak for relapsed or refractory multiple myeloma | Novartis AG | Secura Bio Inc. | Payment unspecified | 3/12/19 |
| Teva to launch a generic version of Novo Nordisk's Victoza as part of patent litigation settlement | Novo Nordisk A/S | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 3/18/19 |
| Intarcia to develop and commercialize Numab's monospecific and multispecific antibodies for diabetes, obesity and autoimmune diseases; executed its option to in-license ND-016, being developed for the treatment of autoimmune disorders | Numab Therapeutics AG | Intarcia Therapeutics Inc. | $69.60 | 3/5/19 |
| Ocello to provide in vitro research services for Merus' MCLA-158 Biclonics program and other undisclosed Biclonics discovery programs | Ocello BV | Merus BV | $1.14 | 3/28/19 |
| Thea to develop and commercialize Olix's OLX-301A against age-related macular degeneration in EU countries, Middle East and Africa | Olix Pharmaceuticals Inc. | Laboratoires Thea | $2.28 | 3/18/19 |
| Oncodesign and Servier to develop LRRK2 kinase inhibitors derived from Nanocyclix platform for Parkinson’s disease with an option for worldwide rights | Oncodesign Biotechnology SA | Servier SA | $371.96 | 3/11/19 |
| Flow Pharma to use Oncoimmunity's Immuneoprofiler software for the development of FlowVax personalized cancer vaccines | Oncoimmunity AS | Flow Pharma Inc. | Payment unspecified | 3/12/19 |
| Xenetic Biosciences to acquire intellectual property rights from Opko Pharmaceuticals for cancer | Opko Health Inc. | Xenetic Biosciences Inc. | Payment unspecified | 3/1/19 |
| Takeda to evaluate Ovensa's Triozan delivery platform for the delivery of antibody to brain in central nervous system disease model | Ovensa Inc. | Takeda Pharmaceutical Co. Ltd. | Payment unspecified | 3/21/19 |
| Oxford Biomedica and Microsoft to improve gene and cell therapy manufacturing using the cloud and machine learning | Oxford Biomedica plc | Microsoft Research | Payment unspecified | 3/12/19 |
| Parexel Biotech to conduct phase IIa trials for Alzprotect's AZP-2006 for the treatment of progressive supranuclear palsy | Parexel Biotech | Alzprotect | Payment unspecified | 3/22/19 |
| PDC*line Pharma and LG Chem to develop and commercialize PDC*lung cancer vaccine in South Korea with an option in other Asian countries | PDC*Line Pharma | LG Life Sciences Ltd. | $123.23 | 3/20/19 |
| Peptidream and Pola to jointly discover and develop new therapeutics, quasi-drugs, and cosmetics using the peptides | Peptidream Inc. | Pola Chemical Industries Inc. | Payment unspecified | 3/27/19 |
| Mochida to develop and commercialize Pfizer's desvenlafaxine in Japan | Pfizer Inc. | Mochida Pharmaceutical Co. Ltd. | Payment unspecified | 3/29/19 |
| Glycostem and Phio to develop natural killer-cell immunotherapies for cancer using self-delivering RNAi technology | Phio Pharmaceuticals Corp. | Glycostem Therapeutics BV | Payment unspecified | 3/28/19 |
| Medexus Pharmaceuticals to distribute Photonamic’s Gliolan for malignant brain tumors in Canada | Photonamic GmbH & Co. KG | Medexus Pharmaceuticals Inc. | Payment unspecified | 3/4/19 |
| Hesperix to obtain worldwide intellectual property rights from Pharmsynthez for cancer | PJSC Pharmsynthez | Hesperix SA | Unknown | 3/1/19 |
| Polpharma Biologics and Bioeq to develop PB-006 for the treatment of multiple sclerosis | Polpharma Biologics | Bioeq GmbH | Payment unspecified | 3/2/19 |
| PRA Health to conduct phase I clinical study of Kalyra's KP-1199 for pain | PRA Health Sciences | Kalyra Pharmaceuticals | Payment unspecified | 3/19/19 |
| Nordic to commercialize Primex's Ozalin for sedative and anesthetic premedication in France | Primex Pharmaceuticals AG | Nordic Group | Payment unspecified | 3/20/19 |
| Sintetica to commercialize Primex's Ozalin for sedative and anesthetic premedication in the U.K. | Primex Pharmaceuticals AG | Sintetica SA | Payment unspecified | 3/27/19 |
| Nantkwest and Promab Biotechnologies to develop targeted natural killer cell therapeutics for multiple myeloma worldwide | Promab Biotechnologies Inc. | Nantkwest Inc. | Payment unspecified | 3/4/19 |
| Bayer to apply Proteonic's 2G unic technology for recombinant protein production worldwide | Proteonic | Bayer AG | Payment Unspecified | 3/28/19 |
| Pierre Fabre to develop and commercialize Puma's Nerlynx as extended adjuvant for breast cancer in part of Africa and Europe, ex-Russia and Ukraine | Puma Biotechnology Inc. | Pierre Fabre SA | $405.00 | 3/29/19 |
| Panaxia and Rafa to conduct clinical trial for registration to examine medical cannabis through a metered-dose inhaler in cancer patients | Rafa Laboratories Ltd. | Panaxia Pharmaceutical Industries Ltd. | Payment unspecified | 3/4/19 |
| Reform to reduce Astellas' viscosity clinical-stage biological pipeline program using technology platform | Reform Biologics LLC | Astellas Pharma Inc. | Payment unspecified | 3/5/19 |
| Reformation and 180 Therapeutics to promote tissue repair and re-generation by targeting the body's own stem cells | Reformation Pharmaceuticals Corp. | 180 Therapeutics LP | Payment unspecified | 3/15/19 |
| Roche to supply Tecentriq to Infinity to use in MARIO-3 study to evaluate IPI-549 against triple negative breast cancer and renal cell cancer | Roche Holding AG | Infinity Pharmaceuticals Inc. | Payment unspecified | 3/14/19 |
| Chugai to use Rosa's PhysioPD research technology to discover and develop drugs | Rosa & Co. LLC | Chugai Pharmaceutical Co. Ltd. | Payment unspecified | 3/12/19 |
| Samsung Biologics to provide CDO services to Eutilex for developing materials used in cancer immunotherapy medicine | Samsung Biologics Co. Ltd. | Eutilex Co. Ltd. | Payment unspecified | 3/20/19 |
| Hanmi to jointly distribute Santen's Diquas and Diquas-S for dry eye treatments in Korea | Santen Pharmaceutical Co. Ltd. | Hanmi Pharmaceutical Co. Ltd. | Payment unspecified | 3/14/19 |
| Seres Therapeutics and Astrazeneca to develop microbiome therapeutics to augment immune oncology | Seres Therapeutics Inc. | Astrazeneca plc | $20.00 | 3/11/19 |
| Sona Nanotec to improve the performance of Romer Labs' RapidChek SELECT pathogen test kits using its gold nanorods | Sona Nanotech Inc. | Romer Labs Division Holding GmbH | Payment unspecified | 3/7/19 |
| Domainex and Spirochem to discover fragment-based drugs | Spirochem AG | Domainex Ltd. | Payment unspecified | 3/20/19 |
| LG Chem to research, develop and commercialize Sprint's discovery stage program for nonalcoholic steatohepatitis and metabolic disorders worldwide | Sprint Bioscience AB | LG Chem Ltd. | $230.00 | 3/28/19 |
| STA to provide CMC development and manufacturing services to Ark for drugs against viral infection and respiratory disease | STA Pharmaceutical Co. Ltd. | Ark Biosciences | Payment unspecified | 3/6/19 |
| STA Pharmaceutical to provide CDMO services for Beta Pharma's R&D and manufacturing of later phase and commercial production | STA Pharmaceutical Co. Ltd. | Beta Pharma Inc. | Payment unspecified | 3/26/19 |
| Pressure Biosciences and Steinbeis Centre to develop method based on optimizing disease-fighting antibodies | Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry | Pressure Biosciences Inc. | Payment unspecified | 3/4/19 |
| Stridebio and Takeda Pharmaceutical to develop in vivo adeno-associated virus based therapies for Friedreich's ataxia and two additional undisclosed targets worldwide | Stridebio LLC | Takeda Pharmaceutical Co. Ltd. | $710.00 | 3/28/19 |
| Leadxpro to obtain rights to Structura Biotechnology's CryoSPARC software to enhance determination of membrane protein drug targets | Structura Biotechnology Inc. | Leadxpro AG | Payment unspecified | 3/3/19 |
| TOT to develop combined therapy of TAB-008 with KN-046 against cancer | Suzhou Alphamab Co. Ltd. | TOT Biopharm Co. Ltd. | Payment unspecified | 3/8/19 |
| 3sbio and Taiwan Liposome to develop liposomal products for oncology and infectious diseases in mainland China | Taiwan Liposome Co. | 3sbio Inc. | $50.00 | 3/4/19 |
| Newsoara to develop and commercialize Taiwanj's JKB-122 for nonalcoholic fatty liver disease or nonalcoholic steatohepatitis and autoimmune hepatitis in Asia except Taiwan | Taiwanj Pharmaceuticals | Newsoara Biopharma Co. Ltd. | $26.00 | 3/2/19 |
| Petra Pharma to develop, manufacture and commercialize Takeda's serabelisib and two additional PI3K?-specific inhibitors against solid tumor worldwide | Takeda Pharmaceutical Co. Ltd. | Petra Pharma Corp. | Payment unspecified | 3/20/19 |
| Targovax to grant Zelluna Immunotherapy a freedom-to-operate worldwide rights agreement to intellectual property relating to mutant RAS T-cell receptor technology | Targovax AS | Zelluna Immunotherapy | $11.60 | 3/14/19 |
| Xortx Therapeutics signs letter of intent to co-develop Teijin Pharma’s TMX-049 worldwide excluding Japan for the treatment of progressive kidney disease | Teijin Ltd. | Xortx Therapeutics Inc. | Payment unspecified | 3/11/19 |
| Daewoong Pharmaceutical to acquire Korean sales rights of Terahvax’s Vivotif vaccine for typhoid fever | Terahvax | Daewoong Pharmaceutical Co. Ltd. | Payment unspecified | 3/19/19 |
| Alphamab and TOT Biopharm to develop combination therapy of KN-046 and TAB-008 against cancer | TOT Biopharm Co. Ltd. | Alphamab Oncology | Payment unspecified | 3/8/19 |
| Blackthorn Therapeutics and Total Brain to enhance patient selection and development of targeted therapies for neurobehavioral disorders | Total Brain Care Co. Ltd. | Blackthorn Therapeutics Inc. | Payment unspecified | 3/4/19 |
| Twoxar and Ono Pharmaceutical to discover and develop neurological disease treatments worldwide using AI technology | Twoxar Inc. | Ono Pharmaceutical Co. Ltd. | Payment unspecified | 3/18/19 |
| L'Oréal and Ubiome to advance new research on the skin microbiome | Ubiome Inc. | L'Oréal SA | Payment unspecified | 3/8/19 |
| Ubivac and an undisclosed pharma company to develop DPV-007 for oral cancer | Ubivac | Undisclosed | Payment unspecified | 3/5/19 |
| Radiomedix and Vect-Horus to enter into a letter-of-intent to co-develop theranostic agent targeting LDL receptor for glioblastoma multiforme diagnosis and radiotherapy | Vect-Horus | Radiomedix Inc. | Payment unspecified | 3/5/19 |
| Ono Pharmaceutical to use Vect-Horus' technology to transport drugs into the brain for treatment of neurodegenerative disease worldwide | Vect-Horus | Ono Pharmaceutical Co. Ltd. | Payment unspecified | 3/26/19 |
| Pfizer acquires minority stake in Vivet Therapeutics with an acquisition option | Vivet Therapeutics | Pfizer Inc. | $690.29 | 3/20/19 |
| Sagent Pharmaceuticals acquires Xellia Pharmaceuticals' Raleigh manufacturing site | Xellia Phamaceuticals ApS | Sagent Pharmaceuticals Inc. | Payment unspecified | 3/1/19 |
| Alexion and Zealand to discover and develop Peptide therapies for complement-mediated diseases worldwide | Zealand Pharma A/S | Alexion Pharmaceuticals Inc. | $695.00 | 3/20/19 |
| Nippon to distribute Zogenix' Fintepla for Dravet syndrome and Lennox Gastaut syndrome in Japan | Zogenix Inc. | Nippon Shinyaku Co. Ltd. | $128.50 | 3/18/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| TSD Life Science to develop ABL Bio's ABL-201 worldwide | ABL Bio Inc. | TSD Life Sciences Co. Ltd. | Payment unspecified | 4/29/19 |
| ADC Therapeutics and Adagene to develop antibody drug conjugates using Safebody technology against a solid tumor target | Adagene Suzhou Ltd. | ADC Therapeutics Sarl | Payment unspecified | 4/24/19 |
| Undisclosed Switzerland company to commercialize AFT Pharmaceuticals’ Maxigesic for treatment of pain in Switzerland | AFT Pharmaceuticals Ltd. | Undisclosed | Payment unspecified | 4/12/19 |
| Medochemie to commercialize AFT Pharmaceuticals’ Maxigesic for treatment of pain in Cyprus | AFT Pharmaceuticals Ltd. | Medochemie Ltd. | Payment unspecified | 4/12/19 |
| Agilent to supply oligo microarrays to Somalogic for use in its Somascan assay | Agilent Technologies Inc. | Somalogic Inc. | Payment unspecified | 4/30/19 |
| Agomab and Argen-x to develop hepatocyte growth factor-mimetic agonistic monoclonal antibodies against fibrosis | Agomab Therapeutics NV | Argen-x NV | Payment unspecified | 4/1/19 |
| Vifor Pharma amended the agreement to sell Akebia's vadadustat to certain third-party dialysis organizations for use in the U.S. | Akebia Therapeutics Inc. | Vifor Pharma Ltd. | $5.00 | 4/8/19 |
| Allele and SCM to develop allogenic therapies using induced pluripotent stem cell technology for diabetes | Allele Biotechnology and Pharmaceuticals Inc. | SCM Lifescience Ltd. | Payment unspecified | 4/15/19 |
| Regeneron and Alnylam to discover, develop and commercialize RNAi therapeutics for ocular and central nervous system diseases, worldwide | Alnylam Pharmaceuticals Inc. | Regeneron Pharmaceuticals Inc. | $1,435.00 | 4/8/19 |
| Tetra Bio-Pharma and Altus to form joint venture to develop cannabinoid receptor targeted therapeutics for pain, oncology and ophthalmology | Altus Formulation Inc. | Tetra Bio-Pharma Inc. | Payment unspecified | 4/29/19 |
| CSC to promote and commercialize APR Applied Pharma's Diclofenac 50 mg powder oral solution for migraine in Russia | APR Applied Pharma Research SA | CSC Pharmaceuticals Handels GmbH | Payment unspecified | 4/3/19 |
| Xoma to acquire royalty rights of five Aronora's hematology assets, including BAY-1213790, BAY-1831865, AB-023, AB-002 and AB-054 | Aronora Inc. | Xoma Corp. | $434.00 | 4/7/19 |
| Arteaus sells royalty interest in Emgality to Royalty Pharma | Arteaus Therapeutics LLC | Royalty Pharma | $260.00 | 4/1/19 |
| Eli Lilly and Avidity Biosciences to discover, develop and commercialize treatments for immunology and other selected indications worldwide | Avidity Biosciences LLC | Eli Lilly and Co. | $440.00 | 4/22/19 |
| Hope Medicine to develop and commercialize Bayer's BAY-1158061 directed against PRL receptor for male and female pattern hair loss and endometriosis worldwide | Bayer AG | Hope Medicine Inc. | Payment unspecified | 4/7/19 |
| Beigene to develop and commercialize Bioatla’s BA-3071 as a monotherapy and in combination with tislelizumab for cancer worldwide | Bioatla LLC | Beigene Co. Ltd. | $269.00 | 4/9/19 |
| Biodextris to provide services related to development and manufacturing of clinical materials of I-Mab Biopharma's nasal adjuvants to treat neurological diseases | Biodextris | I-Mab Biopharma Co. Ltd. | Payment unspecified | 4/5/19 |
| Biorasi to provide clinical development services to Ivix's Libicore in the U.S. and European Union | Biorasi LLC | Ivix Ltd. | Payment unspecified | 4/23/19 |
| Biosyn to supply keyhole kimpet hemocyanin for the manufacture of Neovacs' IFN alpha kinoid | Biosyn Arzneimittel GmbH | Neovacs SA | Payment unspecified | 4/1/19 |
| Elpiscience Biopharma and Bio-Techne to develop anticancer therapeutics | Bio-Techne Corp. | Elpiscience Biopharmaceuticals Inc. | Payment unspecified | 4/22/19 |
| Casi to develop and commercialize Black Belt's TSK-011010 against multiple myeloma worldwide | Black Belt Therapeutics Ltd. | Casi Pharmaceuticals Inc. | $7.95 | 4/16/19 |
| Incyte and Briacell to evaluate the effects of Bria-IMT with INCMGA-0012 and epacadostat against advanced breast cancer | Briacell Therapeutics Corp. | Incyte Corp. | Payment unspecified | 4/2/19 |
| BMS to conduct a phase I/II clinical trial of Famewave's CM-24 in combination with nivolumab against non-squamous non-small cell lung cancer | Bristol-Myers Squibb Co. | Famewave Ltd. | Payment unspecified | 4/12/19 |
| Regeneron to use Calixar's membrane protein stabilization technology to develop antibodies against undisclosed targets | Calixar SAS | Regeneron Pharmaceuticals Inc. | Payment unspecified | 4/29/19 |
| CKD expanded the existing agreement to distribute Can-Fite's Namodenoson against nonalcoholic steatohepatitis in South Korea | Can-Fite Biopharma Ltd. | Chong Kun Dang Pharmaceutical Corp. | $6.00 | 4/15/19 |
| Catalent to provide manufacture and supply services for phase II clinical trial of MGB Biopharma’s MGB-BP-3 against Clostridium difficile associated diarrhea | Catalent Inc. | MGB Biopharma Ltd. | Payment unspecified | 4/25/19 |
| Cellgen Diagnostics and GTC to provide services to accelerate development of companion tests for various oncology therapeutics | Cellgen Diagnostics | Genomic Testing Cooperative | Payment unspecified | 4/3/19 |
| Celltrion to develop, manufacture and supply four antibody drug conjugates against breast cancer, including HER2, CD20 and two additional targets using Iprogen's antibody delivery enhancing domain technology | Celltrion Inc. | Iprogen Biotech Inc. | Payment unspecified | 4/8/19 |
| Chr Hansen and Lonza to form a 50/50 joint venture as a contract development and manufacturing organization for live biotherapeutic products | Chr Hansen Group | Lonza AG | Payment unspecified | 4/2/19 |
| Cantabria to commercialize Crescita's Pliaglis for dermatology in Italy, Portugal, France and Spain | Crescita Therapeutics Inc. | Cantabria Labs Spain | $2.84 | 4/25/19 |
| Orpharma to market Cycle Pharmaceuticals' Nityr for type I tyrosinemia in Australia and New Zealand | Cycle Pharmaceuticals Ltd. | Orpharma Pty Ltd. | Payment unspecified | 4/29/19 |
| Dnanexus and Sutter Health to conduct research on clinico-genomic multiple sclerosis study | Dnanexus Inc. | Sutter Health | Payment unspecified | 4/15/19 |
| Editas and Bluerock to discover and develop new engineered cell medicines in neurology, cardiology, immunology and oncology | Editas Medicine Inc. | Bluerock Therapeutics | Payment unspecified | 4/3/19 |
| Adare to acquire rights for Egalet’s Parvulet technology platform including related intellectual property to develop products worldwide | Egalet Corp. | Adare Pharmaceuticals Inc. | Payment unspecified | 4/15/19 |
| Sandoz to commercialize Eirgenix's trastuzumab biosimilar against HER2+ breast tumor worldwide, excluding China and Taiwan | Eirgenix Inc. | Sandoz International GmbH | Payment unspecified | 4/30/19 |
| Advanz Pharma to acquire Eisai's salagen and panretin against Kaposi's sarcoma and dry mouth | Eisai Co. Ltd. | Advanz Pharma Corp. | $33.30 | 4/1/19 |
| Nippon Kayaku to commercialize Eli Lilly's necitumumab for metastatic non-small-cell lung cancer in Japan | Eli Lilly and Co. | Nippon Kayaku Co. Ltd. | Payment unspecified | 4/22/19 |
| Eddingpharm to acquire Eli Lilly's antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China | Eli Lilly and Co. | Eddingpharm Inc. | $375.00 | 4/22/19 |
| Takeda to acquire an option to use Emendobio's Omni technology for gene editing | Emendobio Inc. | Takeda Pharmaceutical Co. Ltd. | Payment unspecified | 4/24/19 |
| Aurora to use Enwave's radiant energy vacuum technology for cannabis production in the European Union excluding Portugal | Enwave Corp. | Aurora Cannabis Inc. | Payment unspecified | 4/26/19 |
| Thermo Fisher Scientific to use Epicypher’s sample normalization and antibody profiling for chromatin immunoprecipitation technology to deliver antibodies for histone post-translational modifications | Epicypher Inc. | Thermo Fisher Scientific Inc. | Payment unspecified | 4/24/19 |
| Esteve Quimica to supply vadadustat API to Akebia | Esteve Quimica SA | Akebia Therapeutics Inc. | Payment unspecified | 4/9/19 |
| Orgenesis and Excellabio to develop Bioxome technology to produce exosomes against liver fibrosis, aesthetic indications and central nervous system disorder | Excellabio LLC | Orgenesis Inc. | Payment unspecified | 4/11/19 |
| Sichuan Haisco to develop ExIthera's EP-7041 for knee injury in China | ExIthera Pharmaceuticals Inc. | Sichuan Haisco Pharmaceutical Co. Ltd. | $6.00 | 4/2/19 |
| Macrogen and Exosome Plus to develop exosome-based disease diagnosis and treatment solutions | Exosome Plus | Macrogen Inc. | Payment unspecified | 4/19/19 |
| Roche to spinout Nimble Therapeutics to accelerate chemical synthesis technology for the discovery and development of macrocyclic peptidomimetics | F. Hoffmann-La Roche AG | Nimble Therapeutics Inc. | Payment unspecified | 4/30/19 |
| Castle Creek Pharmaceuticals to develop and commercialize Fibrocell Science's FCX-007 gene therapy for the treatment of recessive dystrophic epidermolysis bullosa in the U.S. | Fibrocell Science Inc. | Castle Creek Pharmaceuticals LLC | $135.00 | 4/15/19 |
| Basilea to discover, develop and commercialize new antibiotic classes using Forge's Blacksmith metalloenzyme chemistry platform against infectious disease | Forge Therapeutics Inc. | Basilea Pharmaceutica International Ltd. | $334.00 | 4/24/19 |
| Brammer to manufacture and supply Freeline's FLT-180a for hemophilia B | Freeline Therapeutics | Brammer Biopharmaceuticals LLC | Payment unspecified | 4/30/19 |
| Clinigen to commercialize GC Pharma's Hunterase for the treatment of Hunter syndrome in Japan | GC Pharma | Clinigen Group plc | Payment unspecified | 4/3/19 |
| Gemabiotech entered to manufacture and supply active pharmaceutical ingredient for Savara’s Molgradex | Gemabiotech SA | Savara Inc. | Payment unspecified | 4/26/19 |
| Fulcrum Therapeutics to develop and commercialize GSK's losmapimod for facioscapulohumeral muscular dystrophy worldwide | Glaxosmithkline plc | Fulcrum Therapeutics Inc. | Payment unspecified | 4/23/19 |
| Kaken Pharmaceutical to develop and commercialize Hitgen's small molecule drugs against an undisclosed target using DNA-encoded library design, synthesis and screening platform | Hitgen Ltd. | Kaken Pharmaceutical Co. Ltd. | Payment unspecified | 4/10/19 |
| Johnson & Johnson and Holobiome to collaborate on development of bacterial consortia to treat digestive disorders | Holobiome Inc. | Johnson & Johnson | Payment unspecified | 4/2/19 |
| Thyas to use ID Pharma's Cytotune-Ips tecnology to manufacture differentiated induced pluripotent stem cells against cancer in Japan | ID Pharma Co. Ltd. | Thyas Co. Ltd. | Payment unspecified | 4/12/19 |
| Janssen Pharmaceutica to use Iktos’ artificial intelligence technology for application in small molecule drug discovery projects | Iktos SAS | Janssen Pharmaceutica NV | Payment unspecified | 4/29/19 |
| Roche to evaluate I-Mab Biopharma's TJD-5 in combination with atezolizumab against cancer | I-Mab Biopharma Co. Ltd. | Roche Holding AG | Payment unspecified | 4/10/19 |
| Spectrum to acquire Immungene's FIT technology platform and to develop two early stage therapies against B-cell lymphoma | Immungene Inc. | Spectrum Pharmaceuticals Inc. | $159.00 | 4/15/19 |
| Immunomedics to promote Janssen's erdafitinib for metastatic urothelial cancer in the U.S. | Immunomedics Inc. | Janssen Biotech Inc. | Payment unspecified | 4/8/19 |
| Everest Medicines to develop and commercialize Immunomedics' sacituzumab govitecan against solid tumors in certain Asian countries | Immunomedics Inc. | Everest Medicines | $835.00 | 4/29/19 |
| Aqilion and Immunscape to evaluate and develop drug development project | Immunscape AB | Aqilion AB | Payment unspecified | 4/25/19 |
| Evotec and Indivumed to discover therapeutics for the treatment of colorectal cancer | Indivumed GmbH | Evotec SE | Payment unspecified | 4/11/19 |
| Variant to develop and commercialize Inflamacore's IC-100 for inflammatory renal and autoimmune diseases worldwide | Inflamacore LLC | Variant Pharmaceuticals Inc. | Payment unspecified | 4/22/19 |
| Gilead and Insitro to discover and develop therapies using insitro human platform for nonalcoholic steatohepatitis | Insitro | Gilead Sciences Inc. | $1,050.00 | 4/16/19 |
| International Isotopes to provide contract manufacturing and supply services to Progenics for Azedra and other iodine products | International Isotopes Inc. | Progenics Pharmaceuticals Inc. | Payment unspecified | 4/9/19 |
| Ips Academia Japan to grant Heartseed worldwide rights to use induced pluripotent stem cell-derived cardiomyocytes products for regenerative therapy | Ips Academia Japan Inc. | Heartseed Inc. | Payment unspecified | 4/15/19 |
| Ironwood Pharmaceuticals to spin out Cyclerion Therapeutics for the discovery, development and commercialization of soluble guanylate cyclase modulators for serious and orphan diseases | Ironwood Pharmaceuticals Inc. | Cyclerion Therapeutics Inc. | Payment unspecified | 4/1/19 |
| Ohara and J-Pharma to jointly develop JPH-203 against solid tumors including advanced biliary cancer in Asia, including Japan and China, as well as Africa | J-Pharma Co. Ltd. | Ohara Pharmaceutical Co. Ltd. | Payment unspecified | 4/25/19 |
| Bayer and Khloris Biosciences to develop induced pluripotent stem cells as anti-cancer vaccines | Khloris Biosciences Inc. | Bayer AG | Payment unspecified | 4/2/19 |
| Lakepharma to provide integrated discovery and development services to Twist Bioscience to discover antibody against protein drug targets | Lakepharma Inc. | Twist Bioscience Corp. | Payment unspecified | 4/4/19 |
| Nobelpharma to develop LTT Bio-Pharma's LT-5001 for neurological diseases | LTT Bio-Pharma Co. Ltd. | Nobelpharma Co. Ltd. | Payment unspecified | 4/9/19 |
| Lupin and Natco to jointly commercialize bosentan tablets for pulmonary arterial hypertension | Lupin Ltd. | Natco Pharma Ltd. | Payment unspecified | 4/29/19 |
| Cytovant to develop and commercialize Medigene's T cell immunotherapies, including NY-ESO-1, DC vaccine and T-cell receptors for two additional targets against cancer in East Asia | Medigene AG | Cytovant Sciences HK Ltd. | $1,010.00 | 4/4/19 |
| Aresus Pharma acquires worldwide excluding U.S. rights for Medigene's Veregen | Medigene AG | Aresus Pharma GmbH | $8.80 | 4/8/19 |
| Bausch Health to develop and commercialize MTPC's MT-1303 for autoimmune diseases worldwide, except Japan and other Asian countries | Mitsubishi Tanabe Pharma Corp. | Bausch Health Companies Inc. | Payment unspecified | 4/25/19 |
| Salix to develop and commercialize MTPC's MT-1303 against ulcerative colitis worldwide, excluding Japan and other countries in Asia | Mitsubishi Tanabe Pharma Corp. | Salix Pharmaceuticals Ltd. | Payment unspecified | 4/26/19 |
| Virpax to use Nanomerics’ molecular envelope technology to develop intranasal formulation of NES-100 for chronic pain worldwide | Nanomerics Ltd. | Virpax Pharmaceuticals Inc. | Payment unspecified | 4/16/19 |
| Novartis spins off eye care division, Alcon | Novartis AG | Alcon Inc. | Payment unspecified | 4/9/19 |
| Novo Nordisk to initiate a proof-of-concept study by combining semaglutide with Gilead’s cilofexor and firsocostat in nonalcoholic steatohepatitis patients | Novo Nordisk A/S | Gilead Sciences Inc. | Payment unspecified | 4/12/19 |
| Nuformix and Ebers Tech to develop and commercialize cannabinoid therapeutics | Nuformix Ltd. | Ebers Tech Inc. | $66.40 | 4/9/19 |
| Mati Therapeutics to settle litigation with Ocular Therapeutix related to Dextenza for eye disease | Ocular Therapeutix Inc. | Mati Therapeutics Inc. | Payment unspecified | 4/30/19 |
| Chugai to develop, manufacture and market Oncolys' Telomelysin against cancer in Japan and Taiwan | Oncolys Biopharma Inc. | Chugai Pharmaceutical Co. Ltd. | $465.74 | 4/8/19 |
| Tetra Bio-Pharma to evaluate Ovensa's Triozan delivery platform for targeted delivery of cannabinoids to brain tumor cells | Ovensa Inc. | Tetra Bio-Pharma Inc. | Payment unspecified | 4/11/19 |
| Luye Pharma to develop and commercialize Pharmamar’s Zepsyre for small-cell lung cancer in China | Pharmamar SA | Luye Pharma Group Ltd. | $5.00 | 4/26/19 |
| Immunoforge to develop and commercialize Phasebio's PB-1023 for all diseases, including sarcopenia-related diseases worldwide | Phasebio Pharmaceuticals Inc. | Immunoforge Co. Ltd. | Payment unspecified | 4/9/19 |
| Wacker Biotech and Phasebio to manufacture and commercialize PB-2452 against bleeding | Phasebio Pharmaceuticals Inc. | Wacker Biotech GmbH | Payment unspecified | 4/23/19 |
| Encore to market and distribute Promius' Sernivo spray 0.05%, Promiseb topical cream and Trianex 0.05% in the U.S. | Promius Pharma LLC | Encore Dermatology Inc. | Payment unspecified | 4/2/19 |
| Cipla to co-develop and commercialize Pulmatrix's pulmazole for allergic bronchopulmonary aspergillosis worldwide | Pulmatrix Inc. | Cipla Ltd. | $22.00 | 4/1/19 |
| Puretech and Boehringer to develop immuno-oncology products using Puretech’s lymphatic targeting technology for immune modulation | Puretech Health plc | Boehringer Ingelheim International GmbH | $226.00 | 4/17/19 |
| Teva Pharmaceutical to develop Recro's Verapamil SR capsules for essential hypertension in the U.S. | Recro Gainesville LLC | Teva Pharmaceutical Industries Ltd. | Unknown | 4/16/19 |
| Fosun Pharma to develop, manufacture and commercialize Reneuron's CTX and human retinal progenitor cell therapy programs against disability caused by stroke and retinitis pigmentosa in China | Reneuron Group plc | Shanghai Fosun Pharmaceutical (Group) Co. Ltd. | $112.70 | 4/9/19 |
| Biosense to develop and commercialize Rexahn's RX-3117 against pancreatic cancer and other cancers in Republic of Singapore, China, Hong Kong, Macau and Taiwan with an option to develop the product for additional indications | Rexahn Pharmaceuticals Inc. | Biosense Global LLC | $229.00 | 4/16/19 |
| Oncology Venture to obtain an option to acquire commercial rights of R-Pharm's Ixempra for breast cancer in the European Union | R-Pharm | Oncology Venture A/S | Payment unspecified | 4/4/19 |
| Samsung Biologics to provide manufacturing services for Cytodyn's biodrugs, including Leronlimab for human immunodeficiency virus infection | Samsung Biologics Co. Ltd. | Cytodyn Inc. | $277.00 | 4/1/19 |
| Ascentage to evaluate APG-1387 in combination with Shanghai Junshi Biosciences' toripalimab against solid and hematological tumors | Shanghai Junshi Biosciences Co. Ltd. | Ascentage Pharma Group Corp. Ltd. | Payment unspecified | 4/8/19 |
| HaiHe to evaluate combination of simmitecan hydrochloride with Junshi Biosciences's toripalimab and lucitanib hydrochloride with toripalimab for solid tumors | Shanghai Junshi Biosciences Co. Ltd. | Haihhe Biopharma | Payment unspecified | 4/23/19 |
| Sandoz to sell Shionogi's Rizmoic for opioid-induced constipation in Germany, the U.K., and the Netherlands | Shionogi and Co. Ltd. | Sandoz International GmbH | Payment unspecified | 4/11/19 |
| Biodelivery Sciences International to commercialize Shionogi’s Symproic in the U.S. and Puerto Rico for the treatment of opioid induced constipation | Shionogi Inc. | Biodelivery Sciences International Inc. | $30.00 | 4/4/19 |
| Shanghai Miracogen to use Synaffix's Glycoconnect and Hydraspace technologies for the development and commercialization of antibody drug conjugate product against cancer | Synaffix BV | Shanghai Miracogen Biotechnology Co. Ltd. | $125.00 | 4/10/19 |
| Meroven to market Taimed Biologics' ibalizumab against HIV infection in Middle East and North Africa | Taimed Biologics Inc. | Meroven Ltd. | Payment unspecified | 4/29/19 |
| Tessa and Merck to evaluate combination of TT-12 and Keytruda against metastatic cervical cancer | Tessa Therapeutics Pte Ltd. | Merck & Co. Inc. | Payment unspecified | 4/15/19 |
| Novasep to gain rights to use DNA Flap technology from Theravectys for manufacturing GMP grade lentiviral vectors worldwide | Theravectys | Novasep | Payment unspecified | 4/16/19 |
| Pandion to use Twist Bioscience's antibody optimization technology to develop bispecific antibodies to treat autoimmune and inflammatory disease | Twist Bioscience Corp. | Pandion Therapeutics Inc. | Payment unspecified | 4/11/19 |
| SK Biopharmaceuticals and Twoxar to discover and develop treatments for non-small-cell lung cancer | Twoxar Inc. | SK Biopharmaceuticals | Payment unspecified | 4/17/19 |
| U.S. Bioservice to distribute Biocodex's Diacomit for the treatment of seizures associated with Dravet syndrome | U.S. Bioservices | Biocodex USA | Payment unspecified | 4/24/19 |
| U.S. Bioservices to dispense Janssen Biotech's erdafitinib for the treatment of adults with locally advanced or metastatic urothelial carcinoma | U.S. Bioservices | Janssen Biotech Inc. | Payment unspecified | 4/26/19 |
| Dr. Reddy’s Laboratories to acquire 42 approved, non-marketed abbreviated new drug applications in the U.S. from an undisclosed company | Undisclosed | Dr. Reddy's Laboratories Ltd. | Payment unspecified | 4/13/19 |
| ANI Pharmaceuticals to distribute an undisclosed U.S. based manufacturer's injectable product | Undisclosed | ANI Pharmaceuticals Inc. | $2.00 | 4/15/19 |
| Urogen Pharma and Janssen to conduct an early stage feasibility evaluation in an undisclosed therapeutic area | Urogen Pharma Ltd. | Janssen Research and Development LLC | Payment unspecified | 4/23/19 |
| Velabs and Chiome to discover modulatory and functional antibodies for one of Chiome’s G-protein-coupled receptor target genes worldwide | Velabs Therapeutics GmbH | Chiome Bioscience Inc. | Payment unspecified | 4/24/19 |
| Virpax and Kannaba Technologies to research, develop and commercialize cannabinoid based products using combined delivery technolgoy against pain | Virpax Pharmaceuticals | Kannaba Technologies Inc. | Payment unspecified | 4/8/19 |
| Wuxi to provide development and manufacturing services for NBE-Therapeutics' NBE-002 for cancer | Wuxi Biologics | Kannaba Technologies Inc. | Payment unspecified | 4/8/19 |
| Xcella and Teva to identify rare antibodies against an undisclosed target using xploration single cell screening platform | Xcella Biosciences Inc. | Teva Pharmaceuticals Australia Pty Ltd. | Payment unspecified | 4/9/19 |
| Astellas Pharma to access Xencor’s Xmab bispecific Fc domain technology to generate, develop and commercialize bispecific antibodies for the treatment of cancer worldwide | Xencor Inc. | Astellas Pharma Inc. | Payment unspecified | 4/2/19 |
| Ohara to acquire patent rights related to Zenyaku's ZSTK-474 worldwide | Zenyaku Kogyo Co. Ltd. | Ohara Pharmaceutical Co. Ltd. | Payment unspecified | 4/19/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Abbvie to settle patent litigation with BI for intellectual property related to Humira in the U.S. | Abbvie Inc. | Boehringer Ingelheim International GmbH | Payment unspecified | 5/14/19 |
| Abcellera to develop a platform capable of creating field-ready medical countermeasures within 60 days of a pandemic viral outbreak using Ichor's Trigrid electroporation-mediated nucleic acid administration platform | Abcellera Biologics Inc. | Ichor Medical Systems Inc. | Payment unspecified | 5/10/19 |
| Accredo to supply Titan Pharmaceuticals' Probuphine for opioid use disorder in the U.S. | Accredo Health Group Inc. | Titan Pharmaceuticals Inc. | Payment unspecified | 5/13/19 |
| Forty Seven and Acerta Pharma to evaluate immune oncology triple combination drug in diffuse large B cell lymphoma | Acerta Pharma BV | Forty Seven Inc. | Payment unspecified | 5/10/19 |
| Nordic Bioscience to evaluate AKL Research and Development's Appa for osteoarthritis | AKL Research and Development Ltd. | Nordic Bioscience A/S | Payment unspecified | 5/2/19 |
| Adaptimmune and Alpine Immune Sciences to develop next-generation human induced pluripotent stem cell-derived allogeneic specific peptide enhanced affinity receptor T-cell products for cancer, with an option for worldwide rights | Alpine Immune Sciences Inc. | Adaptimmune Therapeutics plc | $290.00 | 5/14/19 |
| Altasciences to provide safety testing, IND enabling study and clinical trial services for Leidos’ RAP-103 peptide | Altasciences Clinical Research | Leidos Inc. | Payment unspecified | 5/22/19 |
| ACTC and Eisai to evaluate BAN-2401 for Alzheimer's disease | Alzheimer's Clinical Trials Consortium | Eisai Co. Ltd. | Payment unspecified | 5/10/19 |
| Boehringer to evaluate a phase Ib (KISIMA-01) study of Amal Therapeutics' ATP-128 in combination with BI-754091 against stage IV colorectal cancer | Amal Therapeutics SA | Boehringer Ingelheim International GmbH | Payment unspecified | 5/2/19 |
| Lupin to market Aptissen's products in Canada | Aptissen SA | Lupin Ltd. | Payment unspecified | 5/9/19 |
| Intelgenx and Aquestive to co-develop tadalafil oral films for erectile dysfunction worldwide | Aquestive Therapeutics Inc. | Intelgenx Technologies Corp. | Payment unspecified | 5/8/19 |
| Modulus to use Astellas' drug discovery data for small molecule discovery | Astellas Pharma Inc. | Modulus Discovery Inc. | Payment unspecified | 5/30/19 |
| Astrazeneca and Sensei to conduct two phase II combination studies of SNS-301 with Imfinzi in head and neck cancer patients | Astrazeneca plc | Sensei Biotherapeutics Inc. | Payment unspecified | 5/7/19 |
| Medicago to use Atum's Genegps technology for development of virus-like particle vaccine and antibody therapeutics | Atum | Medicago Inc. | Payment unspecified | 5/28/19 |
| Aurora Cannabis and UFC to advance clinical research on hemp derived cannabidiol products for pain, inflammation and injury | Aurora Cannabis Inc. | Ultimate Fighting Championship | Payment unspecified | 5/21/19 |
| Be The Match Biotherapies to provide end-to-end support services for clinical development of Poseida's BCMA and PSMA chimeric antigen receptor T cell programs | Be The Match Biotherapies | Poseida Therapeutics Inc. | Payment unspecified | 5/14/19 |
| Be The Match to support phase III clinical studies of Kiadis' ATIR-101 as an adjunctive treatment in haploidentical hematopoietic stem cell transplantation for blood cancer | Be The Match Biotherapies | Kiadis Pharma Netherlands BV | Payment unspecified | 5/22/19 |
| Verve Therapeutics to access Beam Therapeutics' base editing, gene editing and delivery technologies for human therapeutic applications against certain cardiovascular targets | Beam Therapeutics | Verve Therapeutics Inc. | Payment unspecified | 5/7/19 |
| Neuraxpharm to market Bened Biomedical's PS-128 for central nervous system disorders in Europe | Bened Biomedical Co. Ltd. | Neuraxpharm Arzneimittel GmbH and Co. | Payment unspecified | 5/28/19 |
| Astrazeneca and Benevolentai to use artificial intelligence and machine learning to develop treatments against chronic kidney disease and idiopathic pulmonary fibrosis | Benevolentai Ltd. | Astrazeneca plc | Payment unspecified | 5/1/19 |
| Beam and Bio Palette to cross-license intellectual property rights of genome-based editing technologies to develop human and microbiome-related therapeutics | Bio Palette Co. Ltd. | Beam Therapeutics | Payment unspecified | 5/31/19 |
| Biotem and Calixar to develop therapeutic antibodies against membrane targets | Biotem | Calixar | Payment unspecified | 5/20/19 |
| Caris to develop companion diagnostic for Debiopharm to detect rare FGFR fusions using molecular intelligence transcriptome to evaluate Debio-1347 in patients for a phase II trial against solid tumor | Caris Life Sciences | Debiopharm SA | Payment unspecified | 5/30/19 |
| Eli Lilly to develop and commercialize Centrexion's CNTX-0290 for chronic pain worldwide | Centrexion Therapeutics Corp. | Eli Lilly and Co. | $997.50 | 5/28/19 |
| Novartis to use Codexis' Codeevolver protein engineering platform to develop performance enzymes | Codexis Inc. | Novartis AG | Payment unspecified | 5/15/19 |
| Westmed Medical and Columbia Care to study the therapeutic effectiveness and safety of medical cannabis as a pain reliever in rheumatologic patients with inflammatory arthritis | Columbia Care LLC | Westmed Medical Group | Payment unspecified | 5/21/19 |
| Corerx to manufacture and supply Aimmune’s AR-101 against peanut allergy | Corerx Inc. | Aimmune Therapeutics Inc. | Payment unspecified | 5/14/19 |
| Aslan to develop and commercialize CSL's ASLAN-004 for atopic dermatitis worldwide | CSL Ltd. | Aslan Pharmaceuticals Pte Ltd. | $780.00 | 5/31/19 |
| Takeda to develop Curadev's CRD-5500 for cancer | Curadev Pharma Pvt. Ltd. | Takeda Pharmaceutical Co. Ltd. | Payment unspecified | 5/8/19 |
| Meroven to market and distribute Cure Pharmaceutical's Spee-D in the U.S. | Cure Pharmaceutical Holding Corp. | Meroven LLC | Payment unspecified | 5/3/19 |
| Denovium to combine artificial intelligence platform with Maxygen’s molecular breeding technology for protein engineering | Denovium Inc. | Maxygen LLC | Payment unspecified | 5/22/19 |
| Dyadic and Alphazyme to develop medicines and diagnostic tools using gene expression platform | Dyadic International Inc. | Alphazyme LLC | Payment unspecified | 5/6/19 |
| Dyadic and Serum Institute to develop and manufacture twelve antibodies and vaccine using C1 gene expression platform | Dyadic International Inc. | Serum Institute of India Ltd. | Payment unspecified | 5/7/19 |
| Anji Pharmaceuticals acquires worldwide development rights for Metformin DR from Elcelyx Therapeutics against type II diabetes patients with chronic kidney disease | Elcelyx Therapeutics Inc. | Anji Pharmaceuticals Inc. | Payment unspecified | 5/29/19 |
| Eurofins to provide genetic biomarker testing to support Adial’s AD-04 phase III clinical trial for alcohol use disorder | Eurofins Scientific | Adial Pharmaceuticals LLC | Payment unspecified | 5/7/19 |
| ASC Therapeutics to use Expression Therapeutics’ critical technologies for hemophilia A gene therapy | Expression Therapeutics LLC | ASC Therapeutics | Payment unspecified | 5/16/19 |
| Valirx to acquire worldwide granted patents and intellectual property assets from FIT Biotech | FIT Biotech Oyj plc | Valirx plc | $0.01 | 5/2/19 |
| Bayer and Foundation Medicine to develop and commercialize next generation sequencing-based companion diagnostics for Vitrakvi and other cancer therapies worldwide | Foundation Medicine Inc. | Bayer AG | Payment unspecified | 5/29/19 |
| FSD Pharma and Solarvest Bioenergy to develop algae-based pharmaceutical grade cannabinoids | FSD Pharma Inc. | Solarvest Bioenergy Inc. | $1.00 | 5/7/19 |
| Oncosec to acquire Gaeta Therapeutics' patents and applications related to combination of IL-12 DNA and checkpoint inhibitor therapies against cancer worldwide | Gaeta Therapeutics Ltd. | Oncosec Medical Inc. | Payment unspecified | 5/22/19 |
| Genocea to evaluate Iovance's tumor-infiltrating lymphocyte products using its neoantigen identification platform, Atlas platform | Genocea Biosciences Inc. | Iovance Biotherapeutics Inc. | Payment unspecified | 5/15/19 |
| Gilead Sciences and Goldfinch Bio to discover, develop and commercialize new therapies for diabetic kidney disease and orphan kidney disease | Goldfinch Bio Inc. | Gilead Sciences Inc. | $2,059.00 | 5/8/19 |
| Boehringer Ingelheim and Gubra to develop poly-agonist peptides for obesity | Gubra Aps | Boehringer Ingelheim International GmbH | $272.51 | 5/29/19 |
| An undisclosed pharmaceutical company to use Harbour Biomed's HCAb transgenic mouse platform to discover, develop and commercialize antibodies against cancer | Harbour Biomed Ltd. | Undisclosed Pharmaceutical Company | Payment unspecified | 5/28/19 |
| Harbour Biomed and Chia Tai Tianqing to discover, develop and commercialize biologics for multiple therapeutic targets in oncology and immunology in multiple territories | Harbour Biomed Ltd. | Chia Tai Tianqing Pharmaceutical Group Co. Ltd. | Payment unspecified | 5/5/19 |
| Huons and Genexine to sign memorandum of understanding to develop therapeutics for rare diseases | Huons Co. Ltd. | Genexine Co. Ltd. | Payment unspecified | 5/17/19 |
| Exelixis and Iconic Therapeutics to develop an antibody drug conjugate program for cancer and an option to license ICON-2 | Iconic Therapeutics Inc. | Exelixis Inc. | $7.50 | 5/16/19 |
| Ilera and Ethicann to develop and manufacture botanical THC against chemotherapy induced nausea and vomiting | Ilera Healthcare | Ethicann Pharmaceuticals Inc. | Payment unspecified | 5/22/19 |
| A privately held biotechnology company to acquire Immunocellular's ICT-107, ICT-121, ICT-140 clinical and preclinical programs, intellectual property, technology and know-how | Immunocellular Therapeutics Ltd. | Undisclosed | $1.00 | 5/8/19 |
| GE healthcare and Indi Molecular to develop PET tracer candidates based on PCC technology to identify cytotoxic T-cell markers in immunotherapy | Indi Molecular Inc. | GE Healthcare | Payment unspecified | 5/14/19 |
| HLS Therapeutics to commercialize Indivior's Perseris for schizophrenia in Canada | Indivior plc | HLS Therapeutics Inc. | $5.00 | 5/9/19 |
| Chiesi Farmaceutici to acquire an option to develop and commercialize Inhibrx’s INBRX-101 outside of the U.S. and Canada for alpha-1 antitrypsin deficiency | Inhibrx LLC | Chiesi Farmaceutici SpA | $172.50 | 5/30/19 |
| Innovation and undisclosed pharmaceutical company to sign non-binding term sheet to develop and commercialize Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis worldwide | Innovation Pharmaceuticals Inc. | Undisclosed | Payment unspecified | 5/16/19 |
| Merck to explore Intec Pharma’s accordion pill drug delivery platform for an undisclosed program | Intec Pharma Ltd. | Merck & Co. Inc. | Payment unspecified | 5/16/19 |
| Myungmoon Pharm to commercialize Kerastem’s hair growth therapy in South Korea, China and ASEAN member states | Kerastem Technologies | Myungmoon Pharm Co. Ltd. | $140.00 | 5/14/19 |
| Kite Pharma to evaluate Yescarta with Humanigen’s Lenzilumab in phase I/II study in patients with relapsed or refractory diffuse large B-cell lymphoma | Kite Pharma Inc. | Humanigen Inc. | Payment unspecified | 5/31/19 |
| Kymera and Vertex to discover and develop small molecule protein degraders using Pegasus drug discovery platform for multiple targets | Kymera Therapeutics LLC | Vertex Pharmaceuticals Inc. | $1,070.00 | 5/15/19 |
| Motif Bio to assess delivery of LMS-611 with Lamellar Biomedical's lamellasome technology for cystic fibrosis | Lamellar Biomedical Ltd. | Motif Bio plc | Payment unspecified | 5/1/19 |
| Cumulus Oncology to develop and commercialize Ligand Pharmaceuticals’ VER-250840 for cancer worldwide | Ligand Pharmaceuticals Inc. | Cumulus Oncology Ltd. | $76.00 | 5/17/19 |
| Lonza to manufacture and supply Chiasma’s Mycapssa for acromegaly | Lonza Group AG | Chiasma Inc. | Payment unspecified | 5/14/19 |
| Biontech acquires Mabvax Therapeutics' MVT-5873 and other preclinical antibody assets | Mabvax Therapeutics Holdings Inc. | Biontech SE | Payment unspecified | 5/8/19 |
| Australasian Medical to market and distribute Mannkind's Afrezza inhalation powder for diabetes in Australia | Mannkind Corp. | Australasian Medical and Scientific Ltd. | Payment unspecified | 5/16/19 |
| Eisai to commercialize Medac's methotrexate injection for rheumatoid arthritis in Japan | Medac GmbH | Eisai Co. Ltd. | Payment unspecified | 5/10/19 |
| Vericel to commercialize Mediwound’s Nexobrid in North America for burn care | Mediwound Ltd. | Vericel Corp. | $150.00 | 5/6/19 |
| 14ner Oncology to purchase Merrimack's MM-121 and MM-111 for various cancers | Merrimack Pharmaceuticals Inc. | 14ner Oncology Inc. | $58.00 | 5/28/19 |
| Grow Biotech to distribute MGC Pharma's Cannepil for epilepsy and Cognicann for dementia and Alzheimer's disease in U.K. | MGC Pharma | Grow Biotech plc | Payment unspecified | 5/6/19 |
| Biosyent to commercialize Mithra's Tibelia for postmenopausal osteoporosis in Canada | Mithra Pharmaceuticals | Biosyent Inc. | Payment unspecified | 5/20/19 |
| Hormosan to commercialize Mithra’s Myring for contraception in Germany | Mithra Pharmaceuticals | Hormosan Kwizda GmbH | Payment unspecified | 5/28/19 |
| Molteni to distribute Shionogi's Rizmoic for opioid-induced constipation in Italy and Poland | Molteni Farmaceutici | Shionogi and Co. Ltd. | Payment unspecified | 5/22/19 |
| Kyorin to enter into a memorandum of understanding to co-market MSD Japan's MK-7264 for chronic cough in Japan | MSD Japan | Kyorin Holdings Inc. | Payment unspecified | 5/13/19 |
| Pneuma Respiratory to develop Leads Biolabs' monoclonal antibodies and fusion protein molecules for pulmonary delivery against oncologic or immune-mediated lung diseases | Nanjing Leads Biolabs Co. Ltd. | Pneuma Respiratory Inc. | Payment unspecified | 5/15/19 |
| Lantheus to develop and commercialize Nanomab Technology’s NM-01 biomarker for clinical development and management of immuno-oncology therapies | Nanomab Technology Ltd. | Lantheus Medical Imaging Inc. | Payment unspecified | 5/30/19 |
| Sumitomo Dainippon and Novartis Pharma to co-promote and sell Equa 50mg tablets and Equmet combination LD/HD tablets for type 2 diabetes in Japan | Novartis Pharma KK | Sumitomo Dainippon Pharma Co. Ltd. | Payment unspecified | 5/30/19 |
| Santen extend the 2017 agreement to distribute NTC's levofloxacin/dexamethasone fixed combination eye drops for cataract in Vietnam, Thailand, Singapore, Malaysia, Philippines, Indonesia, Myanmar, Hong Kong, Macau, Brunei, Laos, Cambodia, Sri Lanka, Bangladesh and Pakistan. | NTC Srl | Santen Pharmaceutical Co. Ltd. | Payment unspecified | 5/23/19 |
| Cstone Pharmaceuticals to develop and commercialize Numab Therapeutics’ ND-021 for cancer in greater China, including mainland China, Hong Kong, Macau and Taiwan, South Korea and Singapore | Numab Therapeutics AG | Cstone Pharmaceuticals Co. Ltd. | Payment unspecified | 5/1/19 |
| Hanx to develop and commercialize Onconova's Rigosertib for the treatment of higher-risk myelodysplastic syndromes in greater China | Onconova Therapeutics Inc. | Hanx Biopharmaceuticals Inc. | $51.50 | 5/13/19 |
| Emerge Health to commercialize Oncosec's Tavo for refractory metastatic melanoma in Australia | Oncosec Medical Inc. | Emerge Health Pty Ltd. | Payment unspecified | 5/29/19 |
| Primo Trading to distribute and commercialize Optibiotix's Slimbiome for weight loss in the Thailand | Optibiotix Health plc | Primo Trading Co. Ltd. | Payment unspecified | 5/14/19 |
| Gene Techno Science and Orthorebirth to develop therapeutics for cleft lip or cleft palate | Orthorebirth Co. Ltd. | Gene Techno Science Co. Ltd. | Payment unspecified | 5/10/19 |
| Otonomy to co-promote Glenmark's Otiprio for acute otitis externa in the U.S. | Otonomy Inc. | Glenmark Therapeutics Inc. | Payment unspecified | 5/2/19 |
| Oxford Genetics and CGT Catapult to develop scalable lentiviral manufacturing processes | Oxford Genetics Ltd. | Cell and Gene Therapy Catapult | Payment unspecified | 5/13/19 |
| Genentech to develop and commercialize Parvus' Navacim therapeutics against inflammatory bowel disease, autoimmune liver diseases and celiac disease worldwide | Parvus Therapeutics Inc. | Genentech Inc. | $800.00 | 5/16/19 |
| Patheon Biologics to produce Cantargia's CAN-04 for pancreatic and non-small-cell lung cancers | Patheon Biologics BV | Cantargia AB | Payment unspecified | 5/13/19 |
| Pentapharm and Simcere to jointly develop and commercialize Defibrase in China | Pentapharm AG | Simcere Pharmaceutical Group | Payment unspecified | 5/27/19 |
| FLX Bio to use Personalis’ Immunoid Next to evaluate FLX-475 or in combination with pembrolizumab against cancer | Personalis Inc. | FLX Bio Inc. | Payment unspecified | 5/20/19 |
| Biocure Pharm and Pharos Vaccine to develop anti-CD19 chimeric antigen receptor T-cell therapy products for leukemia and lymphoma worldwide, except China | Pharos Vaccine Inc. | Biocure Pharm Corp. | Payment unspecified | 5/17/19 |
| Panaxia and Plantext to co-develop medical cannabis products for inflammatory bowel disease, Crohn's disease and colitis | Plantext Ltd. | Panaxia Pharmaceutical Industries Ltd. | Payment unspecified | 5/1/19 |
| Presage Biosciences to evaluate Celgene's early stage assets in phase 0 trials and patient responses to microdoses of multiple cancer drugs using Presage's Civo platform | Presage Biosciences Inc. | Celgene Corp. | Payment unspecified | 5/2/19 |
| Vaccitech to use Probiogen’s AGE1.CR duck retina cell line technology to produce viral vectored vaccines, including VTP-100 | Probiogen AG | Vaccitech Ltd. | Payment unspecified | 5/15/19 |
| Rotop to develop and commercialize Progenics' imaging agent, 1404 against prostate cancer in Europe | Progenics Pharmaceuticals Inc. | Rotop Pharmaka GmbH | Payment unspecified | 5/14/19 |
| Prolynx and Daiichi Sankyo to use drug delivery linker technology to extend the intravitreal half-life of Daiichi's candidates | Prolynx LLC | Daiichi Sankyo Co. Ltd. | Payment unspecified | 5/3/19 |
| Qiagen and Inovio to co-develop liquid biopsy-based precision medicine test for VGX-3100 to treat precancerous cervical lesions | Qiagen NV | Inovio Pharmaceuticals Inc. | Payment unspecified | 5/16/19 |
| Reform Biologics to conduct feasibility studies to enhance the formulation of Bayer's two clinical-stage programs | Reform Biologics LLC | Bayer AG | Payment unspecified | 5/14/19 |
| Cincor to develop and commercialize Roche's CIN-107 for resistant hypertension and primary aldosteronism worldwide | Roche Holding AG | Cincor Pharma Inc. | Payment unspecified | 5/14/19 |
| Chiesi to develop Santhera's Raxone for Leber’s hereditary optic neuropathy and all other ophthalmological indications worldwide, except the U.S. and Canada | Santhera Pharmaceuticals AG | Chiesi Farmaceutici SpA | $105.33 | 5/23/19 |
| Bayer to use Sensible Medical Innovations’ Reds technology in a clinical trial to study the efficacy of BAY-1753011 | Sensible Medical Innovations Ltd. | Bayer AG | Payment unspecified | 5/28/19 |
| Meridian to commercialize Siga Technologies' oral Tpoxx for smallpox worldwide except for the U.S. and South Korea | Siga Technologies Inc. | Meridian Medical Technologies Inc. | Payment unspecified | 5/31/19 |
| Skyhawk and Takeda to discover and develop RNA splicing modifiers for neurological diseases using Skystar technology worldwide | Skyhawk Therapeutics Inc. | Takeda Pharmaceutical Co. Ltd. | Payment unspecified | 5/6/19 |
| Perrigo Israel to develop and commercialize Sol-Gel's generic antibiotic foams in the U.S. | Sol-Gel Technologies Ltd. | Perrigo Israel Agencies Ltd. | Payment unspecified | 5/28/19 |
| Arcus to use Strata's drug development platform and biomarkers for evaluation of AB-122 against cancers | Strata Oncology | Arcus Biosciences Inc. | $2.50 | 5/2/19 |
| Synlogic to evaluate combination of SYNB-1891 with Roche's atezolizumab for advanced solid tumors | Synlogic Inc. | Roche Holding AG | Payment unspecified | 5/22/19 |
| Takeda Pharmaceuticals to spin out Phathom Pharmaceuticals to develop and commercialize therapeutics, including vonoprazan for acid-related gastrointestinal disorders in the U.S., Europe and Canada | Takeda Pharmaceutical Co. Ltd. | Phathom Pharmaceuticals Inc. | Payment unspecified | 5/15/19 |
| Novartis to acquire Takeda's Xiidra for dry eye disease worldwide | Takeda Pharmaceutical Co. Ltd. | Novartis AG | $5,300.00 | 5/8/19 |
| Ethicon to acquire Takeda's Tachosil for hemostasis | Takeda Pharmaceutical Co. Ltd. | Ethicon Inc. | $400.00 | 5/8/19 |
| Nuance to develop Teva's bendamustine for the treatment of non-hodgkin's lymphoma in China | Teva Pharmaceutical Industries Ltd. | Nuance Biotech Inc. | Payment unspecified | 5/26/19 |
| Bicycle Therapeutics and DDF to develop therapeutics using bicyclic peptide technology for neurodegenerative diseases, including dementia | The Dementia Discovery Fund | Bicycle Therapeutics Ltd. | Payment unspecified | 5/7/19 |
| Transgene and Astrazeneca to develop oncolytic vaccinia virus candidates using Invir.IO | Transgene SA | Astrazeneca plc | $13.00 | 5/2/19 |
| Trovagene to evaluate the efficacy of onvansertib in combination with Nektar’s Onzeald for metastatic colorectal cancer | Trovagene Inc. | Nektar Therapeutics | Payment unspecified | 5/23/19 |
| Ubiquigent to provide small molecule libraries access to Dorian Therapeutics for development drugs against age-associated diseases | Ubiquigent Ltd. | Dorian Therapeutics Inc. | Payment unspecified | 5/23/19 |
| Valirx to sign letter of intent with Alpha Blue Ocean to form a genetic therapeutic and diagnostic based joint venture | Valirx plc | Alpha Blue Ocean Advisors Ltd. | Payment unspecified | 5/2/19 |
| Vectura to enter settlement for resolving litigation of U.S. sales of GSK's Breo Ellipta, Anoro Ellipta and Incruse Ellipta | Vectura Group plc | Glaxosmithkline plc | $89.70 | 5/3/19 |
| Verve to use Verily's nanoparticle screening platform to develop and optimize new gene editing delivery vehicles for cardiovascular diseases | Verily Life Sciences LLC | Verve Therapeutics Inc. | Payment unspecified | 5/7/19 |
| Hansoh to develop and commercialize Viela Bio's inebilizumab for neuromyelitis optica spectrum disorder and other inflammation/autoimmune and hematologic malignancy indications in China | Viela Bio Inc. | Jiangsu Hansoh Pharmaceutical Group Co. Ltd. | $220.00 | 5/28/19 |
| Viiv Healthcare to evaluate Matinas Biopharma's lipid nanocrystal formulation of antiviral drug candidates | Viiv Healthcare Ltd. | Matinas Biopharma Holdings Inc. | Payment unspecified | 5/15/19 |
| Virogin Biotech and China National Biotec to form joint venture to commercialize oncolytic virotherapies | Virogin Biotech Canada Ltd. | China National Biotec Group | Payment unspecified | 5/8/19 |
| Ginkgo Bioworks acquires Warp Drive Bio's genome mining platform to discover and develop antibiotics for drug-resistant bacterial infections | Warp Drive Bio | Ginkgo Bioworks | Payment unspecified | 5/15/19 |
| Medigen and Zhongji 1 to develop cell therapy in Hong Kong | Zhongji 1 International Medical Group | Medigen Biotechnology Corp. | Payment unspecified | 5/23/19 |
| Iconic to use Zymeworks' Zymelink antibody drug conjugate platform to develop ICON-2 Tissue Factor ADC against cancer worldwide | Zymeworks Inc. | Iconic Therapeutics Inc. | Payment unspecified | 5/14/19 |
| GSK expanded the 2016 agreement, valued at $908M, to gain further access to Zymeworks’ Azymetric technology to develop bispecific and multifunctional therapeutics, paying $1.1B in total | Zymeworks Inc. | Glaxosmithkline plc | $192.00 | 5/17/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Gilead to use Abcellera's expertise in single-cell screening for the discovery of therapeutic antibody candidates against infectious diseases | Abcellera Biologics Inc. | Gilead Sciences Inc. | Payment unspecified | 6/13/19 |
| Alvotech and Abdi Ibrahim to develop and commercialize biosimilar against autoimmune disease in Turkey | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Alvotech | Payment unspecified | 6/3/19 |
| Zai Lab to use Ablexis’ Alivamab mouse platform to discover, develop and commercialize antibody drug candidates | Ablexis LLC | Zai Lab Ltd. | Payment unspecified | 6/3/19 |
| Abveris and Tetragenetics to collaborate on the discovery of antibodies against ion channel targets | Abveris Inc. | Tetragenetics Inc. | Payment unspecified | 6/4/19 |
| Accord Healthcare to distribute Clinigen’s Cardioxane and Savene in Poland as protectant during chemotherapy | Accord Healthcare Inc. | Clinigen Group plc | Payment unspecified | 6/24/19 |
| Qilu Antibiotics Pharmaceutical to purchase Achaogen's plazomicin greater China rights | Achaogen Inc. | Qilu Antibiotics Pharmaceutical Co. Ltd. | Payment unspecified | 6/6/19 |
| Cipla to purchase Achaogen's Zemdri worldwide rights excluding greater China | Achaogen Inc. | Cipla USA Inc. | Payment unspecified | 6/6/19 |
| Chia Tai and Akeso to form a joint venture to develop AK-105 against cancers | Akeso Biopharma Inc. | Chia Tai Tianqing Pharmaceutical Group Co. Ltd. | Payment unspecified | 6/17/19 |
| Allele Biotechnology and Alpine Biotherapeutics to develop human induced pluripotent stem cell-derived cell therapy products against retinal diseases including vision loss | Allele Biotechnology and Pharmaceuticals Inc. | Alpine Biotherapeutics Corp. | Payment unspecified | 6/12/19 |
| Allergy to settle a litigation with Inflamax Research for disclosing inconclusive phase II study of Grass MATA MPL | Allergy Therapeutics plc | Inflamax Research Inc. | $7.60 | 6/27/19 |
| Tedor to use Altus' Flexitab technology to develop sustained release tablets in North America | Altus Formulation Inc. | Tedor Pharma Inc. | Payment unspecified | 6/4/19 |
| Shanghai Junshi Biosciences to develop and commercialize Anwita's AWT-008 for cancer in greater China | Anwita Biosciences Inc. | Shanghai Junshi Biosciences Co. Ltd. | $76.50 | 6/24/19 |
| Laboratoire Arrow to distribute Seqirus' Flucelvax Tetra for influenza infection in France | Arrow Generiques | Seqirus | Payment unspecified | 6/30/19 |
| Arvinas and Bayer to develop Protac targeted protein degraders using Protac technology for pharmaceutical use for human | Arvinas Inc. | Bayer AG | $749.50 | 6/3/19 |
| Otsuka acquires cefixime business from Astellas Pharma | Astellas Pharma Inc. | Otsuka Kagaku KK | Payment unspecified | 6/4/19 |
| Atomwise to screen Enamine's small molecule libraries for cancer using artificial intelligence-powered virtual drug screening | Atomwise | Enamine Ltd. | Payment unspecified | 6/24/19 |
| Avacta and Selexis to develop CHO cell line for manufacture AVA-004 against solid tumor | Avacta Ltd. | Selexis SA | Payment unspecified | 6/20/19 |
| Bayer and Cstone to evaluate CS-1001 in combination with regorafenib against multiple cancers including gastric cancer | Bayer HealthCare Ltd. | Cstone Pharmaceuticals Co. Ltd. | Payment unspecified | 6/9/19 |
| Beigene and Springworks to form joint venture, Mapkure to develop BGB-3245 for cancer | Beigene Co. Ltd. | Springworks Therapeutics Inc. | Payment unspecified | 6/18/19 |
| Beigene received $150M payment for termination of collaboration with Celgene for tislelizumab | Beigene Ltd. | Celgene Corp. | $150.00 | 6/18/19 |
| Abveris to use Berkeley's Beacon optofluidic platform for antibody discovery | Berkeley Lights Inc. | Abveris Inc. | Payment unspecified | 6/17/19 |
| Biocartis to develop and commercialize assays to support Kite's therapies for cancer | Biocartis | Kite Pharma Inc. | Payment unspecified | 6/1/19 |
| Everest Medicines to develop and commercialize Calliditas' Nefecon for IgA nephropathy in China, Hong Kong, Macau, Taiwan and Singapore | Calliditas Therapeutics AB | Everest Medicines | $121.00 | 6/10/19 |
| Gilead to develop and commercialize small molecule immuno-oncology therapies using Carna Biosciences' lipid kinase drug discovery technology worldwide | Carna Biosciences Inc. | Gilead Sciences Inc. | $470.00 | 6/24/19 |
| Catalent to manufacture adeno-associated virus vector for Iveric Bio's IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa and IC-200 for BEST1-related retinal diseases | Catalent Inc. | Iveric Bio Inc. | Payment unspecified | 6/17/19 |
| ANI acquires Coeptis Pharmaceuticals' seven development stage generic products | Coeptis Pharmaceuticals Inc. | ANI Pharmaceuticals Inc. | $14.30 | 6/18/19 |
| Vertex Pharmaceuticals to develop and commercialize Crispr Therapeutics' gene editing products for Duchenne muscular dystrophy and myotonic dystrophy type 1 worldwide | Crispr Therapeutics AG | Vertex Pharmaceuticals Inc. | $1,000.00 | 6/6/19 |
| Debiopharm and Ipsen extended the agreement through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets | Debiopharm SA | Ipsen SA | Payment unspecified | 6/13/19 |
| Zai Lab to develop Deciphera's ripretinib against gastrointestinal stromal tumors and other solid tumors in mainland China, Hong Kong, Macau and Taiwan | Deciphera Pharmaceuticals LLC | Zai Lab Ltd. | $205.00 | 6/10/19 |
| Dualogics and Y-Biologics to discover and develop cancer antibodies | Dualogics LLC | Y-Biologics Inc. | Payment unspecified | 6/10/19 |
| Eczac?basi-Monrol to distribute Telix's TLX250-CDx for renal cell cancer in Turkey, Middle East and North Africa | Eczac?basi-Monrol | Telix Pharmaceuticals Ltd. | Payment unspecified | 6/13/19 |
| Lannett to distribute Elite's generic Dantrolene capsules in the U.S. | Elite Pharmaceuticals Inc. | Lannett Co. Inc. | Payment unspecified | 6/28/19 |
| Ricoh and Elixirgen to develop innovative biomedical products and services for cell differentiation technology-based drug discovery | Elixirgen Scientific LLC | Ricoh Co. Ltd. | Payment unspecified | 6/19/19 |
| Sanofi to use Enable Injections' Enfuse platform to deliver subcutaneous therapeutics | Enable Injections LLC | Sanofi SA | Payment unspecified | 6/3/19 |
| Atlantic Healthcare to acquire worldwide rights to Endologic’s renzapride for gastrointestinal motility disorders | Endologic LLC | Atlantic Healthcare plc | $51.00 | 6/26/19 |
| Bioneer to use ERS Genomics' Crispr/Cas9 genome editing technology to generate and commercialize human cell-based disease models | ERS Genomics Ltd. | Bioneer A/S | Payment unspecified | 6/4/19 |
| Erytech Pharma and SQZ Biotech to develop antigen-specific immune modulating therapies for multiple indications worldwide | Erytech Pharma SA | SQZ Biotechnologies Inc. | $107.00 | 6/24/19 |
| Eton Pharmaceuticals to grant U.S. rights of ET-105 to Aucta Pharmaceuticals for neurological disorders | Eton Pharmaceuticals Inc. | Aucta Pharmaceuticals Inc. | $23.00 | 6/13/19 |
| Alvogen to acquire portfolio of prescription and over the counter drugs of women’s healthcare from Exeltis in Russia, Ukraine and Kazakhstan | Exeltis USA Inc. | Alvogen Inc. | Payment unspecified | 6/11/19 |
| Exscientia and GT Apeiron to develop drugs via new pathways against therapeutic targets, including oncology using artificial intelligence drug discovery platform | Exscientia Co. Ltd. | GT Apeiron Therapeutics | Payment unspecified | 6/11/19 |
| Ferrer to promote Shionogi's Rizmoic for opioid-induced constipation in Spain | Ferrer Internacional SA | Shionogi BV | Payment unspecified | 6/11/19 |
| Kissei to co-promote Ferring's desmopressin acetate for nocturnal polyuria in Japan | Ferring Pharmaceuticals SA | Kissei Pharmaceutical Co. Ltd. | Payment unspecified | 6/18/19 |
| FDB to manufacture and supply Outlook Therapeutics' ONS-5010 for the treatment of wet age-related macular degeneration | Fujifilm Diosynth Biotechnologies | Outlook Therapeutics Inc. | Payment unspecified | 6/3/19 |
| Terns to develop and commercialize Genfit's elafibranor for the treatment of primary biliary cholangitis and nonalcoholic steatohepatitis in greater China | Genfit SA | Terns Pharmaceuticals Inc. | $228.00 | 6/24/19 |
| Janssen obtains option to develop and commercialize Genmab's Hexabody-CD38 against multiple myeloma and diffuse large B-cell lymphoma worldwide | Genmab A/S | Janssen Biotech Inc. | $275.00 | 6/11/19 |
| Ginkgo Bioworks to accelerate the expansion and development of Synlogic's pipeline of synthetic biotic medicines | Ginkgo Bioworks Inc. | Synlogic Inc. | $110.00 | 6/13/19 |
| Stada Arzneimittel to acquire five skin care brands and one pediatric cough remedy from Glaxosmithkline in Europe | Glaxosmithkline plc | Stada Arzneimittel AG | Payment unspecified | 6/7/19 |
| Valneva to terminate agreement with GSK related to vaccines against Lyme disease and chikungunya | Glaxosmithkline plc | Valneva SE | $18.00 | 6/24/19 |
| Glenmark to promote, commercialize and distribute Novartis' Seebri, Onbrize and Ultibro for chronic obstructive pulmonary disease in Brazil | Glenmark Farmaceutica | Novartis AG | Payment unspecified | 6/24/19 |
| Harvest One Cannabis to supply Gencanna's Dream Water, Satipharm, and Livrelief in the U.S. and Europe | Harvest One Cannabis Inc. | Gencanna Global USA Inc. | Payment unspecified | 6/4/19 |
| Medovex and Rion to develop cell therapy for chronic obstructive pulmonary disease | H-cyte Inc. | Rion LLC | Payment unspecified | 6/24/19 |
| Healios and Dainippon adjusted the agreement to develop induced pluripotent stem cell-derived retinal pigment epithelial cells for age related macular degeneration and other eye diseases in Japan | Healios K.K. | Sumitomo Dainippon Pharma Co. Ltd. | $9.23 | 6/14/19 |
| Devonian Health to manufacture and extract Histapharm’s botanical drug containing DAO and develop products for dermatological applications | Histapharm Inc. | Devonian Health Group Inc. | Payment unspecified | 6/3/19 |
| Hitgen to use its technology platform to discover small molecule leads against targets of interest to Gilead | Hitgen Ltd. | Gilead Sciences Inc. | Payment unspecified | 6/3/19 |
| Immunophotonics and CLS to conduct phase Ib/IIa study on IP-001 for solid tumor indications | Immunophotonics Inc. | Clinical Laserthermia Systems Ab | Payment unspecified | 6/14/19 |
| BDD pharma to develop Innovation's Brilacidin tablets for ulcerative colitis using Oralogik technology | Innovation Pharmaceuticals Inc. | BDD Pharma Ltd. | Payment unspecified | 6/6/19 |
| Intralytix and Ferring Pharmaceuticals to develop and commercialize bacteriophage-based drugs for women's health | Intralytix Inc. | Ferring Pharmaceuticals SA | Payment unspecified | 6/17/19 |
| Surterra to advance cannabinoid production using Intrexon’s yeast fermentation platform worldwide | Intrexon Corp. | Surterra Wellness | $145.00 | 6/18/19 |
| Biomx licensed a set of bacterial targets from JSR to develop and commercialize phage therapies for primary sclerosing cholangitis | JSR Corp. | Biomx Ltd. | Payment unspecified | 6/12/19 |
| Just to design and develop manufacturing process for Teva's products | Just Biotherapeutics Inc. | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 6/28/19 |
| Casi Pharmaceuticals to commercialize Juventas’ anti-CD19 T-cell therapy, CNCT-19 for hematological malignancies worldwide | Juventas Therapeutics Inc. | Casi Pharmaceuticals Inc. | $11.60 | 6/17/19 |
| Leadxpro to discover small molecule membrane therapeutics for Astex's targets using cryo-EM | Leadxpro AG | Astex Pharmaceuticals Inc. | Payment unspecified | 6/3/19 |
| Linearx to provide multiple customized linear DNA amplicons to Evotec for research on neurodegenerative diseases | Linearx Inc. | Evotec SE | Payment unspecified | 6/26/19 |
| Lonza to manufacture Gamida Cell's omidubicel for hematologic malignancies | Lonza Group Ltd. | Gamida Cell Ltd. | Payment unspecified | 6/20/19 |
| Astellas to use Lpixel's Imacel for cell evaluation to conduct research on regenerative medicine and cell therapy | Lpixel Inc. | Astellas Pharma Inc. | Payment unspecified | 6/4/19 |
| Medincell and undisclosed company to develop mdc-ANG for central nervous system diseases | Medincell SA | Undisclosed | Payment unspecified | 6/12/19 |
| Intensity to conduct phase I/II clinical study of INT230-6 in combination with Merck's Keytruda for solid tumor including pancreatic, bile duct, squamous cell and non-microsatellite instability high colon cancers | Merck & Co. Inc. | Intensity Therapeutics Inc. | Payment unspecified | 6/25/19 |
| Mesoblast expanded the partnership with JCR Pharmaceuticals for the use of mesenchymal stem cells to treat neonatal hypoxic ischemic encephalopathy | Mesoblast Ltd. | JCR Pharmaceuticals Co. Ltd. | Payment unspecified | 6/12/19 |
| Momenta and Amphastar to settle patent litigation related to enoxaparin sodium injection | Momenta Pharmaceuticals Inc. | Amphastar Pharmaceuticals Inc. | Payment unspecified | 6/18/19 |
| Egis to distribute Mundipharma’s Pelmeg for neutropenia in Central and Eastern Europe | Mundipharma International Corp. Ltd. | Egis Gyogyszergyar RT | Payment unspecified | 6/14/19 |
| Jiangsu Hengrui to develop and commercialize Mycovia's VT-1161 in China, including mainland China, Hong Kong, Macau and Taiwan, for recurrent vulvovaginal candidiasis, onychomycosis and invasive fungal infections | Mycovia Pharmaceuticals Inc. | Jiangsu Hengrui Medicine Co. Ltd. | Payment unspecified | 6/17/19 |
| Mytomorrows to provide support services for the supply of Immodulon’s IMM-101 in Europe for cancer | Mytomorrows | Immodulon Therapeutics Ltd. | Payment unspecified | 6/27/19 |
| Nanolek to sign memorandum of intention to manufacture Sanofi Pasteur's Pentaxim for infectious diseases in Russia | Nanolek LLC | Sanofi SA | Payment unspecified | 6/4/19 |
| Atlas and Nano Medical to distribute nanotechnology products in Mexico, Latin America and Europe | Nanomedical Systems Inc. | Atlas Nanotech | Payment unspecified | 6/27/19 |
| EMD Serono to use Nebula's anonymized genomic data to develop drugs | Nebula Genomics | EMD Serono Inc. | Payment unspecified | 6/11/19 |
| Nordmark to manufacture and supply Vivus's Pancreaze for exocrine pancreatic insufficiency | Nordmark Arzneimittel GmbH & Co. KG | Vivus Inc. | Payment unspecified | 6/25/19 |
| Premark Pharma to develop and commercialize Novartis' PMP-2207 for blepharitis | Novartis AG | Premark Pharma GmbH | Payment unspecified | 6/25/19 |
| Sobi to acquire Novimmune's all assets relating to emapalumab in the field of immunology and an option to develop NI-1801 and NI-1701 in the field of immuno-oncology | Novimmune SA | Swedish Orphan Biovitrum AB | $516.60 | 6/12/19 |
| Undisclosed pharma company to enter agreement with Noxxon Pharma to evaluate NOX-A12 for a new indication | Noxxon Pharma AG | Undisclosed pharma company | Payment unspecified | 6/24/19 |
| Gilead and Nurix to discover, develop and commercialize E3 ligase modulating targeted protein degradation drugs for cancer and other diseases worldwide | Nurix Inc. | Gilead Sciences Inc. | $2,345.00 | 6/19/19 |
| Merck and Oncolytics to conduct a phase II clinical study of pelareorep in combination with paclitaxel and avelumab against metastatic breast cancer | Oncolytics Biotech Inc. | Merck KGaA | Payment unspecified | 6/5/19 |
| Oncotherapy to develop, manufacture and sell Thyas's T cell with peptide vaccine worldwide for cancer | Oncotherapy Science Inc. | Thyas Co. Ltd. | Payment unspecified | 6/18/19 |
| Agropur to manufacture, supply and distribute Optibiotix's Slimbiome for weight loss in the U.S., Canada and Mexico | Optibiotix Health plc | Agropur Cooperative | Payment unspecified | 6/24/19 |
| Denovo Biopharma to develop, manufacture and commercialize Orion's ORM-12741 against neuropsyciatric indications like Alzheimer's disease, schizophrenia and depression worldwide | Orion Corp. | Denovo Biopharma LLC | Payment unspecified | 6/18/19 |
| Oxford Biomedica and Santen to research and develop gene therapy products plus to generate preclinical proof of concept against inherited retinal disease with OXB's lentiviral vectors | Oxford Biomedica plc | Santen Pharmaceutical Co. Ltd. | Payment unspecified | 6/26/19 |
| Particle Sciences to manufacture Hoth Therapeutics' Biolexa therapeutic for atopic dermatitis | Particle Sciences Inc. | Hoth Therapeutics Inc. | Payment Unspecified | 6/10/19 |
| Patheon U.K. to provide Savara manufacturing services for drug products specified from time to time | Patheon U.K. Ltd. | Savara Inc. | Payment unspecified | 6/27/19 |
| Patheon to provide manufacturing services to Cara Therapeutics for CR-845 for the treatment of pain and uremic pruritus | Patheon U.K. Ltd. | Cara Therapeutics Inc. | Payment unspecified | 6/27/19 |
| Pharmain to investigate drug carrier and delivery protected graft co-polymer technology in combination with Peptidream’s peptide discovery and development programs | Pharmain Ltd. | Peptidream Inc. | Payment unspecified | 6/5/19 |
| Effrx to register and commercialize Pharmaxis's Bronchitol for cystic fibrosis in Switzerland | Pharmaxis Ltd. | Effrx Pharmaceuticals SA | Payment unspecified | 6/13/19 |
| C4X Discovery to integrate Taxonomy3 technology with Phoremost's siteseeker screening platform to develop therapies against Parkinson's disease | Phoremost Ltd | C4X Discovery Holdings plc | Payment unspecified | 6/25/19 |
| Bicycle Therapeutics to award contract to Physiomics to support immune-oncology program | Physiomics plc | Bicycle Therapeutics Ltd. | Payment unspecified | 6/28/19 |
| Odyssey and Prevacus to sign a letter of intent to form joint venture for development of neurosteroid against orphan disorders | Prevacus Inc. | Odyssey Group International Inc. | Payment unspecified | 6/4/19 |
| Odyssey and Prevacus to sign a letter of intent to form joint venture for the development of neurosteroids including, PRV-001 against pediatric Niemann-Pick type C disease, leukodystrophies, Krabbe disease and metachromatic leukodystrophy | Prevacus Inc. | Odyssey Group International Inc. | Payment unspecified | 6/4/19 |
| Purec to develop and manufacture mesenchymal stem cell regenerative medicine products to Fujifilm for treatment of congenital osteogenesis imperfecta | Purec Co. Ltd. | Fujifilm Corp. | Payment unspecified | 6/19/19 |
| Ono Pharmaceutical to develop and commercialize Rafael Pharmaceuticals’ CPI-613 in Japan, South Korea, Taiwan and Association of Southeast Asian Nations countries | Rafael Pharmaceuticals Inc. | Ono Pharmaceutical Co. Ltd. | $163.20 | 6/25/19 |
| Leidos Biomedical to award subcontract to Reaction Biology to develop drugs against colorectal cancer using surface plasmon resonance technology | Reaction Biology Corp. | Leidos Biomedical Research Inc. | Payment unspecified | 6/4/19 |
| Regis Technologies to manufacture Hoth Therapeutics' Biolexa therapeutic for atopic dermatitis | Regis Technologies Inc. | Hoth Therapeutics Inc. | Payment Unspecified | 6/10/19 |
| Resolution Bioscience and Janssen to investigate a Resolution HRD liquid biopsy assay as a companion diagnostic for niraparib against metastatic castration-resistant prostate cancer | Resolution Bioscience Inc. | Janssen Research & Development LLC | Payment unspecified | 6/19/19 |
| Samsung Biologics to manufacture U.S. biopharmaceutical's early-stage asset | Samsung Biologics Co. Ltd. | Undisclosed U.S. biopharmaceutical | $301.00 | 6/4/19 |
| Seven and Eight Biopharmaceuticals and Roche to evaluate combination of BDB-001 with atezolizumab against solid tumors | Seven and Eight Biopharmaceuticals Inc. | Roche Holding AG | Payment unspecified | 6/19/19 |
| Shanghai Huaaotai Biological to transfer HOT-1010 technology rights to Shanghai Junshi | Shanghai Huaota Biopharma Co. Ltd. | Shanghai Junshi Biosciences Co. Ltd. | $13.33 | 6/24/19 |
| EOC Pharma to develop, manufacture and market Shionogi’s epertinib in China, Hong Kong and Macau for breast cancer | Shionogi & Co. Ltd. | EOC Pharma Ltd. | Payment unspecified | 6/24/19 |
| Eddingpharm to commercialize Shionogi’s lusutrombopag for thrombocytopenia in China, Hong Kong, and Macau | Shionogi & Co. Ltd. | Eddingpharm Inc. | Payment unspecified | 6/24/19 |
| Sorrento Therapeutics and Lifetech Scientific to form joint venture Shenzhen Yunma Biotechnology to commercialize water-soluble cannabinoid formulation technologies for multiple indications in Asia, excluding Japan | Sorrento Therapeutics Inc. | Lifetech Scientific Inc. | Payment unspecified | 6/4/19 |
| GSK to conduct phase Ib study to evaluate Springworks' nirogacest in combination with belantamab mafodotin against relapsed or refractory multiple myeloma | Springworks Therapeutics Inc. | Glaxosmithkline plc | Payment unspecified | 6/27/19 |
| Starpharma to develop dendrimer enhanced product version of AstraZeneca’s undisclosed oncology product | Starpharma Holdings Ltd. | Astrazeneca plc | $5.00 | 6/3/19 |
| Straub Medical to conduct pilot study of Emmaus' L-glutamine against type II diabetes | Straub Medical Ag | Emmaus Medical Inc. | Payment unspecified | 6/24/19 |
| Suda Pharmaceuticals to develop and supply oral spray cannabinoid derivatives to Cann Pharmaceutical for epilepsy, melanoma and motion sickness worldwide | Suda Pharmaceuticals Ltd. | Cann Pharmaceutical Australia Ltd | $1.50 | 6/5/19 |
| CMS to develop and commercialize Sun Pharma's Cyclosporine A for dry eye disease in greater China including mainland China, Hong Kong, Macao and Taiwan | Sun Pharmaceutical Industries Ltd. | China Medical System Holdings Ltd. | Payment unspecified | 6/27/19 |
| China Medical System to develop and commercialize Sun Pharmaceutical's Tildrakizumab against psoriasis and psoriatic arthritis in greater China | Sun Pharmaceutical Industries Ltd. | China Medical System Holdings Ltd. | Payment unspecified | 6/27/19 |
| TLC to develop and manufacture liposomal formulation of Birdie Biopharmaceuticals' TLR7/8 using Nanox technology for cancer | Taiwan Liposome Co. | Birdie Biopharmaceuticals Inc. | $49.00 | 6/25/19 |
| Tedor Pharma to manufacture Adial's AD-04 | Tedor Pharma Inc. | Adial Pharmaceuticals LLC | Payment unspecified | 6/6/19 |
| Tessa Therapeutics and CSGKC to form a joint venture to develop cell therapies for cancer in China | Tessa Therapeutics Pte Ltd. | Sino-Singapore Guangzhou Knowledge City Investment and Development Co. Ltd. | $120.00 | 6/12/19 |
| Bristol-Myers Squibb to develop liver tissue model for screening the toxicity of drugs using Draper’s human organ systems platform | The Charles Stark Draper Laboratory Inc. | Bristol-Myers Squibb Co. | Payment unspecified | 6/27/19 |
| Theramex to commercialize Therapeuticsmd's Bijuva and Imvexxy for menopause worldwide, excluding the U.S., Canada and Israel | Therapeuticsmd Inc. | Theramex | $49.39 | 6/7/19 |
| Theravance Biopharma and Mylan expanded the agreement for nebulized revefenacin to include China and certain adjacent territories | Theravance Biopharma Ireland Ltd. | Mylan NV | $72.50 | 6/17/19 |
| Tilt Biotherapeutics and Merck to assess combination of TILT-123 with Avelumab for solid tumors | Tilt Biotherapeutics Ltd. | Merck KGaA | Payment unspecified | 6/25/19 |
| TOT Biopharm and Shanghai Junshi to develop a combination therapy by combining TAB-008 & JS-001 against hepatocellular carcinoma | TOT Biopharm Co. Ltd. | Shanghai Junshi Biosciences Co. Ltd. | Payment unspecified | 6/19/19 |
| Ultragenyx Pharmaceutical and Arcturus Therapeutics expanded the 2015 collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets | Ultragenyx Pharmaceutical Inc. | Arcturus Therapeutics Holdings Inc. | $39.60 | 6/20/19 |
| TTY Biopharm and an undisclosed international company to develop generic version of octreotide LAR in overseas markets | Undisclosed | TTY Biopharm Co. Ltd. | $5.00 | 6/25/19 |
| Pfizer's Centers for Therapeutic Innovation and Uniquest to develop drug candidates for cancer in Australia | Uniquest Pty Ltd. | Pfizer Pty Ltd. (Australia) | Payment unspecified | 6/3/19 |
| Astellas to use Vect Horus' Vectrans technology to transport the antibody to the brain for central nervous system diseases | Vect-Horus | Astellas Pharma Inc. | Payment unspecified | 6/4/19 |
| Vernalis and Phoremost to develop therapeutics for cancer | Vernalis Research Ltd. | Phoremost Ltd. | Payment unspecified | 6/12/19 |
| Sanofi Genzyme to acquire option to develop and commercialize Voyager’s selected adeno-associated virus capsids for up to two non-central nervous system indications worldwide | Voyager Therapeutics Inc. | Sanofi Genzyme | $116.00 | 6/14/19 |
| Sanofi Genzyme to return VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program to Voyager Therapeutics | Voyager Therapeutics Inc. | Sanofi Genzyme | $20.00 | 6/18/19 |
| Seraxis and Wake Forest Baptist Health to further develop SR-01 for diabetes | Wake Forest Baptist Health | Seraxis Inc. | Payment unspecified | 6/19/19 |
| Widetrial to provide Oncotelic's OT-101 under expanded access program for pancreatic cancer, advanced melanoma, colorectal cancer and glioblastoma | Widetrial Inc. | Oncotelic Inc. | Payment unspecified | 6/3/19 |
| Willow Biosciences and Noramco to jointly develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol | Willow Biosciences Inc. | Noramco Inc. | Payment unspecified | 6/4/19 |
| Stada Arzneimittel to develop and commercialize Xbrane's Spherotide for cancer in Europe | Xbrane Biopharma AB | Stada Arzneimittel AG | Payment unspecified | 6/4/19 |
| Y-Biologics and Genosco to test combination of immune checkpoint inhibitors and small-molecule cancer drugs | Y-Biologics Inc. | Genosco | Payment unspecified | 6/3/19 |
| Yposkesi to manufacture and produce Axovant's cGMP adeno-associated virus to advance gene therapy programs | Yposkesi SAS | Axovant Gene Therapies Ltd. | Payment unspecified | 6/21/19 |
| Yposkesi to manufacture lentiviral vectors for Servier to use in allogenic chimeric antigen receptor T cell technology development for cancer | Yposkesi SAS | Servier SA | Payment unspecified | 6/5/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Alnylam and 23andme to offer 23andme health + ancestry kits to relatives of customers with TTR-related hereditary amyloidosis | 23andme Inc. | Alnylam Pharmaceuticals Inc. | Payment unspecified | 7/16/19 |
| 3P to manufacture Toleranzia's TOL-2 for preclinical and clinical studies | 3P Biopharmaceuticlas SL | Toleranzia AB | Payment unspecified | 7/2/19 |
| Acerus Pharmaceuticals amended and restated the exclusive agreement with Aytu Bioscience for the commercialization of Natesto in the U.S. to move the partnership from an out-license model to a co-promotion arrangement extending to 2027 | Acerus Pharmaceuticals Corp. | Aytu Bioscience Inc. | Payment unspecified | 7/29/19 |
| AD Pharma to fund the development and commercialization of Acura Pharmaceuticals' LTX-03 against pain | Acura Pharmaceuticals Inc. | Abuse Deterrent Pharmaceutical LLC | $21.30 | 7/2/19 |
| Adamis and Kaleo to settle patent infringement of Adamis’ Zimhi naloxone product and Symjepi trademark | Adamis Pharmaceuticals Corp. | Kaleo Inc. | Payment unspecified | 7/18/19 |
| Innovation to develop and commercialize Alfasigma's brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis | Alfasigma SpA | Innovation Pharmaceuticals Inc. | $24.00 | 7/22/19 |
| Alkermes and Amneal to settle patent litigation related to Vivitrol in the U.S. | Alkermes plc | Amneal Pharmaceuticals Inc. | Payment unspecified | 7/29/19 |
| Genesis to commercialize Alnylam Pharmaceuticals' Onpattro against hereditary ATTR amyloidosis in 12 countries | Alnylam Pharmaceuticals Inc. | Genesis Pharma SA | Payment unspecified | 7/30/19 |
| Cristalia to develop and commercialize Alteogen's ALT-P1 for growth disorders | Alteogen Inc. | Cristalia | $42.40 | 7/31/19 |
| Cipla Gulf to commercialize Alvotech’s AVT-02 in selected emerging markets for autoimmune diseases | Alvotech Swiss AG | Cipla Gulf FZ LLC | Payment unspecified | 7/29/19 |
| Aptus Clinical to design phase I/II clinical study for Valirx's VAL-301 for endometriosis | Aptus Clinical Ltd. | Valirx plc | Payment unspecified | 7/4/19 |
| Arbutus to sell its remaining royalty interest of Onpattro for hereditary transthyretin-mediated amyloidosis to Omers | Arbutus Biopharma Corp. | Omers | $20.00 | 7/2/19 |
| Aridis to grant option rights of AR-301, AR-105, AR-101 and AR-201 with MabIgx technology to Serum for bacterial infections worldwide, excluding few territories | Aridis Pharmaceuticals Inc. | Serum International BV | $43.50 | 7/16/19 |
| Raqualia Pharma and Aska Pharmaceutical to develop therapies using ion channel drug development technology | Aska Pharmaceutical Co. Ltd. | Raqualia Pharma Inc. | Payment unspecified | 7/1/19 |
| Jiangsu Wanbang to commercialize Aucta's vigabatrin for central nervous system disorders in China | Aucta Pharmaceuticals Inc. | Jiangsu Wanbang Biochemical Pharmaceutical Co. Ltd. | Payment unspecified | 7/25/19 |
| Aurigene to discover and develop small molecules against cancer for Exelixis worldwide | Aurigene Discovery Technologies Ltd. | Exelixis Inc. | $498.40 | 7/31/19 |
| Avid Bioservices to provide manufacturing services to undisclosed pharmaceutical company to develop drugs | Avid Bioservices Inc. | Undisclosed | Payment unspecified | 7/8/19 |
| Kiss Industries to formulate and sell Axim Biotechnologies' chewing gum containing cannabinoids in the U.S. and Mexico | Axim Biotechnologies Inc. | Kiss Industries | Payment unspecified | 7/9/19 |
| Bayer and BMS to evaluate the combination of Stivarga and Opdivo against micro-satellite stable metastatic colorectal cancer | Bayer AG | Bristol-Myers Squibb Co. | Payment unspecified | 7/18/19 |
| Be The Match to support clinical trials of Tmunity's T cell immunotherapies against solid tumor and hematological cancer using Matchsource supply chain software | Be The Match Biotherapies | Tmunity Therapeutics Inc. | Payment unspecified | 7/9/19 |
| Sun Pharmaceutical to develop Luzhu Biotechnology's K-3 for psoriasis, rheumatoid arthritis, ankylosing spondylitis and K-11 for cancer | Beijing Luzhu Biotechnology Co. Ltd. | Beijing Science Sun Pharmaceutical Co. Ltd. | $1.22 | 7/24/19 |
| Adamis to use Belcher’s patents for Adamis’ Symjepi as part of patent litigation settlement worldwide | Belcher Pharmaceuticals Inc. | Adamis Pharmaceuticals Corp. | Unknown | 7/24/19 |
| Bioneer and Bio-Manguinhos to collaborate on in vitro diagnostics and new drugs in Latin America | Bioneer Corp. | Bio-Manguinhos/Fiocruz | Payment unspecified | 7/8/19 |
| Genmab to develop and commercialize Blink's CD47 antibodies using Duobody platform against cancer | Blink Biomedical SAS | Genmab A/S | $202.25 | 7/12/19 |
| Brammer Biopharmaceuticals to manufacture Amicus Therapeutics' intrathecal adeno-associated virus Batten disease gene therapy programs | Brammer Biopharmaceuticals LLC | Amicus Therapeutics Inc. | Payment unspecified | 7/1/19 |
| Boehringer and Bridge Biotherapeutics to develop BBT-877 against fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis worldwide | Bridge Biotherapeutics Inc. | Boehringer Ingelheim International GmbH | $1,286.52 | 7/18/19 |
| Ra Pharmaceuticals to develop and commercialize zilucoplan long acting formulation using Camurus's Fluidcrystal technology worldwide | Camurus AB | Ra Pharmaceuticals Inc. | $71.50 | 7/16/19 |
| Chimerix to develop and commercialize Cantex Pharmaceuticals' CX-01 for acute myeloid leukemia worldwide | Cantex Pharmaceuticals Inc. | Chimerix Inc. | $617.50 | 7/26/19 |
| Cediprof to distribute Lannett's Levothyroxine sodium tablets in the U.S., excluding Puerto Rico and the Virgin Islands | Cediprof Inc. | Lannett Co. Inc. | $20.00 | 7/3/19 |
| Celltrion and Nan Fung to establish a joint venture, Vcell Healthcare Ltd. to develop and commercialize CT-P13, CT-P10 and CT-P6 in China | Celltrion Inc. | Nan Fung Group Holdings Ltd. | Payment unspecified | 7/18/19 |
| Kyowa to produce monoclonal antibodies using Chiome's technology platform | Chiome Bioscience Inc. | Kyowa Kirin | Payment unspecified | 7/29/19 |
| Cipla EU and Jiangsu Acebright to set up a joint venture in China to manufacture local respiratory products | Cipla Europe NV | Jiangsu Acebright Pharmaceutical Co. Ltd. | Unknown | 7/16/19 |
| Aura Biosciences to use Clearside's Suprachoroidal space microinjector for delivery of therapeutics against ocular cancers worldwide | Clearside Biomedical Inc. | Aura Biosciences Inc. | Payment unspecified | 7/9/19 |
| Clover Therapeutics and Genentech to conduct research on genetics of ocular diseases | Clover Therapeutics | Genentech Inc. | Payment unspecified | 7/10/19 |
| Convelo and Genentech to discover and develop remyelinating therapies for neurological disorders, including multiple sclerosis worldwide | Convelo Therapeutics Inc. | Genentech Inc. | Payment unspecified | 7/16/19 |
| CVS Caremark to distribute Titan Pharmaceuticals' Probuphine implant for opioid use disorder in the U.S. | CVS Caremark | Titan Pharmaceuticals Inc. | Payment unspecified | 7/9/19 |
| Upsher-Smith acquires assets of Zembrace and Tosymra from Dr. Reddy's in the U.S. | Dr. Reddy's Laboratories Ltd. | Upsher-Smith Laboratories Inc. | $110.50 | 7/23/19 |
| Gilead Sciences to develop and commercialize Durect's HIV product using Saber technology | Durect Corp. | Gilead Sciences Inc. | $320.00 | 7/22/19 |
| Confo Therapeutics and Dynabind to discover undisclosed G protein-coupled receptor modulating compounds worldwide | Dynabind GmbH | Confo Therapeutics NV | Payment unspecified | 7/3/19 |
| Egeen to conduct clinical phase IIb trial of Cyxone’s rabeximod against rheumatoid arthritis in select Eastern European countries | Egeen Inc. | Cyxone AB | Payment unspecified | 7/19/19 |
| Exscientia and Rallybio to form joint venture for the discovery of small molecule therapeutics for rare diseases using artificial intelligence drug discovery platform | Exscientia Co. Ltd. | Rallybio LLC | Payment unspecified | 7/23/19 |
| Ono to develop, manufacture and commercialize Forty's 5F9 and other antibodies against CD47 in Japan, South Korea, Taiwan and the ASEAN countries | Forty Seven Inc. | Ono Pharmaceutical Co. Ltd. | $119.80 | 7/10/19 |
| Astellas to develop and commercialize Frequency’s FX-322 for sensorineural hearing loss worldwide, excluding the U.S. | Frequency Therapeutics | Astellas Pharma Inc. | $625.00 | 7/17/19 |
| Dionymed to distribute Fruit Slabs' cannabis portfolio against pain, anxiety and sleep disorder in Central Valley and Northern California | Fruit Slabs | Dionymed Brands Inc. | Payment unspecified | 7/11/19 |
| Gilead to develop Galapagos's GLPG-1690 for idiopathic pulmonary fibrosis, with an option to develop GLPG-1972 in the U.S. for osteoarthritis and other clinical programs outside of Europe | Galapagos NV | Gilead Sciences Inc. | $6,525.00 | 7/14/19 |
| Avalon and GE Healthcare to accelerate the standardization, automation and bio-production for Chimeric antigen receptor T cell therapy, cellular immunotherapy and exosomes/extracellular vesicles based regenerative therapeutics | GE Healthcare | Avalon Globocare Corp. | Payment unspecified | 7/22/19 |
| Hikma to commercialize Gedeon Richter's cariprazine for schizophrenia in Bahrain, Egypt, Jordan, Iraq, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Sudan, Syria and United Arab Emirates | Gedeon Richter Ltd. | Hikma Pharmaceuticals plc | Payment unspecified | 7/25/19 |
| Beijing SL Pharmaceutical to advance the development of Gemphire's gemcabene for dyslipidemias in China | Gemphire Therapeutics Inc. | Beijing SL Pharmaceutical Co. Ltd. | $2.50 | 7/24/19 |
| Yaopharma to acquire all stock rights of Glaxosmithkline's lamivudine tablets against infections | Glaxosmithkline plc | Yaopharma Co. Ltd. | $36.64 | 7/8/19 |
| Torrent to co-market Glenmark's remogliflozin etabonate for type 2 diabetes in India | Glenmark Pharmaceuticals Ltd. | Torrent Pharmaceuticals Ltd. | Payment Unspecified | 7/11/19 |
| Ecobrands to distribute Green Gorilla's organic hemp cannabidiol products in Europe and Scandinavia | Green Gorilla | Ecobrands AS | $10.00 | 7/17/19 |
| Grupo RPH to manufacture and distribute Telix Pharmaceuticals' TLX591-Cdx for prostate cancer in Brazil | Grupo RPH Radiopharmacus SA | Telix Pharmaceuticals Ltd. | Payment unspecified | 7/3/19 |
| Wuxi Pharmatech to develop Guangdong Zhongsheng Pharmaceutical's ZSYM-011 for the treatment of diabetic macular edema | Guangdong Zhongsheng Pharmaceutical Co. Ltd. | Wuxi Pharmatech (Cayman) Inc. | Payment unspecified | 7/1/19 |
| Guangzhou Treatgut Biotech and Guangzhou Moon Biotech to discover, develop and promote microecological drugs for ulcerative colitis | Guangzhou Treatgut Biotech | Guangzhou Moon Biotech | Payment unspecified | 7/16/19 |
| GVK BIO to develop set of injectables for Biological E | GVK Biosciences Pvt. Ltd. | Biological E Ltd. | Payment unspecified | 7/31/19 |
| Daewoong to co-promote Lundbeck's Ebixa for Alzheimer disease in Korea | H Lundbeck A/S | Daewoong Pharmaceutical Co. Ltd. | Payment unspecified | 7/12/19 |
| Endo to commercialize Helsinn's Pracinostat for acute myeloid leukemia in Canada | Helsinn Group | Endo International plc | Payment unspecified | 7/31/19 |
| Hikma to manufacture and supply 14 essential generic medicines for Civica Rx in the U.S. | Hikma Pharmaceuticals plc | Civica Inc. | Payment unspecified | 7/23/19 |
| Roche to use Imaginab's minibody CD8 T-cell imaging agent for cancer clinical trials | Imaginab Inc. | Roche Holding AG | Payment unspecified | 7/9/19 |
| Immunoprecise Antibodies and Entos Pharmaceuticals to antibody against an immuno-oncology target using B cell select platform | Immunoprecise Antibodies Ltd. | Entos Pharmaceuticals Inc. | Payment unspecified | 7/15/19 |
| Incyte and Zai Lab to develop and commercialize INCMGA-0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan | Incyte Corp. | Zai Lab Ltd. | $77.50 | 7/2/19 |
| Aum Biosciences to develop and commercialize Inflection Biosciences' IBL-302 for cancers worldwide | Inflection Biosciences Ltd. | Aum Biosciences Pte. Ltd. | Payment unspecified | 7/17/19 |
| Inscopix and Biogen to research and develop therapies for chronic pain | Inscopix | Biogen Inc. | Payment unspecified | 7/15/19 |
| Glaukos to research, develop, manufacture and commercialize Intratus’ drug delivery platform for dry eye disease, glaucoma and other corneal disorders worldwide | Intratus Inc. | Biogen Inc. | Payment unspecified | 7/22/19 |
| Iontas to optimize human monoclonal antibodies for Teva's targets | Iontas Ltd. | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 7/29/19 |
| Celsius to identify the predictive response biomarkers in Janssen's Vega study using single cell genomics and machine learning platform | Janssen Biotech Inc. | Celsius Therapeutics Inc. | Payment unspecified | 7/9/19 |
| Celgene to develop and commercialize Jounce' JTX-8064 for cancer worldwide | Jounce Therapeutics Inc. | Celgene Corp. | $530.00 | 7/22/19 |
| Onkure to develop Kdac Therapeutics' OKI-422 against cancer | Kdac Therapeutics Inc. | Onkure Inc. | Payment unspecified | 7/23/19 |
| LGC to manufacture Aptahem’s Apta-1 for concluding toxicological studies | LGC Group | Aptahem AB | Payment unspecified | 7/4/19 |
| SQ Innovation to use Ligand's captisol technology to develop captisol-enabled furosemide formulation for edema in heart failure patients worldwide | Ligand Pharmaceuticals Inc. | SQ Innovation AG | Payment unspecified | 7/8/19 |
| Lonza to manufacture and supply Omeros' narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy | Lonza Group AG | Omeros Corp. | Payment unspecified | 7/31/19 |
| Gilead and Lyndra to develop and commercialize ultra-long-acting oral human immunodeficiency virus therapies | Lyndra Therapeutics Inc. | Gilead Sciences Inc. | Payment unspecified | 7/9/19 |
| Lysando and Aicuris to develop Artilysin based drugs for bacterial infections, including hospital-acquired pneumonia, sepsis and cystic fibrosis | Lysando AG | Aicuris Anti-infective Cures GmbH | Payment unspecified | 7/9/19 |
| Puretech Health acquires LYT-100 for the treatment of lymphatic and immunofibrotic diseases, including lymphedema from Lyticon | Lyticon LLC | Puretech Health plc | Payment unspecified | 7/17/19 |
| I-Mab to develop and commercialize Macrogenics' enoblituzumab for cancer in mainland China, Hong Kong, Macau and Taiwan | Macrogenics Inc. | I-Mab Biopharma (Shanghai) Co. Ltd. | $150.00 | 7/10/19 |
| Aequus to distribute Medicom’s Evolve line of dry eye products in Canada | Medicom Healthcare | Aequus Pharmaceuticals Inc. | Payment unspecified | 7/29/19 |
| Mercachem to provide services to Gotham Therapeutics for accelerated hit generation and hit-to-lead expansion for epitranscriptomic target space | Mercachem Holding BV | Gotham Therapeutics Corp. | Payment unspecified | 7/17/19 |
| Merck and Phanes to enter a memorandum of understanding to develop and manufacture biologics for solid tumors | Merck & Co. Inc. | Phanes Therapeutics | Payment unspecified | 7/24/19 |
| Novartis and Mirati to evaluate the combination of MRTX-849 and TNO-155 against solid tumors | Mirati Therapeutics Inc. | Novartis AG | Payment unspecified | 7/9/19 |
| SCM and Mitoimmune to develop therapies against intractable, inflammatory, and rare diseases using clonal mesenchymal stem cells and mitochondria technology | Mitoimmune Therapeutics Inc. | SCM Lifescience Ltd. | Payment unspecified | 7/11/19 |
| Evotec acquired assets from Ncardia to advance induced pluripotent stem cells platform | Ncardia AG | Evotec SE | Payment unspecified | 7/24/19 |
| Lannett to distribute Neolpharma's generic levothyroxine sodium tablets for thyroid deficiency in the U.S. | Neolpharma Group | Lannett Co. Inc. | $20.00 | 7/8/19 |
| Ocumension to develop and commercialize Nicox's NCX-4251 for blepharitis in mainland China, Hong Kong, Macau and Taiwan | Nicox SA | Ocumension Therapeutics | $11.57 | 7/2/19 |
| Nimbus expanded the collaboration with Celgene to include Hematopoietic Progenitor Kinase 1 (HPK1) program against oncology | Nimbus Therapeutics Inc. | Celgene Corp. | Payment unspecified | 7/9/19 |
| Nosopharm and Evotec to advance development of NOSO-502 for Enterobacteriace infection and NOSO-2G for the treatment of complicated urinary tract infections and complicated intra-abdominal infections | Nosopharm SAS | Evotec SE | Payment unspecified | 7/3/19 |
| Novamedica to manufacture Unipharm's Melaxen in Russia | Novamedica | Unipharm Inc. | Payment unspecified | 7/26/19 |
| Mundipharma to commercialize Novartis' medicines for glaucoma and external eye diseases in Taiwan | Novartis AG | Mundipharma International Corp. Ltd. | Payment unspecified | 7/25/19 |
| Recordati to acquire Novartis' Signifor, Signifor LAR and LCI-699 for Cushing’s disease and acromegaly | Novartis AG | Recordati SpA | $390.00 | 7/12/19 |
| Gilead to develop and commercialize Novartis' three preclinical programs and agents against three undisclosed targets for human rhinovirus, influenza and herpes viruses worldwide | Novartis AG | Gilead Sciences Inc. | $291.00 | 7/19/19 |
| Pepdesign to use Numaferm’s technology platform for manufacturing diabetes and obesity drugs | Numaferm GmbH | Pepdesign SIA | Payment unspecified | 7/22/19 |
| Mundipharma to commercialize Orexo's Zubsolv (buprenorphine/naloxone) for the treatment of opioid dependence in Australia and New Zealand | Orexo AB | Mundipharma Pty Ltd. | Payment unspecified | 7/10/19 |
| Desitin to distribute Orphelia's Kigabeq for infantile spasms in Germany | Orphelia Pharma SA | Desitin Arzneimittel GmbH | Payment unspecified | 7/16/19 |
| Aevi Genomic Medicine to develop and commercialize OSI Pharmaceuticals’ OSI-027 for congenital lymphatic malformations worldwide | OSI Pharmaceuticals Inc. | Aevi Genomic Medicine Inc. | $0.50 | 7/15/19 |
| Paragon Gene Therapy to provide development and manufacturing services for Avexis’ Zolgensma for spinal muscular atrophy | Paragon Bioservices Inc. | Avexis Inc. | Payment unspecified | 7/16/19 |
| Paragon to manufacture Novavax's Nanoflu and Resvax | Paragon Bioservices Inc. | Novavax Inc. | Payment unspecified | 7/31/19 |
| Paragon Gene Therapy to provide clinical manufacturing capabilities and capacity for Amicus' multiple active preclinical lysosomal disorder programs | Paragon Gene Therapy | Amicus Therapeutics Inc. | Payment unspecified | 7/2/19 |
| Penn Pharmaceutical to manufacture and supply Zogenix's Fintepla for epilepsy | Pen Pharmaceutical Services Ltd. | Zogenix Inc. | Payment unspecified | 7/17/19 |
| Peptidream to use peptide discovery platform system technology for the identification of novel macrocyclic/constrained peptides for use as peptide-drug conjugates against multiple targets of interest selected by Novartis | Peptidream Inc. | Novartis AG | Payment unspecified | 7/1/19 |
| Shijiazhuang to register, market and distribute Peptonic Medical's Vagivital for Vaginitis in People's Republic of China | Peptonic medical AB | Shijiazhuang Yuanjia Biotechnology Co. Ltd. | $0.14 | 7/25/19 |
| Asieris Meditech to develop and commercialize Photocure’s Cevira for human papillomavirus induced cervical precancerous lesions worldwide | Photocure ASA | Asieris Pharmaceuticals Co. Ltd. | $250.00 | 7/1/19 |
| Mundipharma to distribute, market and sell Prestige Biopharma’s Tuznue in western European markets, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria | Prestige Biopharma | Mundipharma International Corp. Ltd. | Payment unspecified | 7/2/19 |
| Pharmapark to commercialize Prestige Biopharma's trastuzumab biosimilar in the Russian Federation | Prestige Biopharma Pte. Ltd. | Pharmapark LLC | Payment unspecified | 7/8/19 |
| Kappa to use Probiotix' LPLDL to address cardiovascular health in the 27 countries, largely in Europe, including Russia and Singapore | Probiotix Health Ltd. | Kappa Bioscience AS | Payment unspecified | 7/1/19 |
| Tenshindo to use Probiotix' LPLDL to address cardiovascular health in Japan | Probiotix Health Ltd. | Tenshindo Inc. | Payment unspecified | 7/3/19 |
| Pro Med to distribute Mobidiag's Amplidiag and Novodiag in African countries, including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya and Uganda | Promed Diagnostics Ltd. | Mobidiag Oy | Payment unspecified | 7/1/19 |
| Jazz Pharmaceuticals acquires Redx Pharma's pan-RAF inhibitor program for treatment of cancer | Redx Pharma plc | Jazz Pharmaceuticals plc | $206.50 | 7/10/19 |
| Neurimmune to develop and commercialize AAV gene therapies using Regenxbio's NAV technology for neurodegenerative diseases worldwide | Regenxbio Inc. | Neurimmune Holding AG | Payment unspecified | 7/24/19 |
| Pfizer to use Regenxbio's intellectual property related to NAV AAV9 vector to develop and commercialize gene therapies for Friedreich's ataxia | Regenxbio Inc. | Pfizer Inc. | Payment unspecified | 7/31/19 |
| Sanara Medtech to develop and commercialize antimicrobial products using Rochal Industries’ patents and pending patent applications worldwide | Rochal Industries LLP | Sanara Medtech Inc. | $3.00 | 7/8/19 |
| Sanofi to acquire OTC rights to Roche's Tamiflu for marketing, scientific engagement and distribution against influenza in the U.S. | Roche Holding AG | Sanofi SA | Payment unspecified | 7/23/19 |
| Avion to develop and commercialize Romeg's Gloperba for gout in the U.S. | Romeg Therapeutics LLC | Avion Pharmaceuticals LLC | Payment unspecified | 7/16/19 |
| Salix to settle intellectual property litigation with Teva related to Apriso in the U.S. | Salix Pharmaceuticals Inc. | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 7/31/19 |
| Merck to commercialize Samsung's SB-8 biosimilar for Non-small-cell lung carcinoma in Europe | Samsung Bioepis | Merck & Co. Inc. | Payment unspecified | 7/19/19 |
| Samsung to manufacture and supply UCB's anti-tau candidate for treatment progressive supranuclear palsy | Samsung Biologics Co. Ltd. | UCB SA | Payment unspecified | 7/31/19 |
| Myokardia re-acquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi for $50M upfront, with an additional $30M payable to Sanofi by June 30, 2020 | Sanofi SA | Myokardia Inc. | $80.00 | 7/22/19 |
| Sanofi to manufacture Opiant Pharmaceuticals' OPNT-OO4 (drinabant) for the treatment of acute cannabinoid overdose | Sanofi SA | Opiant Pharmaceuticals Inc. | Payment unspecified | 7/23/19 |
| Bayer to use Sensyne Health's clinical artificial intelligence platform for development of cardiovascular therapeutics | Sensyne Health plc | Bayer AG | $6.43 | 7/31/19 |
| Servier Australia and Biocurate to sign memorandum of understanding to accelerate discovery of therapeutics and drugs | Servier Laboratories (Australia) Pty Ltd. | Biocurate Pty Ltd. | Payment unspecified | 7/15/19 |
| Kurve Technology and Seurat Therapeutics to use drug delivery device for IGF-1 for migraine prevention in adults | Seurat Therapeutics Inc. | Kurve Technology Inc. | Payment unspecified | 7/2/19 |
| AMR Centre to research, develop and manufacture Shionogi's COT-143 against Pseudomonas aeruginosa infection worldwide | Shionogi & Co. Ltd. | AMR Centre Ltd. | Payment unspecified | 7/22/19 |
| Mallinckrodt to develop and commercialize Silence's SLN-500 and with an option to up to two RNAi therapeutics against autoimmune diseases worldwide | Silence Therapeutics plc | Mallinckrodt plc | $2,104.00 | 7/18/19 |
| Genentech and Skyhawk to discover, develop and commercialize small molecules for oncology and neurological diseases using Skystar technology platform worldwide | Skyhawk Therapeutics Inc. | Genentech Inc. | $2,000.00 | 7/16/19 |
| Merck and Skyhawk to discover, develop and commercialize small molecules for neurological diseases and cancers using Skystar technology platform worldwide | Skyhawk Therapeutics Inc. | Merck & Co. Inc. | $600.00 | 7/8/19 |
| Alfasigma USA acquires Sloan Pharma's Zelnorm for irritable bowel syndrome with constipation | Sloan Pharma | Alfasigma USA Inc. | Payment unspecified | 7/8/19 |
| Casimir to develop Soleno's diazoxide choline controlled-release tablets for Prader-Willi syndrome | Soleno Therapeutics Inc. | Casimir Inc. | Payment unspecified | 7/25/19 |
| Sosei Heptares and Genentech to discover, develop and commercialize G protein-coupled receptor modulating small molecules and/or biologics for range of diseases worldwide | Sosei Heptares | Genentech Inc. | $1,026.00 | 7/16/19 |
| Spectronrx to develop, manufacture and supply Y-mabs' radiolabelled omburtamab against central nervous system tumor | Spectronrx | Y-mabs Therapeutics Inc. | Payment unspecified | 7/1/19 |
| Abzena to use Synaffix's Glycoconnect and Hydraspace technologies to develop therapies | Synaffix BV | Abzena plc | Payment unspecified | 7/23/19 |
| Syneos Health to provide commercialization services of Acerus Pharmaceuticals’ Natesto in the U.S. | Syneos Health Inc. | Acerus Pharmaceuticals Corp. | Payment unspecified | 7/30/19 |
| Teva to launch Hanmi's Hialuma for pain in osteoarthritis in the U.S. | Teva Pharmaceutical Industries Ltd. | Hanmi Pharmaceutical Co. Ltd. | Payment unspecified | 7/2/19 |
| Stowe to use TGV Health's intellectual property related to Zian, an anti-microbial molecule, to develop STE-006 for various eye and ear infections | TGV Group | Harrow Health Inc. | Payment unspecified | 7/29/19 |
| Mayfield to acquire intellectual property related TGV-Health's MAY-66 against bacterial infections | TGV Group | Mayfield Pharmaceuticals Inc. | Payment unspecified | 7/28/19 |
| Cannvas to develop and commercialize True Focus' natural, nutraceutical formulations to prevent THC overconsumption | True Focus International | Cannvas Medtech Inc. | $2.99 | 7/30/19 |
| Undisclosed U.S. based CMO to manufacture Leaf Pharmaceuticals’ LEAF-1404 for cancer | Undisclosed | Leaf Pharmaceuticals | Payment unspecified | 7/11/19 |
| Valeo Pharma to register, distribute and market an undisclosed pharmaceutical manufacturer's low molecular weight heparin biosimilar against deep vein thrombosis and pulmonary embolism in Canada | Undisclosed international pharmaceutical manufacturer | Valeo Pharma Inc. | Payment unspecified | 7/8/19 |
| Vaxart and Janssen to evaluate oral vaccine platform for universal influenza vaccine program worldwide | Vaxart Inc. | Janssen Vaccines & Prevention BV | Payment unspecified | 7/9/19 |
| Sanofi to develop and commercialize Verastem’s Copiktra for cancer in Russia and Commonwealth of Independent States, Turkey, the Middle East and Africa | Verastem Oncology Inc. | Sanofi SA | $47.00 | 7/25/19 |
| Vgxi to manufacture GT-EPIC based personalized cancer therapeutics to Geneos | Vgxi Inc. | Geneos Therapeutics Inc. | Payment unspecified | 7/22/19 |
| Ewopharma to distribute Vianex’s amikacin in Switzerland for bacterial infections | Vianex SA | Ewopharma AG | Payment unspecified | 7/30/19 |
| Lloyd to manufacture Viriom's Elpida and other drugs against human immunodeficiency virus infection in Indonesia | Viriom Inc. | Lloyd Laboratories Inc. | Payment unspecified | 7/2/19 |
| Morphosys to acquire option to develop and commercialize Vivoryon's small-molecule glutaminyl-peptide cyclotransferase-like inhibitors, including PQ-912 for cancer worldwide | Vivoryon Therapeutics AG | Morphosys AG | $16.85 | 7/8/19 |
| Abbisko Therapeutics to develop and commercialize X4 Pharmaceuticals' mavorixafor for oncology in greater China | X4 Pharmaceuticals Inc. | Abbisko Therapeutics Co. Ltd. | Payment unspecified | 7/16/19 |
| Boehringer Ingelheim and Yuhan to develop GLP1R/FGF21R agonist for the treatment of nonalcoholic steatohepatitis and related liver diseases | Yuhan Corp. | Boehringer Ingelheim International GmbH | $870.00 | 7/1/19 |
| Celgene selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the 2014 Azymetric collaboration and licensing agreement with Zymeworks | Zymeworks Inc. | Celgene Corp. | $7.50 | 7/17/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| ADC Therapeutics to use Freenome's multiomics platform to develop biomarker for relapsed or refractory diffuse large B-cell lymphoma | ADC Therapeutics Sarl | Freenome Inc. | Payment unspecified | 8/26/19 |
| Processa to develop and commercialize Akashi’s HT-100 for multiple fibrotic related diseases worldwide | Akashi Therapeutics | Processa Pharmaceuticals Inc. | $122.36 | 8/29/19 |
| Biotheus to obtain Alligator's antibody from Alligator-Gold platform for the creation of up to three bispecific molecules in greater China | Alligator Bioscience AB | Biotheus Inc. | $143.00 | 8/20/19 |
| Fannin Innovation to develop Atrapos Therapeutics' PM-43I for asthma | Atrapos Therapeutics LLC | Fannin Innovation Studio Inc. | Payment unspecified | 8/20/19 |
| Kyowa Kirin to amend the 2006 license agreement to acquire non-oncology rights of tivozanib in Aveo territories, including the U.S. and EU | Aveo Oncology Inc. | Kyowa Kirin Co. Ltd. | $416.00 | 8/1/19 |
| LEO Pharma to develop and market Bausch Health's brodalumab for psoriasis worldwide outside Europe, U.S. and Canada | Bausch Health Ireland Ltd. | LEO Pharma A/S | Payment unspecified | 8/13/19 |
| Neuropore to discover small molecule therapeutics for multiple targets, including amyotrophic lateral sclerosis using Benevolentai's artificial intelligence | Benevolentai Ltd. | Neuropore Therapies Inc. | Payment unspecified | 8/5/19 |
| Beroni and Newsouth Innovations to form joint venture, Penao Co. for the development of Penao against cancer | Beroni Group Ltd. | Newsouth Innovations Pty Ltd. | Payment unspecified | 8/28/19 |
| Vaxil to use BGN’s P-Esbp macromolecule to deliver a targeted cancer therapy worldwide | BGN Technologies | Vaxil Biotherapeutics Ltd. | Payment unspecified | 8/28/19 |
| Biologics to provide pharmacy services for Bayer Healthcare's Nubeqa for non-metastatic castration-resistant prostate cancer | Biologics Inc. | Bayer Healthcare Pharmaceuticals Inc. | Payment unspecified | 8/1/19 |
| Kyongbo Pharm to commercialize Can-Fite Biopharma's piclidenoson for psoriasis in South Korea | Can-Fite Biopharma Ltd. | Kyongbo Pharm Co. Ltd. | $4.00 | 8/1/19 |
| Celgene to divest Otezla and related assets to Amgen | Celgene Corp. | Amgen Inc. | $13,400.00 | 8/25/19 |
| Target Group to manufacture and distribute Cgreen’s True Focus in the U.S., Europe and the Caribbean as a tetrahydrocannabinol antidote | Cgreen Inc. | Target Group Inc. | $1.50 | 8/8/19 |
| Regenxbio to use Clearside's SCS Microinjector to deliver AAV gene therapies, including RGX-314 against wet age-related macular degeneration, diabetic retinopathy and other conditions worldwide | Clearside Biomedical Inc. | Regenxbio Inc. | $136.00 | 8/29/19 |
| Cmab Biopharma to develop and manufacture Suzhou Kintor's ascrinvacumab against cancer | Cmab Biopharma Co. Ltd. | Suzhou Kintor Pharmaceuticals Inc. | Payment unspecified | 8/20/19 |
| Cognate to manufacture Caladrius' CLBS-14 against no-option refractory disabling angina | Cognate Bioservices Inc. | Caladrius Biosciences Inc. | Payment unspecified | 8/7/19 |
| Columbia Care and Moller to develop cannabinoid-infused products to be sold worldwide, including Europe and the U.S. | Columbia Care LLC | Moller Pharma GmbH | Payment unspecified | 8/30/19 |
| Alvogen to distribute Covis Pharma’s Alvesco for asthma in Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Poland, Romania, Russia and Slovakia | Covis Pharma Sarl | Alvogen Inc. | Payment unspecified | 8/7/19 |
| Mustang to use CSL Behring’s cytegrity cell line to produce MB-107 for immunodeficiency | CSL Behring LLC | Mustang Bio Inc. | Payment unspecified | 8/27/19 |
| Celgene to use Darwinhealth's quantitative systems biology discovery platform to identify new targets for cancer drug development | Darwinhealth | Celgene Corp. | Payment unspecified | 8/28/19 |
| Diplomat Pharmacy and Allergy Partners to dispense in-office and in-home delivery for infusion drugs and biologics against various diseases | Diplomat Pharmacy Inc. | Allergy Partners PA | Payment unspecified | 8/8/19 |
| Calliditas to commercialize Falk Pharma's Budenofalk for all indications except orphan indications outside of liver targets in the U.S. | Dr Falk Pharma GmbH | Calliditas Therapeutics AB | $44.94 | 8/12/19 |
| Innovent to develop and commercialize Eli Lilly's OXM-3 for diabetes in China | Eli Lilly and Co. | Innovent Biologics Inc. | Payment unspecified | 8/21/19 |
| Enable Injections and Genentech to develop enfuse along with multiple molecule development programs | Enable Injections Inc. | Genentech Inc. | Payment unspecified | 8/21/19 |
| Cara to use Enteris' Peptelligence to develop and commercialize Korsuva tablet for pruritis, worldwide, excluding Japan and South Korea | Enteris Biopharma Inc. | Cara Therapeutics Inc. | $8.00 | 8/20/19 |
| E-Therapeutics to partner with an undisclosed pharma company to identify novel disease pathways and small molecules using its network-driven drug discovery approach for neurodegenerative disease | E-Therapeutics plc | Undisclosed | Payment unspecified | 8/13/19 |
| Evotec and Nosopharm to develop antibacterial agents against gram-negative bacteria | Evotec SE | Nosopharm SAS | Payment unspecified | 8/1/19 |
| Sanofi exercised the option to progress development of Exscientia's bispecific small-molecule project | Exscientia Ltd. | Sanofi SA | Payment unspecified | 8/5/19 |
| Ultragenyx and Genetx to develop GTX-102 for Angelman syndrome with an option to acquire Genetx | Genetx Biotherapeutics LLC | Ultragenyx Pharmaceutical Inc. | $45.00 | 8/14/19 |
| Toolgen to develop Genexine's Hyleukin-7 and other pipeline clinical candidates for human papilloma virus infections, lymphopenia and advanced solid tumors | Genexine Co. Ltd. | Toolgen Inc. | Payment unspecified | 8/20/19 |
| Pfizer and GSK form a 32/68 consumer healthcare joint venture, GSK Consumer Healthcare | Glaxosmithkline plc | Pfizer Inc. | Payment unspecified | 8/1/19 |
| IPS Specials and Grow Biotech to conduct clinical trials for Columbia Care's Beneseed tablets in the U.K. | Grow Biotech plc | Columbia Care LLC | Payment unspecified | 8/22/19 |
| Novartis to develop Iconic's ICON-4 for age-related macular degeneration with an option | Iconic Therapeutics Inc. | Novartis AG | Payment unspecified | 8/22/19 |
| Abbvie to conduct phase I study to evaluate combinations of Idera's tilsotolimod, nab-paclitaxel ABBV-368 and ABBV-181 against metastatic head and neck cancer | Idera Pharmaceuticals Inc. | Abbvie Inc. | Payment unspecified | 8/27/19 |
| Immatics Biotechnologies and Celgene to develop and commercialize T-lymphocyte cell therapies for multiple cancers worldwide | Immatics Biotechnologies GmbH | Celgene Corp. | $1,590.00 | 8/28/19 |
| Innovent and Shenogen Pharma to evaluate combination of Tyvyt with SNG-1005 against advanced cancer | Innovent Biologics Inc. | Shenogen Pharma Group Ltd. | Payment unspecified | 8/5/19 |
| Cyclerion Therapeutics to use Insphero's 3D Insight human liver models to evaluate praliciguat in nonalcoholic steatohepatitis and fibrotic liver disease patients | Insphero AG | Cyclerion Therapeutics Inc. | Payment unspecified | 8/27/19 |
| Hikma to acquire Insys Therapeutics' naloxone and epinephrine nasal spray | Insys Therapeutics Inc. | Hikma Pharmaceuticals plc | Payment unspecified | 8/9/19 |
| Chilion to acquire Insys' Syndros and Buprenorphine products | Insys Therapeutics Inc. | Chilion Group Holdings U.S. Inc. | $12.20 | 8/6/19 |
| Nabis to distribute Integrated Cannabis' infused pre-roll line Tarantula in California | Integrated Cannabis Company Inc. | Nabis | Payment unspecified | 8/27/19 |
| Glaxosmithkline exercised its option to license Ionis' antisense medicines against chronic hepatitis B virus infection | Ionis Pharmaceuticals Inc. | Glaxosmithkline plc | $262.00 | 8/27/19 |
| Ips Academia Japan to grant pluripotent stem cells related patent rights to Rheincell | Ips Academia Japan Inc. | Rheincell Therapeutics GmbH | Payment unspecified | 8/5/19 |
| Ips Academia Japan and Time Therapeutics to develop and sell therapeutic and prophylactic agents for Alzheimer's disease worldwide | Ips Academia Japan Inc. | Time Therapeutics Inc. | Payment unspecified | 8/16/19 |
| Xoma to acquire royalty rights of Janssen's clinical drug candidates | Janssen Biotech Inc. | Xoma Corp. | $2.50 | 8/12/19 |
| JMI Laboratories to evaluate Motif Bio's iclaprim against Listeria monocytogenes infection | JMI Laboratories | Motif Bio plc | Payment unspecified | 8/19/19 |
| Oncology Pharma to sign a letter of intent to codevelop Kalos Therapeutics' KTH-222 worldwide for the treatment of wide variety of cancers | Kalos Therapeutics Inc. | Oncology Pharma Inc. | Payment unspecified | 8/19/19 |
| Par Pharmaceutical to acquire U.S. marketing rights for the generic version of Keryx's Auryxia in litigation settlement | Keryx Biopharmaceuticals Inc. | Par Pharmaceutical Inc. | Payment unspecified | 8/5/19 |
| Path Bioanalytics to develop Laurel therapeutics' cavosonstat to treat cystic fibrosis worldwide, excluding Asia | Laurel Therapeutics Inc. | Path Bioanalytics | Payment unspecified | 8/20/19 |
| Aevi to acquire an option to develop and commercialize Medimmune's MEDI-2338 against adult-onset Still's disease worldwide | Medimmune LLC | Aevi Genomic Medicine Inc. | $162.00 | 8/6/19 |
| Onconova to conduct study to develop rigosertib using Mission Bio's Tapestri platform for targeted single-cell DNA analysis | Mission Bio Inc. | Onconova Therapeutics Inc. | Payment unspecified | 8/12/19 |
| Dexcel Pharma to commercialize Mithra’s Estelle and Myring contraceptive products in Israel | Mithra Pharmaceuticals | Dexcel Pharma | Payment unspecified | 8/20/19 |
| Nanjing Hicin to develop Nerviano Medical Sciences' I111b for acute myeloid leukemia worldwide | Nerviano Medical Sciences Srl | Nanjing Hicin Pharmaceutical Co. Ltd. | $25.28 | 8/8/19 |
| Italfarmaco to enter into a binding term sheet agreement with Neupharma to develop and commercialize inhaled teicoplanin for infections in cystic fibrosis patients | Neupharma Inc. | Italfarmaco SpA | Payment unspecified | 8/1/19 |
| CMSH to develop Neurelis' NRL-1 for seizure disorder in greater China | Neurelis Inc. | China Medical System Holdings Ltd. | Payment unspecified | 8/20/19 |
| Adaptimmune and Noile-Immune to develop SPEAR T-cell products using proliferation inducing and migration enhancing technology against solid tumors worldwide | Noile-Immune Biotech Inc. | Adaptimmune Therapeutics plc | $312.00 | 8/26/19 |
| Pharming to develop and commercialize Novartis’ CDZ-173 for activated phosphoinositide 3-kinase delta syndrome in U.S., Europe and worldwide | Novartis AG | Pharming Group NV | $20.00 | 8/13/19 |
| Toolgen and Nsage to research and develop stem cell therapy | Nsage Corp. | Toolgen Inc. | Payment unspecified | 8/22/19 |
| Generex Biotechnology Corp. acquired an additional 38% of Olaregen Therapeutix Inc. | Olaregen Therapeutix Inc. | Generex Biotechnology Corp. | Payment unspecified | 8/19/19 |
| Ology to provide manufacturing and stockpiling services to PHV’s Nipah vaccine | Ology Bioservices Inc. | Public Health Vaccines LLC | $9.00 | 8/12/19 |
| Onco360 to dispense Karyopharm's Nubeqa for non-metastatic castration-resistant prostate cancer | Onco360 | Karyopharm Therapeutics Inc. | Payment unspecified | 8/2/19 |
| Onco360 to dispense Celgene's Inrebic for myelofibrosis | Onco360 | Celgene Corp. | Payment unspecified | 8/16/19 |
| Oncologie and Merck to evaluate Bavituximab in combination with Keytruda for advanced gastric or gastroesophageal cancer | Oncologie Inc. | Merck & Co Inc. | Payment unspecified | 8/12/19 |
| Oncology Supply to distribute Emmaus Life Sciences' Endari for sickle cell disease | Oncology Supply | Emmaus Life Sciences Inc. | Payment unspecified | 8/28/19 |
| Orexo and Gaia to develop and commercialize a digital therapy for improving access to opioid use disorder treatment | Orexo AB | Gaia AG | Payment unspecified | 8/20/19 |
| Pharmaceutical Product Development to conduct clinical study for Harbour Biomed's oncology and immunology therapies | Pharmaceutical Product Development LLC | Harbour BioMed | Payment unspecified | 8/27/19 |
| Janssen Products to sell and distribute Pharmamar's Yondelis and other products in the U.S. and 40 more countries | Pharmamar SA | Janssen Products Inc. | Payment unspecified | 8/26/19 |
| Presage Biosciences to evaluate Bristol-Myers Squibb's early stage oncology targets in phase 0 trials using Presage's Civo platform | Presage Biosciences Inc. | Bristol-Myers Squibb Co. | Payment unspecified | 8/27/19 |
| Huons to distribute Prestige Bio's biosimilars, including HD-204 and PBP-1502 in South Korea | Prestige Biopharma | Huons Co. Ltd. | Payment unspecified | 8/28/19 |
| Asterion to acquire Preveceutical's intellectual property related to a Sol-Gel nasal delivery system, including cannabis and cannabinoids formulations | Preveceutical Medical Inc. | Asterion Ltd. | $2.65 | 8/6/19 |
| Rallybio acquires Prophylix’s rare disease programs | Prophylix Pharma AS | Rallybio LLC | Payment unspecified | 8/22/19 |
| Crozet Biopharma to develop Public Health Vaccines' single dose Nipah virus vaccine | Public Health Vaccines LLC | Crozet Biopharma LLC | $10.80 | 8/26/19 |
| Selecta and Asklepios to jointly develop and commercialize AAV gene therapies using Immtor platform for the treatment of rare and orphan genetic diseases | Selecta Biosciences Inc. | Asklepios Biopharmaceutical Inc. | Unknown | 8/6/19 |
| Haihe Biopharma and Junshi Biosciences to evaluate the combination of glumetinib and toripalimab for solid cancers | Shanghai Junshi Biosciences Co. Ltd. | Haihe Biopharma | Payment unspecified | 8/26/19 |
| Undisclosed company to develop and commercialize antibody-based products against solid tumors using Siamab's tumor-associated carbohydrate antigen discovery technology | Siamab Therapeutics Inc. | Undisclosed | $202.00 | 8/19/19 |
| Sinotherapeutics to distribute Lannett's Posaconazole delayed-release tablets 100mg in the U.S. | Sinotherapeutics Inc. | Lannett Co. Inc. | Payment unspecified | 8/28/19 |
| ADC Therapeutics and Sophia Genetics to identify genomic markers associated with phase II clinical trial of ADCT-402 in relapsed or refractory diffuse large B-cell lymphoma patients | Sophia Genetics Sa | ADC Therapeutics Sarl | Payment unspecified | 8/6/19 |
| Sosei and Takeda to discover, develop and commercialize G protein-coupled receptor targeting small molecules and biologics worldwide with initial focus on gastrointestinal disorders | Sosei Heptares | Takeda Pharmaceutical Co. Ltd. | $1,226.00 | 8/5/19 |
| AstraZeneca to purchase Sobi's priority review voucher for single new drug application or biologics license application | Swedish Orphan Biovitrum AB | Astrazeneca plc | $95.00 | 8/22/19 |
| Cspc Pharmaceuticals to develop and commercialize Synermore's omalizumab biosimilar for asthma and chronic idiopathic urticaria in China, excluding Hong Kong, Macau and Taiwan | Synermore Biologics Co. Ltd. | Cspc Pharmaceuticals Group Ltd. | $8.79 | 8/19/19 |
| Themis and Merck to discover and develop undisclosed vaccine candidates using virus vector-based platform | Themis Bioscience GmbH | Merck & Co. Inc. | $200.00 | 8/22/19 |
| Tetra Bio-Pharma to form joint venture with Thorne to develop compounds for chronic inflammatory conditions worldwide | Thorne Research Inc. | Tetra Bio-Pharma Inc. | Payment unspecified | 8/21/19 |
| Tonix acquires Trimaran’s assets related to certain pyran-based compounds, including TNX-1600 for post-traumatic stress disorder and central nervous system disorders | Trimaran Pharma Inc. | Tonix Pharmaceuticals Holding Corp. | $3.57 | 8/19/19 |
| Conagen acquires Undisclosed company's fermentation-based technology for glycoproteins production | Undisclosed | Conagen Inc. | Payment unspecified | 8/21/19 |
| Vizient to award Innovative Technology Contract to Kadiri Health for helicoll to treat diabetic leg ulcer and burn wounds | Vizient Inc. | Kadiri Health LLC | Payment unspecified | 8/16/19 |
| Newsoara to develop and commercialize Zenith's ZEN-3694 for all indications, including cancer in China, Hong Kong, Taiwan, and Macau | Zenith Epigenetics Ltd. | Newsoara Biopharma Co. Ltd. | $78.00 | 8/6/19 |
| Hoth to co-develop Zylo's anandamide loaded Z-pods for cutaneous lupus erythematosus | Zylo Therapeutics LLC | Hoth Therapeutics Inc. | Payment unspecified | 8/21/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Clovis and 3BP to discover 3B-201 and 3B-202 plus radiopharmaceuticals for three targets using 3BP’s technology platform worldwide and the U.S., excluding Europe, Russia, Turkey, Israel | 3B Pharmaceuticals GmbH | Clovis Oncology Inc. | $12.00 | 9/23/19 |
| Adaptive Biotechnologies to use next-generation sequencing-based Clonoseq assay to assess minimal residual disease across multiple drug development programs within the Amgen hematology portfolio worldwide | Adaptive Biotechnologies Corp. | Amgen Inc. | Payment unspecified | 9/17/19 |
| Adhex Pharma to manufacture Klaria Pharma's KL-00119 against migraine for clinical registration trial | Adhex Pharma | Klaria Pharma Holding Ab | Payment unspecified | 9/18/19 |
| Adrexpharma to distribute Medipharm’s cannabis concentrate derivative products in Germany | Adrexpharma GmbH | Medipharm Labs Inc. | Payment unspecified | 9/24/19 |
| Anchiano Therapeutics to acquire option rights to develop and commercialize ADT Pharmaceuticals' Pan-RAS inhibitor and PDE10/?-catenin inhibitor programs for cancer worldwide | ADT Pharmaceuticals | Anchiano Therapeutics | $3.00 | 9/23/19 |
| China National Biotec Group to distribute AAT's Algeness in mainland China | Advanced Aesthetic Technologies Inc. | China National Biotec Group | Payment unspecified | 9/19/19 |
| Talem and Agonox to sign a letter of intent to form a joint venture for the development of antibody therapeutics to target T cell mediated anti-tumor activity worldwide | Agonox Inc. | Talem Therapeutics | $720.00 | 9/24/19 |
| Albany Molecular Research to manufacture Translate Bio's preclinical and clinical-stage programs | Albany Molecular Research Inc. | Translate Bio MA Inc. | Payment unspecified | 9/12/19 |
| Horus expanded the agreement to distribute Alimera's Iluvien for diabetic macular edema in Belgium, the Netherlands and Luxembourg | Alimera Sciences Inc. | Horus Pharma SAS | Payment unspecified | 9/12/19 |
| Alivamab Discovery Services to provide Alivamab Mouse technology to discover and deliver antibodies for Janssen | Alivamab Discovery Services LLC | Janssen Research & Development LLC | Payment unspecified | 9/16/19 |
| Adhera Therapeutics to co-promote Allegis Pharmaceuticals' Nitrolingual Pumpspray to treat angina pectoris due to coronary artery disease | Allegis Pharmaceuticals LLC | Adhera Therapeutics Inc. | Payment unspecified | 9/6/19 |
| Allied and CBD Group to form joint venture for distribution of cannabinoid-based cosmetic and natural health products in China, Hong Kong and throughout Asia | Allied Corp. | CBD Group Asia Ltd. | Payment unspecified | 9/11/19 |
| Generex to acquire 51% of Altucell | Altucell Inc. | Generex Biotechnology Corp. | Payment unspecified | 11/25/19 |
| American Cryostem and Biosolutions to conduct clinical study on Atcell for post-concussion syndrome | American Cryostem Corp. | Biosolutions Clinical Research Center LLC | Payment unspecified | 9/11/19 |
| Apex to distribute Direct Biologics' mesenchymal stem cell derived exosomes | Apex Biologix | Direct Biologics LLC | Payment unspecified | 9/19/19 |
| Applied Biomath and Verseau to deliver the pharmacology, pharmacokinetic and target engagement analysis for treatment of cancer | Applied Biomath LLC | Verseau Therapeutics Inc. | Payment unspecified | 9/3/19 |
| Oxford Cannabinoid Technologies to acquire option rights to develop and commercialize Askat's CB2 receptor agonist, AAT-730 | Askat Inc. | Oxford Cannabinoid Technologies | Payment unspecified | 9/20/19 |
| Aslan and Bukwang to form joint venture Jaguahr Therapeutics to develop aryl hydrocarbon receptor antagonists | Aslan Pharmaceuticals Pte. Ltd. | Bukwang Pharmaceutical Co. Ltd. | $5.00 | 9/30/19 |
| Theragnostics to use Astrazeneca's intellectual property rights to develop radionuclide-labelled PARP inhibitors against cancer | Astrazeneca plc | Theragnostics Ltd. | Payment unspecified | 9/5/19 |
| Atomwise and Hansoh Pharmaceutical to design and discover eleven undisclosed target proteins in multiple therapeutic areas using artificial intelligence technology | Atomwise | Hansoh Pharmaceutical Group Company Ltd. | $1,500.00 | 9/11/19 |
| Atomwise and Oncostatyx to establish a joint venture to discover and develop KDM5B inhibitors for triple-negative breast cancer | Atomwise | Oncostatyx LLC | Payment unspecified | 9/10/19 |
| Atomwise and Atropos to launch joint venture for discovery of senescence modulating small molecules for cancer | Atomwise | Atropos Therapeutics Inc. | Unknown | 9/11/19 |
| Poly Pharmaceuticals to co-promote Aytu Bioscience's Tuzistra XR in the U.S. | Aytu Bioscience Inc. | Poly Pharmaceuticals Inc. | Payment unspecified | 9/4/19 |
| BC Platforms to provide clinical and genomic data management solution to Debiopharm oncology products | BC Platforms | Debiopharm SA | Payment unspecified | 9/18/19 |
| Be The Match to support clinical trials of Celyad's allogeneic CAR-T therapies for cancer | Be The Match Biotherapies | Celyad SA | Payment unspecified | 9/10/19 |
| Beam and Prime Medicine to research and develop prime editing technology to treat sickle cell disease and single base transition mutations in the U.S. | Beam Therapeutics Inc. | Prime Medicine Inc. | Payment unspecified | 9/30/19 |
| R-Pharm to sign letter of intent to develop and commercialize Beijing Health's nonavalent HPV vaccine against HPV infections and cervical cancer in Russia | Beijing Health Guard Biotechnology Co. Ltd. | R-Pharm | Payment unspecified | 9/5/19 |
| Novartis to use Benevolentai's technology to interrogate clinical trial and experimental data for oncology assets | Benevolentai Ltd. | Novartis Pharma AG | Payment unspecified | 9/5/19 |
| Vaxil Bio to use BGN's E-selectin targeted polymer to develop and commercialize targeted cancer therapy worldwide | BGN Technologies | Vaxil Biotherapeutics Ltd. | Payment unspecified | 9/23/19 |
| Bioglan to manufacture Follicum's FOL-005 against hair loss for phase II clinical trial | Bioglan Pharmaceuticals Co. | Follicum AB | Payment unspecified | 9/26/19 |
| Avanos to develop and commercialize Bioq Pharma's non-opioid post-operative pain pharmaceutical product in the U.S., Canada and Mexico | Bioq Pharma Inc. | Avanos Medical Inc. | Payment unspecified | 9/17/19 |
| Oncoheroes Biosciences to develop and commercialize Boehringer's volasertib for the treatment of pediatric cancer indications worldwide | Boehringer Ingelheim International GmbH | Oncoheroes Biosciences Inc. | Payment unspecified | 9/16/19 |
| Biomotiv and BMS to form and fund new companies to develop novel therapeutics against multiple diseases, with an acquisition option for BMS | Bristol-Myers Squibb Co. | Biomotiv LLC | Payment unspecified | 9/4/19 |
| Medicure International acquires the U.S. and Canadian marketing rights of Cadila Healthcare's Zypitamag (pitavastatin) | Cadila Healthcare Ltd. | Medicure International Inc. | $7.00 | 9/30/19 |
| Caredx and Nanostring to develop Histomap for identifying allograft rejection in transplant biopsy tissue | Caredx Inc. | Nanostring Technologies Inc. | Payment unspecified | 9/24/19 |
| Oxford Nanopore to use Caribou's CRISPR-Cas9 related intellectual property for nanopore sequencing worldwide | Caribou Biosciences Inc. | Oxford Nanopore Ltd. | Payment unspecified | 9/19/19 |
| Phio Pharmaceuticals to evaluate its self-delivering RNAi compounds to synergistically modify Carisma's chimeric antigen receptor macrophages for use in cancer | Carisma Therapeutics Inc. | Phio Pharmaceuticals Corp. | Payment unspecified | 9/9/19 |
| Catalent to manufacture Acura's LTX-03 tablets for pain | Catalent Inc. | Acura Pharmaceuticals Inc. | Payment unspecified | 9/9/19 |
| Catalent to manufacture and supply Minerva's roluperidone for the treatment of schizophrenia | Catalent Inc. | Minerva Neurosciences Inc. | $8.43 | 9/18/19 |
| Takeda to use Cerveau's MK-6240-[18F] in PET scanning for neurodegenerative diseases | Cerveau Technologies Inc. | Takeda Pharmaceutical Co. Ltd. | Payment unspecified | 9/27/19 |
| An undisclosed company to distribute Cesca Therapeutics' X-Series products worldwide, excluding China | Cesca Therapeutics Inc. | Undisclosed | $2.00 | 9/9/19 |
| Clinigen to distribute Cheplapharm's Etopophos and Vepesid against cancer in Australia and New Zealand | Cheplapharm Arzneimittel GmbH | Clinigen Group plc | Payment unspecified | 9/1/19 |
| Symbio to develop, manufacture and commercialize Chimerix’s brincidofovir worldwide for all human indications, excluding smallpox | Chimerix Inc. | Symbio Pharmaceuticals Ltd. | $185.00 | 9/30/19 |
| Mundipharma to develop and commercialize Cidara's intravenous rezafungin and option for subcutaneous rezafungin for fungal infections worldwide, excluding the U.S. and Japan | Cidara Therapeutics Inc. | Mundipharma International Corp. Ltd. | $615.76 | 9/3/19 |
| Kalbe to sell CJ Healthcare’s K-CAB for gastroesophageal reflux in Indonesia | CJ Healthcare Corp. | PT Kalbe Farma Tbk | Payment unspecified | 9/18/19 |
| Convenience Valet to distribute Medterra's cannabinoid products in the U.S. | Convenience Valet | Medterra CBD LLC | Payment unspecified | 9/26/19 |
| Wize Pharma to develop Copernicus Therapeutics' WP-REP1, an ophthalmic nonviral gene therapy, for the treatment of choroideremia worldwide | Copernicus Therapeutics Inc. | Wize Pharma Inc. | Payment unspecified | 9/4/19 |
| Fujifilm exercised its option with Cynata Therapeutics for a worldwide license to develop and commercialize CYP-001 for graft-versus-host disease | Cynata Therapeutics Ltd. | Fujifilm Corp. | Payment unspecified | 9/17/19 |
| Dariohealth and Dance Biopharm to integrate mist smart inhaler with digital platform for chronic disease patients | Dariohealth Corp. | Dance Biopharm Inc. | Payment unspecified | 9/11/19 |
| Alexion Pharmaceuticals to develop and commercialize Eidos' AG-01 for TTR amyloidosis in Japan | Eidos Therapeutics Inc. | Alexion Pharmaceuticals Inc. | $50.00 | 9/9/19 |
| Thermo Fisher to develop companion diagnostic using Oncomine test to identify RET-altered non-small-cell lung cancer and thyroid cancer patients for Eli Lilly's LOXO-292 | Eli Lilly and Co. | Thermo Fisher Scientific Inc. | Payment unspecified | 9/2/19 |
| Raqualia and Epigeneron to discover, with an option to develop and commercialize therapeutics using Locus-specific ChIP for idiopathic pediatric nephrosis syndrome | Epigeneron Inc. | Raqualia Pharma Inc. | Payment unspecified | 9/17/19 |
| Evotec and Takeda Pharmaceutical to develop five small molecule discovery programs against oncology, gastroenterology, neuroscience and rare diseases | Evotec SE | Takeda Pharmaceutical Co. Ltd. | $850.00 | 9/24/19 |
| Bluebird bio to conduct clinical studies for Forty Seven's FSI-174 and magrolimab as conditioning regimen prior to ex vivo lentiviral vector hematopoietic stem cell gene therapy | Forty Seven Inc. | Bluebird bio Inc. | Payment unspecified | 9/30/19 |
| Fujitsu and Peptidream to discover and develop peptide drugs using Digital Annealer | Fujitsu Ltd. | Peptidream Inc. | Payment unspecified | 9/20/19 |
| Futura Medical and Cbderma to form joint venture to develop Dermasys for cannabidiol delivery | Futura Medical plc | Cbderma Technology Ltd. | Payment unspecified | 9/10/19 |
| Gaba Therapeutics and Atai Life to develop GRX-917 for mood disorders, including anxiety and depression | Gaba Therapeutics | Atai Life Sciences AG | Payment unspecified | 9/20/19 |
| Adalta and GE Healthcare to develop i-bodies as diagnosis in immunotherapy | General Electric Co. | Adalta Pty Ltd. | Payment unspecified | 9/16/19 |
| DAS Therapeutics acquires GT Biopharma's GTB-004 for myasthenia gravis | GT Biopharma Inc. | DAS Therapeutics Inc. | $6.20 | 9/19/19 |
| Silanes to launch Hanmi's Amosartan plus and Amosartan Q for dyslipidemia and hypertension in Latin America | Hanmi Pharmaceutical Co. Ltd. | Laboratorios Silanes SA De CV | Payment unspecified | 9/11/19 |
| Happify and Sanofi to develop digital therapeutics for multiple sclerosis worldwide | Happify Inc. | Sanofi SA | Payment unspecified | 9/17/19 |
| Blanver to commercialize Helsinn's Pracinostat for acute myeloid leukemia in South America | Helsinn Healthcare SA | Blanver Farmoquimica Ltda | Payment unspecified | 9/2/19 |
| Pacific Alliance Group to acquire a majority stake in Hisun Bioray Bio-pharmaceutical | Hisun Bioray Bio-pharmaceutical Co. Ltd. | Pacific Alliance Group | $556.97 | 9/4/19 |
| Batavia to use Horizon's GS knockout CHO K1 cell line expression system to develop antibody expressing cell lines | Horizon Discovery Group plc | Batavia Biosciences BV | Payment unspecified | 9/3/19 |
| Glenmark to use Horizon's GS knockout CHO K1 cell line expression system to manufacture biotherapeutics | Horizon Discovery Group plc | Glenmark Pharmaceuticals Ltd. | Payment unspecified | 9/30/19 |
| Hummingbird and Amgen to codiscover antibody therapeutics using rational drug discovery platform against cancers | Hummingbird Bioscience Pte. Ltd. | Amgen Inc. | $1,200.00 | 9/19/19 |
| Novartis and IFM Due to research and develop cGAS/STING programs against inflammatory and autoimmune diseases, with an option to acquire IFM Due | IFM Due | Novartis AG | $840.00 | 9/5/19 |
| Ildong to market Glaxosmithkline's Relenza for the treatment of influenza A and B virus infections | Il Dong Pharmaceutical Co. Ltd. | Glaxosmithkline plc | Payment unspecified | 9/6/19 |
| I-Mab Biopharma and Junshi Biosciences to evaluate the combination of TJD-5 with toripalimab to treat cancers in China | I-Mab Biopharma Co. Ltd. | Shanghai Junshi Biosciences Co. Ltd. | Payment unspecified | 9/10/19 |
| I-Mab and Merck to evaluate the combination of TJC-4 and Keytruda for multiple cancer types in a phase I clinical trial | I-Mab Biopharma Co. Ltd. | Merck & Co. Inc. | Payment unspecified | 9/23/19 |
| Immunomedics and Roche Holding to evaluate the safety and efficacy of the combination of Tecentriq (atezolizumab) and sacituzumab govitecan as a front-line treatment of patients with metastatic or inoperable locally advanced triple-negative breast cancer | Immunomedics Inc. | Roche Holding AG | Payment unspecified | 9/30/19 |
| Immunomedics and GBG Forschungs to develop sacituzumab govitecan as a treatment for newly diagnosed breast cancer patients | Immunomedics Inc. | GBG Forschungs-GmbH | Payment unspecified | 9/30/19 |
| Adhera to use Indegene's co-commercialization model to advance the commercialization of Prestalia in the U.S. | Indegene | Adhera Therapeutics Inc. | Payment unspecified | 9/10/19 |
| Selexis to commercialize Inflamacore's IC-100 for multiple inflammatory conditions | Inflamacore LLC | Selexis SA | Payment unspecified | 9/5/19 |
| Inflammasome and Boehringer Ingelheim to develop up to three therapies using intravitreal drug delivery technology for retinal diseases | Inflammasome Therapeutics Inc. | Boehringer Ingelheim International GmbH | $160.00 | 9/20/19 |
| Btcp Pharma acquires Insys’ Subsys for cancer pain management | Insys Therapeutics Inc. | Btcp Pharma LLC | $20.00 | 9/26/19 |
| Tris to market, sell and distribute Intellipharmaceutics' Desvenlafaxine Succinate ER in the U.S. | Intellipharmaceutics International Inc. | Tris Pharma Inc. | Payment unspecified | 9/5/19 |
| Roslin Technologies to use Ips Academia Japan's patents related to iPS cell-derived cells | Ips Academia Japan Inc. | Roslin Technologies Ltd. | Payment unspecified | 9/4/19 |
| Astrazeneca amended the agreement to obtain exclusive rights to develop, manufacture and commercialize Ironwood Pharmaceuticals' linaclotide in China | Ironwood Pharmaceuticals Inc. | Astrazeneca plc | Payment unspecified | 9/16/19 |
| Duchembio to develop and commercialize Isotopen's Solucin targeted radionuclide therapy for neuroendocrine tumors in South Korea | Isotopen Technologien München AG | Duchembio Co. Ltd. | Payment unspecified | 9/2/19 |
| Simcere and JW Pharmaceutical to develop and commercialize URC-102 against gout in China, Hongkong and Macau | JW Pharmaceutical Corp. | Simcere Pharmaceutical Group | Payment unspecified | 9/27/19 |
| Kahr Medical and Roche to evaluate the combination of DSP-107 with atezolizumab in phase I/II study to treat non-small-cell lung cancer | Kahr Medical Ltd. | Roche Holding AG | Payment unspecified | 9/9/19 |
| Kamada extended its strategic supply agreement with Takeda Pharmaceutical for Glassia through 2021, receiving royalties of 12% on net sales through August 2025 and 6% afterward until 2040 | Kamada Ltd. | Takeda Pharmaceutical Ltd. | Payment unspecified | 9/4/19 |
| Healthcare Royalty Partners to purchase Karyopharm's royalty to develop and commercialize Xpovio against heavily pretreated multiple myeloma worldwide | Karyopharm Therapeutics Inc. | Healthcare Royalty Partners | $150.00 | 9/16/19 |
| Boston Pharmaceuticals to develop and commercialize Kempharm's serdexmethylphenidate and d-methylphenidate based therapeutics for attention deficit and hyperactivity disorder worldwide | Kempharm Inc. | Boston Pharmaceuticals | $493.00 | 9/3/19 |
| Lexicon Pharmaceuticals to receive $260M for termination of the alliance with Sanofi for development and commercialization of Zynquista | Lexicon Pharmaceuticals Inc. | Sanofi SA | $260.00 | 9/12/19 |
| Huons to develop and commercialize Lipac's TSD-001 for various indications | Lipac Oncology LLC | Huons Co. Ltd. | Payment unspecified | 9/16/19 |
| Lonza to manufacture Celltrion Healthcare's Remsima for autoimmune diseases, including Crohn’s disease and rheumatoid arthritis | Lonza Group AG | Celltrion Healthcare Co. Ltd. | Payment unspecified | 9/3/19 |
| Cayman to use Lubrigreen Biosynthetics' patents related to fatty acid hydroxy fatty acid products | Lubrigreen Biosynthetics LLC | Cayman Chemical Co. Inc. | Payment unspecified | 9/3/19 |
| Boehringer Ingelheim and Lupin to develop and commercialize LNP-3794 and KRAS inhibitor combination drug to treat KRAS-driven cancers | Lupin Ltd. | Boehringer Ingelheim International GmbH | $720.00 | 9/4/19 |
| Lupin divests injectables business to Neopharma in Japan | Lupin Ltd. | Neopharma | Payment unspecified | 9/30/19 |
| BJ Bioscience and Medx to develop BJ-001 companion diagnostic for cancer | Medx (Suzhou) Translational Medicine Co. Ltd. | BJ Bioscience Inc. | Payment unspecified | 9/4/19 |
| Grunenthal to develop and commercialize Mesoblast’s MPC-06-ID for chronic low back pain in Europe and Latin America | Mesoblast Ltd. | Grunenthal GmbH | $1,150.00 | 9/9/19 |
| Mitsubishi to co-promote Santen’s Alesion 0.05% ophthalmic solution in Japan | Mitsubishi Tanabe Pharma Corp. | Santen Pharmaceutical Co. Ltd. | Payment unspecified | 9/20/19 |
| Daiichi Sankyo to commercialize Mitsubishi Tanabe's edaravone for amyotrophic lateral sclerosis in Brazil | Mitsubishi Tanabe Pharma GmbH | Daiichi Sankyo Co. Ltd. | Payment unspecified | 9/17/19 |
| Taisho to develop and commercialize Moberg's MOB-015 against onychomycosis in Japan | Moberg Pharma AB | Taisho Pharmaceutical Co. Ltd. | $50.00 | 9/30/19 |
| Mylan to distribute Eisai's Teceris for metastatic breast cancer in India | Mylan NV | Eisai Pharmaceuticals India Pvt. Ltd. | Payment unspecified | 9/20/19 |
| Hillstream to acquire Nanoproteagen's immuno-oncology assets, including HSB-114 and Quatramer technology | Nanoproteagen Inc. | Hillstream Biopharma Inc. | Payment unspecified | 9/10/19 |
| Eisai and Nichi-Iko Pharmaceutical to collaborate for the generic pharmaceutical business in China | Nichi-Iko Pharmaceutical Co. Ltd. | Eisai Co. Ltd. | Payment unspecified | 9/30/19 |
| Nissan and Veritas to discover small molecule drugs targeting nucleic acids | Nissan Chemical Corp. | Veritas In Silico Inc. | Payment unspecified | 9/6/19 |
| Amplyx acquired worldwide rights of Novartis’ MAU-868 for BK viral disease | Novartis Pharmaceuticals Corp. | Amplyx Pharmaceuticals Inc. | Payment unspecified | 9/16/19 |
| Cansino Biologics to develop, manufacture and commercialize Ocugen’s OCU-400 for inherited retinal diseases in greater China | Ocugen Inc. | Cansino Biologics Inc. | Payment unspecified | 9/30/19 |
| Optinose to grant Currax certain patent rights to market Onzetra Xsail in the U.S., Canada and Mexico | Optinose AS | Currax Pharmaceuticals LLC | $5.48 | 9/25/19 |
| Or-Genix and Fission Labs to develop molecule to formulate products for blemishes, oily skin and alopecia to be sold in Latin America | Or-Genix Therapeutics Inc. | Fission Labs Latam | Payment unspecified | 9/30/19 |
| Xoma acquires royalty interest in six clinical stage assets from Palobiofarma | Palobiofarma SL | Xoma Corp. | $10.00 | 9/26/19 |
| Peptidream and JSR to identify peptides applicable to the affinity chromatography process | Peptidream Inc. | JSR Corp. | Payment unspecified | 9/20/19 |
| Hanmi Pharmaceutical to use Phanes' antibody sequences to discover and develop bi and multi-specific antibodies for oncology worldwide | Phanes Therapeutics | Hanmi Pharmaceutical Co. Ltd. | Payment unspecified | 9/24/19 |
| Pharmaceutics to manufacture and supply Sagent's generic Fulvestrant Injection 250mg/5ml against breast cancer | Pharmaceutics International Inc. | Sagent Pharmaceuticals Inc. | Payment unspecified | 9/23/19 |
| Pharmeco to produce and distribute Roche's emicizumab for hemophilia A in Russia | Pharmeco | Roche Holding AG | Payment unspecified | 9/25/19 |
| Sandoz to commercialize Polpharma Biologics' natalizumab biosimilar for relapsing-remitting multiple sclerosis worldwide | Polpharma Biologics SA | Sandoz AG | Payment unspecified | 9/3/19 |
| Bayer to use Probiogen's Glymaxx to develop undisclosed antibody candidate for oncology | Probiogen AG | Bayer AG | Payment unspecified | 9/10/19 |
| Reprocell to distribute Neucyte's induced pluripotent stem cell-derived glutamatergic and gabaergic induced neurons in North America and Europe | Reprocell Inc. | Neucyte Inc. | Payment unspecified | 9/25/19 |
| Ribometrix and Vertex to develop RNA-targeted small molecule therapeutic candidates for serious diseases worldwide | Ribometrix Inc. | Vertex Pharmaceuticals Inc. | $720.00 | 9/30/19 |
| Askbio acquires Rovermed's nanotechnology cargo delivery platform assets | Rovermed Biosciences LLC | Asklepios Biopharmaceutical Inc. | Payment unspecified | 9/17/19 |
| Mindmed acquires Savant's 18-MC to treat drug addiction | Savant HWP Inc. | Mind Medicine Inc. | Payment unspecified | 9/16/19 |
| Astrazeneca to use Schrodinger's advanced computing platform to accelerate the drug discovery | Schrodinger LLC | Astrazeneca plc | Payment unspecified | 9/4/19 |
| Takeda and Schrodinger expanded the collaboration to discover multi-targets for various diseases using computational silico platform | Schrodinger LLC | Takeda Pharmaceuticals Co. Ltd. | Payment unspecified | 9/5/19 |
| Undisclosed pharmaceutical company to use Secarna’s Lnaplus oligonucleotides in oncology research | Secarna Pharmaceuticals GmbH & Co. KG | Undisclosed | Payment unspecified | 9/10/19 |
| Selexis to provide cell line expression technologies to develop Zyversa's IC-100 for multiple inflammatory conditions | Selexis SA | Zyversa Therapeutics Inc. | Payment unspecified | 9/5/19 |
| Sengine and Atomwise to form joint venture to accelerate the oncology drug discovery using platform technologies | Sengine Precision Medicine Inc. | Atomwise | Payment unspecified | 9/10/19 |
| Kalbe Genexine to develop and commercialize Shanghai Henlius' HLX-10 in 10 countries | Shanghai Henlius Biotech Co. Ltd. | Kalbe Genexine Biologics | $682.00 | 9/12/19 |
| Siegfried to manufacture and supply Aprea Therapeutics' APR-246 against cancer | Siegfried Hameln GmbH | Aprea Therapeutics AB | Payment unspecified | 9/19/19 |
| Solti to conduct clinical research on Context Therapeutics' Apristor in breast cancer patients | Solti Breast Cancer Research Group | Context Therapeutics LLC | Payment unspecified | 9/16/19 |
| Soricimed and IAG to develop SOR-C13 for solid cancer tumors | Soricimed Biopharma Inc. | Image Analysis Group | Payment unspecified | 9/5/19 |
| Sparsha to manufacture Nemaura Pharma's transdermal therapeutic systems in the U.S., Canadian and Latin American markets | Sparsha | Nemaura Pharma Ltd. | Payment unspecified | 9/27/19 |
| Terrascend to commercialize Syqe Medical's Syqe Inhaler in Canada | Syqe Medical Ltd. | Terrascend Corp. | Payment unspecified | 9/16/19 |
| Nippon Shokubai to develop TAK-Circulator’s TAKC-02 for steroid resistant severe asthma | Tak-Circulator Co. Ltd. | Nippon Shokubai Co. Ltd. | Payment unspecified | 9/10/19 |
| Genmab and Tempus to advance disease targets and biomarkers for generating treatments in oncology | Tempus Inc. | Genmab A/S | Payment unspecified | 9/9/19 |
| Johnson & Johnson exercised commercial option to license and advance Teneobio's undisclosed multispecific product for development in an oncology indication in return for milestones and royalties | Teneobio Inc. | Johnson & Johnson | Payment unspecified | 9/30/19 |
| Terumo to manufacture Teribone 28.2 microg for Asahi Kasei Pharma to treat osteoporosis with high risk of fractures | Terumo Corp. | Asahi Kasei Pharma Corp. | Payment unspecified | 9/20/19 |
| Super-Pharm to purchase 50% stake in Teva’s pharmaceutical preparations business to form a new company | Teva Pharmaceutical Industries Ltd. | Super Pharm Ltd. | Payment unspecified | 9/1/19 |
| Thermo Fisher to develop, commercialize and manufacture Frontier's 3-BNC-117 for HIV infection | Thermo Fisher Scientific Inc. | Frontier Biotechnologies Inc. | Payment unspecified | 9/26/19 |
| Zymeworks to use Trianni's mouse technology to discover and develop fully human monoclonal antibodies | Trianni Inc. | Zymeworks Inc. | Payment unspecified | 9/10/19 |
| Neucyte to develop and commercialize Trillium's preclinical compound for treatment of refractory epilepsy in the form of Dravet syndrome and related disorders worldwide | Trillium Therapeutics Inc. | Neucyte Inc. | Payment unspecified | 9/24/19 |
| Glycotope to use Tubulis' antibody drug conjugate (ADC) technologies, Tub-tag to identify the ADC candidates | Tubulis GmbH | Glycotope GmbH | Payment unspecified | 9/11/19 |
| Antibody technology company to evaluate Scancell's pipeline of monoclonal antibodies targeting TaGs using Avidimab technology against cancer | Undisclosed | Scancell Ltd. | Payment unspecified | 9/4/19 |
| Grunenthal and Uniquest to develop non-opioid drug therapies for chronic neuropathic pain | Uniquest Pty Ltd. | Grunenthal GmbH | Payment unspecified | 9/3/19 |
| Can-Fite and Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases | Univo Pharmaceuticals Ltd. | Can-Fite Biopharma Ltd. | $0.50 | 9/10/19 |
| VBI Vaccines and GSK to evaluate the combination of VBI-1901 with AS01B adjuvant in phase I/IIa clinical study against recurrent glioblastoma | VBI Vaccines Inc. | Glaxosmithkline plc | Payment unspecified | 9/10/19 |
| Alytas to use Velabs Therapeutics' microfluidic-based technology to develop immune-based therapy against obesity worldwide | Velabs Therapeutics GmbH | Alytas therapeutics GmbH | Payment unspecified | 9/3/19 |
| Widetrial further agreed to provide expanded access programs to Mateon Therapeutics to develop OT-101 for pancreatic cancer | Widetrial Inc. | Mateon Therapeutics Inc. | Payment unspecified | 9/9/19 |
| China Pharma to enter memorandum of understanding to develop World Health Advanced Technologies' Enercel in China | World Health Advanced Technologies Ltd. | China Pharma Holdings Inc. | Payment unspecified | 9/11/19 |
| X-Chem and Maruho to discover and develop compounds for novel targets against human diseases worldwide | X-Chem Inc. | Maruho Co. Ltd. | Payment unspecified | 9/4/19 |
| Flexion to develop and commercialize Xenon's XEN-402 with FX-301 for post-operative pain worldwide | Xenon Pharmaceuticals Inc. | Flexion Therapeutics Inc. | $127.75 | 9/9/19 |
| Merck and Y-Trap to develop and commercialize antibody-ligand traps for cancer immunotherapy | Y-Trap Inc. | Merck KGaA | Payment unspecified | 9/19/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| 3P to develop and manufacture Zhittya’s FGF-1 for clinical studies against Parkinson’s disease | 3P Biopharmaceuticlas SL | Zhittya Regenerative Medicine Inc. | Payment unspecified | 10/21/19 |
| 4D pharma and Merck to discover and develop live biotherapeutics as vaccines in up to three undisclosed indications | 4D pharma plc | Merck & Co. Inc. | $1,047.50 | 10/8/19 |
| Reata Pharmaceuticals agreed to pay Abbvie $330M plus royalties to reacquire ex-U.S. development, manufacturing and commercialization rights for the Nrf2 activators bardoxolone methyl and omaveloxolone, as well as other next-generation candidates | Abbvie Inc. | Reata Pharmaceuticals Inc. | $330.00 | 10/10/19 |
| Disc Medicine to develop Abbvie's series of hemojuvelin antagonist monoclonal antibodies for anemia worldwide | Abbvie Inc. | Disc Medicine | Payment unspecified | 10/29/19 |
| Abzena to manufacture Sonnet Biotherapeutics' SON-1010 for solid tumor | Abzena plc | Sonnet Biotherapeutics Inc. | Payment unspecified | 10/22/19 |
| EPI Health to acquire Aclaris Therapeutics' worldwide intellectual property rights related to Rhofade for the treatment persistent facial erythema | Aclaris Therapeutics Inc. | EPI Health LLC | $55.00 | 10/10/19 |
| Emerge Health to distribute and commercialize Adamis Pharmaceuticals' Symjepi (epinephrine) in Australia and New Zealand | Adamis Pharmaceuticals Corp. | Emerge Health Pty. Ltd. | Payment unspecified | 10/1/19 |
| Indivior to provide Addex Therapeutics with an additional $800,000 to accelerate research progress in their collaboration to develop further oral gamma-aminobutyric acid subtype B positive allosteric modulator compounds for the treatment of addiction | Addex Therapeutics Ltd. | Indivior plc | $0.80 | 10/8/19 |
| Pfizer to develop Akcea Therapeutics' AKCEA-ANGPTL3-LRx against cardiovascular and metabolic diseases worldwide | Akcea Therapeutics Inc. | Pfizer Inc. | $1,550.00 | 10/7/19 |
| Aldevron to provide GMP manufacturing capacity for PTC's gene therapy against Friedreich ataxia and Angelman syndrome programs | Aldevron LLC | PTC Therapeutics Inc. | Payment unspecified | 10/7/19 |
| Pharmbio Korea to commercialize Alvogen's Teriparatide for osteoporosis in South Korea | Alvogen Inc. | Pharmbio Korea Co. Ltd. | Payment unspecified | 10/21/19 |
| Kamada to commercialize Alvogen's Teriparatide for osteoporosis in Israel | Alvogen Inc. | Kamada Ltd. | Payment unspecified | 10/21/19 |
| Jamp Pharma to commercialize Alvogen's Teriparatide for osteoporosis in Canada | Alvogen Inc. | Jamp Pharma Corp. | Payment unspecified | 10/21/19 |
| Emerald Organic Growth to develop and commercialize Amarantus Biosciences' eltoprazine, engineered skin substitute, mesencephalic astrocyte-derived neurotrophic factor against Attention-deficit/hyperactivity disorder, Parkinson’s, skin burns and vision loss worldwide | Amarantus Bioscience Holdings Inc. | Emerald Organic Products Inc. | $100.00 | 10/24/19 |
| Novocodex to develop and commercialize Ambrx's ARX-305 for CD70-positive cancers in China | Ambrx Inc. | Novocodex Biopharmaceuticals Co. Ltd. | Payment unspecified | 10/23/19 |
| Amerisourcebergen to provide dispensing and distribution services to Karyopharm's Xpovio against relapsed or refractory multiple myeloma | Amerisourcebergen Drug Corp. | Karyopharm Therapeutics Inc. | Payment unspecified | 10/1/19 |
| Beigene and Amgen to develop and commercialize oncology drugs worldwide, including China | Amgen Inc. | Beigene Co. Ltd. | $3,984.00 | 10/31/19 |
| Stallergenes and Anergis to evaluate the effects of the second-generation virosome-based continuous overlapping peptides allergen immunotherapy from Greer in a therapeutic model of birch allergy in mice | Anergis SA | Stallergenes Greer plc | Payment unspecified | 10/17/19 |
| Applied Genetic Technologies and Otonomy to co-develop and co-commercialize AAV-based gene therapy for sensorineural hearing loss | Applied Genetic Technologies Corp. | Otonomy Inc. | Payment unspecified | 10/1/19 |
| Puretech Health plc acquired the remaining 10% minority interests in Ariya Therapeutics Inc. | Ariya Therapeutics Inc. | Puretech Health plc | Payment unspecified | 10/1/19 |
| Editas and Asklepios to develop AAV vector delivery of genome editing medicines to treat neurological diseases | Asklepios Biopharmaceutical Inc. | Editas Medicine Inc. | Payment unspecified | 10/15/19 |
| ASM Aerosol to provide manufacturing and supply services for Foamix’s Amzeeq and FMX-103 | ASM Aerosol-Service AG | Foamix Pharmaceuticals Ltd. | Payment unspecified | 10/21/19 |
| Daiichi to acquire Astellas' Nasea, Perdipine and Oldeca for emesis and hypertension in Korea, Thailand, the Philippines, Indonesia, China and Taiwan | Astellas Pharma Inc. | Daiichi Sankyo Co. Ltd. | $88.44 | 10/15/19 |
| Cheplapharm Arzneimittel to commercialize Astrazeneca's Losec worldwide, excluding China, Japan, the U.S. and Mexico | Astrazeneca plc | Cheplapharm Arzneimittel GmbH | $276.00 | 10/1/19 |
| Imaginab and Astrazeneca to evaluate the utility and value of Imaginab's CD8 ImmunoPET technology in immuno-oncology drug development | Astrazeneca plc | Imaginab Inc. | Payment unspecified | 10/14/19 |
| Cheplapharm to commercialize Astrazeneca's Seroquel and Seroquel XR for schizophrenia and bipolar disorder in Europe and Russia | Astrazeneca plc | Cheplapharm Arzneimittel GmbH | $239.00 | 10/30/19 |
| Telix Pharmaceuticals and Aushealth to develop new therapeutics using molecularly targeted radiation platform for lung and ovarian cancer | Aushealth | Telix Pharmaceuticals Ltd. | $20.97 | 10/29/19 |
| Avacta to use its Affimer technology with pyrrolobenzodiazepine-based warhead and linker technologies to generate drug conjugates for cancer | Avacta Group plc | ADC Therapeutics SA | Payment unspecified | 10/10/19 |
| Aytu and Validus to co-promote Zolpimist for insomnia in the U.S. | Aytu Bioscience Inc. | Validus Pharmaceuticals LLC | Payment unspecified | 10/1/19 |
| Ginkgo Bioworks to use Berkeley Lights' optofluidic platform to develop development workflow for synthetic biology products | Berkeley Lights Inc. | Ginkgo Bioworks | $150.00 | 10/1/19 |
| Bioglan to manufacture Lobsor Pharmaceuticals' Lecigon for Parkinson's disease in Europe | Bioglan AB | Lobsor Pharmaceuticals AB | Payment unspecified | 10/2/19 |
| Allievex to develop Biomarin's tralesinidase alfa for MPS IIIB or Sanfilippo Syndrome Type B | Biomarin Pharmaceutical Inc. | Allievex Corp. | Payment unspecified | 10/23/19 |
| Basf and Biomillenia to identify dermocosmetic active ingredients for skin health | Biomillenia SAS | Basf SE | Payment unspecified | 10/7/19 |
| Q Biomed to enter settlement agreement with Bionucleonics to complete the outright acquisition of the non-opioid cancer bone pain drug strontium-89 chloride USP | Bionucleonics Inc. | Q Biomed Inc. | Payment unspecified | 10/2/19 |
| Ipsen to develop and commercialize Blueprint's BLU-782 for fibrodysplasia ossificans progressiva worldwide | Blueprint Medicines Corp. | Ipsen | $535.00 | 10/16/19 |
| Cycle Pharmaceuticals to use Catalent's Zydis technologies to develop formulations targeting rare metabolic and neurological disorders | Catalent Inc. | Cycle Pharmaceuticals Ltd. | Payment unspecified | 10/31/19 |
| Celmatix and Evotec to discover and develop preclinical programs for women's reproductive health | Celmatix Inc. | Evotec SE | Payment unspecified | 10/9/19 |
| Aytu Bioscience acquires Cerecor's Pediatric Portfolio | Cerecor Inc. | Aytu Bioscience Inc. | $43.00 | 10/10/19 |
| Cesca and Healthbanks to form joint venture Immunecyte Life Sciences to commercialize CAR-Txpress for use in immune cell banking, cell-based contract development and manufacturing services | Cesca Therapeutics Inc. | Healthbanks Biotech USA Inc. | Payment unspecified | 10/22/19 |
| Bausch Health to develop and commercialize Clearside's Xipere for macular edema associated with uveitis in the U.S. and Canada | Clearside Biomedical Inc. | Bausch Health Companies Inc. | $20.00 | 10/23/19 |
| Regenxbio to pay $2M for exercising its option to license Clearside Biomedical's SCS Microinjector | Clearside Biomedical Inc. | Regenxbio Inc. | $2.00 | 10/30/19 |
| Clinigen Group launched a managed access program to provide Progenics Pharmaceuticals' Azedra (iobenguane I 131) outside the U.S. | Clinigen Group plc | Progenics Pharmaceuticals Inc. | Payment unspecified | 10/10/19 |
| Cmab Biopharma to provide development and manufacturing services for BJ Bioscience's BJ-005 to suppport IND requirements of China and the US | Cmab Biopharma Inc. | BJ Bioscience Inc. | Payment unspecified | 10/11/19 |
| Cobra Biologics to manufacture Combigene’s CG-01 for clinical studies in epilepsy and commercial production | Cobra Biologics Holding AB | Combigene Ab | $0.16 | 10/14/19 |
| Kitov Pharma amended the marketing and distribution agreement with Coeptis Pharmaceuticals for commercialization of Consensi for the treatment of pain caused by osteoarthritis and amlodipine besylate for hypertension | Coeptis Pharmaceuticals Inc. | Kitov Pharma Ltd. | $99.50 | 10/11/19 |
| Redhill Biopharma to commercialize Cosmo's Aemcolo for Traveler’s Diarrhea in the U.S. | Cosmo Pharmaceuticals NV | Redhill Biopharma Ltd. | $112.00 | 10/18/19 |
| Takeda Pharmaceutical acquired an exclusive worldwide license to develop and commercialize CNP-101/TAK-101 from Cour Pharmaceutical Development | Cour Pharmaceutical Development Co. Inc. | Takeda Pharmaceutical Co. Ltd. | $420.00 | 10/22/19 |
| Sundial Growers to use Crescita's transdermal delivery technologies to develop topicals containing cannabis and hemp worldwide | Crescita Therapeutics Inc. | Sundial Growers Inc. | Payment unspecified | 10/28/19 |
| Cryoport to provide temperature-controlled logistics solutions to Adaptimmune's ADP-A2M4CD8 to treat cancer | Cryoport Inc. | Adaptimmune Therapeutics plc | Payment unspecified | 10/9/19 |
| Servier acquires CTI Biopharma's Pixuvri | CTI Biopharma Corp. | Servier | Payment unspecified | 10/1/19 |
| Axcella Health to use Cytoo's Myoscreen for development of novel Axa candidates against dysregulated muscle metabolism | Cytoo SA | Axcella Health Inc. | Payment unspecified | 10/23/19 |
| Parexel and Datavant to enable the connection of real-world data across all clinical trials by combining standard data workflow with connectivity technology | Datavant | Parexel International | Payment unspecified | 10/9/19 |
| Dicerna and Roche to develop DCR-HBVS and oligonucleotide therapeutics for HBV infection worldwide | Dicerna Pharmaceuticals Inc. | Roche Holding AG | $1,670.00 | 10/30/19 |
| Elevar and Neopharma to form 50/50 joint venture for commercialization of rivoceranib for gastric cancer in Middle East and North Africa and India | Elevar Therapeutics | Neopharma | Payment unspecified | 10/3/19 |
| Emerson to manufacture Biokier’s BKR-017 in type 1 diabetes patients | Emerson Resources Inc. | Biokier Inc. | Payment unspecified | 10/1/19 |
| Undislcosed company to research, develop and commercialize nucleic acid therapies using Entos' Fusogenix non-viral delivery technology | Entos Pharmaceuticals Inc. | Undisclosed | $109.00 | 10/2/19 |
| Exagen to support clinical study of Horizon’s pegloticase with methotrexate using Avise MTX test | Exagen Diagnostics Inc. | Horizon Therapeutics plc | Payment unspecified | 10/24/19 |
| Excelera to distribute Pfizer’s Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy | Excelerarx Corp. | Pfizer Inc. | Payment unspecified | 10/3/19 |
| Adaptate Biotherapeutics spins out from Gammadelta Therapeutics to focus on gamma delta T-cell-based cell therapy products | Gammadelta Therapeutics Ltd. | Adaptate Biotherapeutics Ltd. | Payment unspecified | 10/16/19 |
| GC Pharma to market Merck's Glucophage for diabetes in Korea | GC Pharma Ltd. | Merck Biopharma Co. Ltd. | Payment unspecified | 10/11/19 |
| Bavarian Nordic to acquire Glaxosmithkline's Rabipur and Encepur against rabies and tick-borne encephalitis worldwide | Glaxosmithkline plc | Bavarian Nordic A/S | $884.83 | 10/21/19 |
| Glenmark Holding to spin-off Ichnos Sciences for development of five clinical-stage assets in oncology, autoimmune disease and pain using bispecific antibodies based on the T-cell receptor platform | Glenmark Holding SA | Ichnos Sciences Inc. | Payment unspecified | 10/15/19 |
| Gilead to use Glympse’s Glympse Inside biomarkers to study treatments in nonalcoholic steatohepatitis patients | Glympse Bio Inc. | Gilead Sciences Inc. | Payment unspecified | 10/28/19 |
| Great Bay Bio and Guangzhou Boji Medical to form joint venture to develop GBB-101 against anemia | Guangzhou Boji Medical & Biotechnological Co. Ltd. | Great Bay Bio | Payment unspecified | 10/18/19 |
| Guangzhou Institutes of Biomedicine and Health (GIBH) to spinout Legion Pharma for the development of anti-tuberculosis therapies discovered through a partnership between the University of Birmingham and GIBH | Guangzhou Institutes of Biomedicine and Health | Legion Pharma | Payment unspecified | 10/23/19 |
| Leadxpro and Lundbeck to research on small molecule structure-based drug discovery of membrane protein targets | H Lundbeck A/S | Leadxpro AG | Payment unspecified | 10/7/19 |
| Medavate to acquire Neocart assets from Histogenics | Histogenics Corp. | Medavate Corp. | $7.00 | 5/8/19 |
| Hitgen to discover small molecule therapeutics for Galapagos' targets | Hitgen Ltd. | Galapagos NV | Payment unspecified | 10/16/19 |
| Shionogi and Hsiri Therapeutics to research and develop therapeutics for nontuberculous mycobacterial diseases and tuberculosis | Hsiri Therapeutics Inc. | Shionogi & Co. Ltd. | Payment unspecified | 10/11/19 |
| Foundation Medicine to support Ideaya's phase I/II clinical trial of IDE-196 against metastatic uveal melanoma by enabling the Foundationone CDx genomic approach | Ideaya Biosciences Inc. | Foundation Medicine Inc. | Payment unspecified | 10/8/19 |
| Immugenyx LLC partnered with an undisclosed global pharmaceutical company to develop humanized mice as a tool for drug development and testing | Immugenyx LLC | Undisclosed global pharmaceutical company | $0.08 | 10/23/19 |
| Alexion to acquire Immune Pharma's bertilimumab for inflammatory diseases | Immune Pharmaceuticals Inc. | Alexion Pharmaceuticals Inc. | Payment unspecified | 10/23/19 |
| Ph Pharma and Immunome to discover and develop antibody drug conjugates against oncology targets | Immunome Inc. | Ph Pharma Co. Ltd. | $100.00 | 10/21/19 |
| Innovent Biologics and Hutchison China Meditech expanded the agreement testing sintilimab and surufatinib in solid tumors | Innovent Biologics Inc. | Hutchison China Meditech Ltd. | Payment unspecified | 10/10/19 |
| Insilico Medicine and Jiangsu Chia Tai Fenghai Pharmaceutical to develop therapeutics against triple-negative breast cancer using artificial intelligence drug discovery platform | Insilico Medicine Inc. | Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. | $200.00 | 10/9/19 |
| Chemdiv and Insilico Medicine to provide drug discovery solutions by combining artificial intelligence techniques with an integrated drug discovery shared risk platform | Insilico Medicine Inc. | Chemdiv Inc. | Payment unspecified | 10/16/19 |
| Akero and Insphero to characterize the effects of AKR-001 on liver cells using three-dimensional insight human liver disease platform for nonalcoholic steatohepatitis and non-alcoholic fatty liver disease | Insphero AG | Akero Therapeutics Inc. | Payment unspecified | 10/3/19 |
| Neptune Wellness and IFF to codevelop hemp derived cannabidiol products in the U.S. | International Flavors & Fragrances Inc. | Neptune Wellness Solutions Inc. | Payment unspecified | 10/2/19 |
| Roche to evaluate the Inxmed's IN-10018 in combination with Cobimetinib against melanoma | Inxmed (Shanghai) Co. Ltd. | Roche Holding AG | Payment unspecified | 10/17/19 |
| ITG Isotope Technologies Garching to enter supply agreement with Nordic Nanovector for the medical radioisotope no-carrier-added Lutetium-177 (177Lu) endolucinbeta to support research and development, clinical and commercial supply of Betalutin | ITG Isotope Technologies Garching GmbH | Nordic Nanovector ASA | Payment unspecified | 10/8/19 |
| Neumentum to develop Janssen's JNJ-10450232 for pain worldwide | Janssen Pharmaceutica NV | Neumentum Inc. | Payment unspecified | 10/10/19 |
| Seneca Biopharma to enter non-binding term sheet to develop and commercialize Qyuns Therapeutics' monoclonal antibodies to treat autoimmune diseases worldwide | Jiangsu Qyuns Therapeutics Co. Ltd. | Seneca Biopharma Inc. | Payment unspecified | 10/30/19 |
| Jubilant Radiopharma to distribute Q Biomed's Metastron for cancer pain in the U.S. | Jubilant Radiopharma | Q Biomed Inc. | Payment unspecified | 10/3/19 |
| Biocon to develop and commercialize Just Evotec's biosimilar asset | Just-Evotec Biologics | Biocon Ltd. | Payment unspecified | 10/10/19 |
| Crispr and KSQ to use intellectual property related to cell therapy programs for editing gene targets identified using Crispromics for oncology | KSQ Therapeutics | Crispr Therapeutics AG | Payment unspecified | 10/15/19 |
| Lannett to distribute Respirent's generic Advair Diskus for asthma and chronic obstructive pulmonary disease in the U.S. | Lannett Co. Inc. | Respirent Pharmaceuticals Co. Ltd. | Payment unspecified | 10/1/19 |
| Leo Pharma and Foamix Pharmaceuticals settled patent litigation related to Finacea with Teva | Leo Pharma A/S | Teva Pharmaceutical Industries Ltd. | Payment unspecified | 10/21/19 |
| Lonza Biologics to manufacture Cellectis SA's allogeneic universal CAR T-cell candidates targeting hematological malignancies | Lonza Biologics | Cellectis SA | Payment unspecified | 10/2/19 |
| Lonza Group to manufacture Prevail Therapeutics' PR-001 and PR-006 for neurodegenerative disease | Lonza Group AG | Prevail Therapeutics Inc. | Payment unspecified | 10/8/19 |
| Lonza Group to manufacture Mesoblast's remestemcel-L for pediatric steroid-refractory acute graft-vs.-host disease | Lonza Group AG | Mesoblast Ltd. | Payment unspecified | 10/17/19 |
| GSK to use Lyell’s technologies to enhance benefit/risk profile of cancer cell therapies | Lyell Immunopharma Inc. | Glaxosmithkline plc | Payment unspecified | 10/8/19 |
| Sotio to receive an option to codevelop Maverix’s MVX-5005 and related compounds for cancer in Europe | Maverix Oncology Inc. | Sotio AS | $138.00 | 10/14/19 |
| Editas to use Maxcyte's technology and instruments to develop engineered cell medicines for cancer and hematological diseases | Maxcyte Inc. | Editas Medicine Inc. | Payment unspecified | 10/7/19 |
| MB Research Labs to conduct IND studies for Nanoviricides' NV-HHV-101 in dermal sensitization and ocular irritation | Mb Research Laboratories Inc. | Nanoviricides Inc. | Payment unspecified | 10/31/19 |
| Aetion to integrate Evidence Platform with Mckesson's Iknowmed for oncology research | Mckesson Corp. | Aetion Inc. | Payment unspecified | 10/15/19 |
| Medicasafe to provide Amneal's generic version of Suboxone through data-generating medication system for opioid dependence | Medicasafe Inc. | Amneal Pharmaceuticals Inc. | Payment unspecified | 10/3/19 |
| Medigen to use Medinet's immune cell Gamma Delta T cell to develop cell therapies against cancer in Taiwan | Medinet Co. Ltd. | Medigen Biotechnology Corp. | Payment unspecified | 10/7/19 |
| Immunoqure and Memo Therapeutics to develop autoantibodies from APS-1 memory B cells using Dropzylla technology | Memo Therapeutics AG | Immunoqure Ag | Payment unspecified | 10/2/19 |
| Novartis to use Microsoft data and Artificial Intelligence to transform medicine | Microsoft Corp. | Novartis AG | Payment unspecified | 10/1/19 |
| Abbott to commercialize Mithra's Myring for contraception in China | Mithra Pharmaceuticals | Abbott Laboratories | Payment unspecified | 10/14/19 |
| Mayne to use and commercialize Mithra's Estelle as a contraceptive in the U.S. | Mithra Pharmaceuticals SA | Mayne Pharma Group Ltd. | $295.00 | 10/1/19 |
| Dong Koo to commercialize Moberg's MOB-015 against onychomycosis in Republic of Korea | Moberg Pharma AB | Dong Koo Pharmaceutical Co. Ltd. | Payment unspecified | 10/21/19 |
| Orphan Pacific to commercialize MSD's Diazoxide for hypoglycemia in Japan | MSD Japan | Orphan Pacific Inc. | Payment unspecified | 10/15/19 |
| Gedeon Richter to develop and commercialize Mycovia's VT-1161 for recurrent vulvovaginal candidiasis in Europe, Latin America, Australia, Russia and other Commonwealth of Independent States countries | Mycovia Pharmaceuticals Inc. | Gedeon Richter plc | Payment unspecified | 10/16/19 |
| Next Oncology to provide PDX models to Crown Bioscience for preclinical drug development against cancer | Next Oncology Inc. | Crown Bioscience Inc. | Payment unspecified | 10/28/19 |
| Yakult Honsha to co-promote Nihon Servier's liposomal irinotecan against pancreatic cancer in Japan | Nihon Servier Co. Ltd. | Yakult Honsha Co. Ltd. | Payment unspecified | 10/8/19 |
| Recordati to acquire Novartis' Signifor, Signifor LAR and LCI-699 for Cushing’s disease and acromegaly | Novartis AG | Recordati SpA | $390.00 | 10/23/19 |
| Eyevance Pharmaceuticals acquired Tobradex ST for steroid-responsive inflammatory ocular conditions and Natacyn (natamycin ophthalmic suspension) 5%, for the treatment of fungal blepharitis, conjunctivitis and keratitis from Novartis AG | Novartis AG | Eyevance Pharmaceuticals Inc. | Payment unspecified | 10/17/19 |
| Bluebird Bio and Novo Nordisk to develop in vivo genome editing therapies for hemophilia and severe genetic diseases | Novo Nordisk A/S | Bluebird Bio Inc. | Payment unspecified | 10/9/19 |
| Eisai and Numab to discover and develop multi-specific antibody immunotherapies for cancer using Numab’s Match platform worldwide | Numab Therapeutics AG | Eisai Co. Ltd. | Payment unspecified | 10/1/19 |
| Oncosec Medical to receive a $30M investment from Grand Decade Developments in exchange for an exclusive license to develop, manufacture, commercialize Oncosec’s current and future products, including Tavo and Visceral Lesion Applicator (VLA), in greater China and 35 other Asian countries | Oncosec Medical Inc. | Grand Decade Developments Ltd. | $30.00 | 10/11/19 |
| Veriton to commercialize Orphelia Pharma's Kigabeq for infantile spasms in the U.K. | Orphelia Pharma SA | Veriton Pharma Ltd. | Payment unspecified | 10/29/19 |
| Ovizio to supply Iline F microscope and Bioconnect system to Celgene to automate the manufacturing of engineered T-cell investigational products | Ovizio Imaging Systems Nv/Sa | Celgene Corp. | Payment unspecified | 10/22/19 |
| Pandion and Astellas to develop and commercialize immunomodulators for type 1 diabetes and multiple pancreatic autoimmune worldwide | Pandion Therapeutics Inc. | Astellas Pharma Inc. | $795.00 | 10/30/19 |
| PDS Biotechnology modified the clinical trial collaboration agreement with a subsidiary of Merck to evaluate the combination of PDS-0101 with Keytruda (pembrolizumab) for recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 infection | PDS Biotechnology Corp. | Merck & Co. Inc. | Payment unspecified | 10/3/19 |
| Astrazeneca to use Petagene's Petasuite software cloud for the integration of genomics into its drug discovery platform | Petagene Ltd. | Astrazeneca plc | Payment unspecified | 10/16/19 |
| Pharmahemp to distribute Allied's cannabidiol extract products in the European and Asian markets | Pharmahemp d.o.o | Allied Corp. | Payment unspecified | 10/2/19 |
| Specialised Therapeutics to commercialize Pharmamar's Yondelis in Australia, New Zealand and South East Asia against advanced sarcoma | Pharmamar SA | Specialised Therapeutics Asia Pte. Ltd. | Payment unspecified | 10/14/19 |
| Luina Bio to manufacture LNC Therapeutics' live biotherapeutic product to treat obesity and metabolic disorders | Pharmasynth Pty Ltd. | LNC Therapeutics SA | Payment unspecified | 10/22/19 |
| Casi to develop and market Pharmathen’s long-acting injectable microsphere in China for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors | Pharmathen SA | Casi Pharmaceuticals Inc. | Payment unspecified | 10/29/19 |
| Novartis to develop and commercialize Pliant’s PLN-1474 for nonalcoholic steatohepatitis and fibrotic diseases worldwide | Pliant Therapeutics Inc. | Novartis AG | $80.00 | 10/23/19 |
| Premier to supply Amphastar's seven shortage drugs in the U.S. | Premier Inc. | Amphastar Pharmaceuticals Inc. | Payment unspecified | 10/8/19 |
| Prometheus and Takeda to discover, develop and commercialize therapies and companion diagnostics for inflammatory bowel disease worldwide | Prometheus Biosciences Inc. | Takeda Pharmaceutical Co. Ltd. | $420.00 | 10/3/19 |
| Brii Biosciences to develop and commercialize Qpex Biopharma's portfolio for multi-drug resistant gram-negative infections in mainland China, Hong Kong, Macau and Taiwan | Qpex Biopharma Inc. | Brii Biosciences Inc. | Payment unspecified | 10/22/19 |
| An undisclosed South American laboratory to enter negotiations to develop and commercialize Quantum Genomics' firibastat for arterial hypertension in Latin America | Quantum Genomics Corp. | Undisclosed South American laboratory | Payment unspecified | 10/7/19 |
| Pegbio to evaluate Quiapeg's Uni-Qleaver technology for biobetters | Quiapeg Pharmaceuticals Ab | Pegbio Co. Ltd. | Payment unspecified | 10/23/19 |
| Medison Pharma to commercialize Rigel's fostamatinib for all indications in Canada and Israel | Rigel Pharmaceuticals Inc. | Medison Pharma Ltd. | $40.00 | 10/1/19 |
| Bayer and Riken Innovation to discover therapeutics across indications | Riken Innovation Co. Ltd. | Bayer AG | Payment unspecified | 10/9/19 |
| Selexis to develop Tenebio's human heavy-chain antibodies to treat multiple myeloma, lymphoma and prostate cancer | Selexis SA | Teneobio Inc. | Payment unspecified | 10/17/19 |
| Carna Biosciences to use Seranovo's DES formulation platform to develop oral formulation of kinase inhibitor | Seranovo BV | Carna Biosciences Inc. | Payment unspecified | 10/4/19 |
| Novogene to develop companion diagnostics for Shenzhen Chipscreen's chiauranib against small cell lung cancer | Shenzhen Chipscreen Biosciences Ltd. | Novogene Co. Ltd. | Payment unspecified | 10/8/19 |
| Rain Therapeutics to use Sign Path's Correqt technology to develop Tarlox against cancer | Signpath Pharma Inc. | Rain Therapeutics Inc. | $78.00 | 10/31/19 |
| Skyflair Asia to distribute Peptonic medical's Vagivital for vaginitis in Hong Kong | Skyflair Asia | Peptonic medical AB | Payment unspecified | 10/31/19 |
| Alexion to develop and co-promote Stealth's elamipretide for mitochondrial diseases in the U.S. | Stealth Biotherapeutics Inc. | Alexion Pharmaceuticals Inc. | $45.00 | 10/10/19 |
| Goldfinch to develop and commercialize Takeda's CB1 monoclonal antibody for rare and metabolic kidney diseases worldwide | Takeda Pharmaceutical Co. Ltd. | Goldfinch Bio Inc. | Payment unspecified | 10/3/19 |
| Acino to acquire Takeda's OTC and prescription pharmaceutical assets in Near East, Middle East and Africa | Takeda Pharmaceutical Co. Ltd. | Acino Holding AG | $200.00 | 10/15/19 |
| Tannergap to distribute Napo Pharmaceuticals' Mytesi on a named-patient basis outside of the U.S., Canada and Israel | Tannergap Inc. | Napo Pharmaceuticals Inc. | Payment unspecified | 10/31/19 |
| Tedor Pharma to manufacture Sequential's triple combination drug product for the short-term treatment of transient insomnia | Tedor Pharma Inc. | Sequential Medicine Ltd. | Payment unspecified | 10/16/19 |
| GE Healthcare to commercialize Theragnostics' Galliprost for prostate cancer worldwide | Theragnostics Ltd. | GE Healthcare Inc. | Payment unspecified | 10/9/19 |
| Menarini to commercialize Tillotts' Asacol for inflammatory bowel disease in People's Republic of China | Tillotts Pharma AG | The Menarini Group | Payment unspecified | 10/28/19 |
| LEO Pharma to enter an option with Ubiquigent to develop compounds for dermatolgical diseases | Ubiquigent Ltd. | LEO Pharma A/S | Payment unspecified | 10/30/19 |
| Vaxess and GC Pharma to develop and commercialize influenza vaccine using mimix smart release patch technology smart release patch technology in the U.S., Europe and South Korea | Vaxess Technologies Inc. | GC Pharma Ltd. | Payment unspecified | 10/16/19 |
| Cipla to acquire Venus Remedies' Elores in India | Venus Remedies Ltd. | Cipla Ltd. | Payment unspecified | 10/17/19 |
| Mitsubishi to develop and commercialize Viela Bio's inebilizumab for neuromyelitis optica spectrum disorder in Japan and other Asian regions | Viela Bio Inc. | Mitsubishi Tanabe Pharma Corp. | $30.00 | 10/8/19 |
| Hope Biosciences to use Virtrial's telehealth platform for autologous, adipose-derived culture expanded mesenchymal stem cell study to treat spinal cord injury/disorder | Virtrial LLC | Hope Biosciences Inc. | Payment unspecified | 10/9/19 |
| Y-Biologics and Pascal Biosciences to discover and develop bispecific antibodies for leukemia | Y-Biologics Inc. | Pascal Biosciences Inc. | Payment unspecified | 10/29/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| 3P Biopharmaceuticals to develop In3bio’s IN-02 against cancer | 3P Biopharmaceuticals | In3bio Ltd. | Payment unspecified | 11/28/19 |
| ABL Bio to use GenScript's sdAb and mAb targeting tumor antigens and SMAB Platform for development of bispecific antibody molecules for immuno-oncology and neurodegenerative diseases | ABL Bio Inc. | Genscript Biotech Co. | Payment unspecified | 11/18/19 |
| Accord to market, commercialise and sell Adienne's Tepadina against hematological diseases and solid tumors in Europe and India | Adienne Pharma & Biotech SA | Accord Healthcare Inc. | Payment unspecified | 11/18/19 |
| Simcere Pharmaceutical to develop and commercialize Aeromics' AER-271 against stroke and other indications in Greater China | Aeromics LLC | Simcere Pharmaceutical Co. Ltd. | Payment unspecified | 11/4/19 |
| Biosyent to license and supply AFT Pharmaceuticals’ pain management products in Canada | AFT Pharmaceuticals Ltd. | Biosyent Inc. | Payment unspecified | 11/25/19 |
| Urogen to develop and commercialize Agenus' zalifrelimab in combination with UGN-201 through intravesical delivery for urinary tract cancers, worldwide ex-Argentina, Brazil, Chile, Colombia, Peru, Venezuela | Agenus Inc | Urogen Pharma Ltd. | $210.00 | 11/11/19 |
| Aker Biomarine to supply Acasti's Capre for severe hypertriglyceridemia | Aker Biomarine Antarctic As | Acasti Pharma Inc. | Payment unspecified | 11/4/19 |
| Yas Holding to commercilize Alvogen's generic pharmaceuticals portfolio for autoimmune and inflammation and blood diseases in Middle East and North Africa | Alvogen Inc. | Yas Holding | Payment unspecified | 11/25/19 |
| Yas Holding to commercialize three Alvotech's biosimilars in Middle East and North Africa | Alvotech | Yas Holding | $45.00 | 11/4/19 |
| Alvotech and Stada to commercialize seven biosimilars in EU and selected markets outside EU for autoimmunity, oncology, ophthalmology and inflammatory conditions | Alvotech ehf | Stada Arzneimittel AG | Payment unspecified | 11/6/19 |
| Revolution to evaluate RMC-4630 in combination with Amgen's AMG-510 in a phase Ib KRASG12C mutant advanced solid tumor study | Amgen Inc. | Revolution Medicines Inc. | Payment unspecified | 11/4/19 |
| Brii to develop and commercialize AN2's clinical-stage antibacterial compound for tuberculosis in China | An2 Therapeutics Inc. | Brii Biosciences | Payment Unspecified | 11/21/19 |
| Idorsia and Antares to develop drug-device product combining selatogrel for acute myocardial infarction worldwide | Antares Pharma Inc. | Idorsia Ltd. | Payment unspecified | 11/19/19 |
| Zambon to develop and commercialize Aquestive Therapeutics' Riluzole oral film against amyotrophic lateral sclerosis in Europe | Aquestive Therapeutics Inc. | Zambon SpA | Payment unspecified | 11/13/19 |
| Ardelyx and Kyowa Kirin to identify and design compounds against two undisclosed targets | Ardelyx Inc. | Kirin Holdings Co. Ltd. | $540.50 | 11/25/19 |
| Ardena to support manufacturing feasibility and capacity of Hillstream's quatramer portfolio, including HSB-1216 for small cell lung cancer | Ardena Holding NV | Hillstream Biopharma Inc. | Payment unspecified | 11/4/19 |
| Brii Bio to develop and commercialize Artizan's three portfolio programs for infectious diseases in China | Artizan Biosciences Inc. | Brii Biosciences | Payment Unspecified | 11/21/19 |
| Woolsey Pharmaceuticals to develop and commercialize Asahi Kasei's fasudil against neurodegenerative diseases in the U.S., Europe and all other territories outside of Japan, China, South Korea and Taiwan | Asahi Kasei Pharma Corp. | Woolsey Pharmaceuticals Inc. | Payment unspecified | 11/25/19 |
| Antengene to develop and commercialize Astrazeneca's AZD-0364 against cancer worldwide | Astrazeneca plc | Antengene Corp. | Payment unspecified | 11/7/19 |
| Abbisko to develop Astrazeneca's AZD-4547 for treatment of FGFR-driven cancers | Astrazeneca plc | Abbisko Therapeutics Co. Ltd. | Payment unspecified | 11/6/19 |
| Ningbo Tai Kang Medical Technology to develop and commercialize Astrazeneca’s AZD-3229 for the treatment of gastrointestinal stromal tumors worldwide | Astrazeneca plc | Ningbo Tai Kang Medical Technology Co. Ltd. | Payment unspecified | 11/8/19 |
| Novoheart and Astrazeneca to codevelop invitro human heart-in-a-jar model of heart failure | Astrazeneca plc | Novoheart Ltd. | Payment unspecified | 11/26/19 |
| Asuragen to develop and commercialize companion diagnostics for Wave's Huntington's disease therapeutics | Asuragen Inc. | Wave Life Sciences Ltd. | Payment unspecified | 11/25/19 |
| Avantgen and an undisclosed biopharmaceutical company to develop anti-cancer antibody therapeutic using natural killer cell engager technology worldwide | Avantgen Inc. | Undisclosed | Payment unspecified | 11/7/19 |
| Wellmarker to use Azoth Bio's AI-powered platform to develop cancer drugs | Azoth Bio Inc. | Wellmarker Bio Co. Ltd. | Payment unspecified | 11/4/19 |
| Samsung Biologics to use Berkeley's Beacon Optofluidic platform for cell line development | Berkeley Lights Inc. | Samsung Biologics Co. Ltd. | Payment unspecified | 11/26/19 |
| Ananda Scientific to develop and commercialize BGN Technologies' topical cannabinoid products for psoriasis and other skin disorders | BGN Technologies | Ananda Scientific Inc. | Payment unspecified | 11/19/19 |
| Torii to commercialize Biocryst's BCX-7353 for hereditary angioedema attacks in Japan | Biocryst Pharmaceuticals Inc. | Torii Pharmaceutical Co. Ltd. | $42.00 | 11/5/19 |
| Coherus to distribute Bioeq’s biosimilar for retinopathies in the U.S. | Bioeq IP AG | Coherus Biosciences Inc. | Payment unspecified | 11/6/19 |
| Abcam to develop conjugation-ready recombinant products using Brickbio's site-selective protein modification platform | Brickbio Inc. | Abcam plc | Payment unspecified | 11/8/19 |
| Pfizer and Bristol-Myers Squibb to conduct GUARD-AF to evaluate the effect of atrial fibrillation screening on health outcomes in older population | Bristol-Myers Squibb Co. | Pfizer Inc. | Payment unspecified | 11/15/19 |
| Exactus to supply hemp-derived CBD oil resins to Canntab's hard pill formulations for therapeutic applications in the U.S. | Canntab Therapeutics Ltd. | Exactus Inc. | Payment unspecified | 11/20/19 |
| Catalent to manufacture Beigene's Brukinsa in the U.S. | Catalent Inc. | Beigene Co. Ltd. | Payment unspecified | 11/21/19 |
| Skyhawk Therapeutics and Celgene to discover and develop small molecules that modulate RNA splicing for autoimmune disorders, oncology and immuno-oncology | Celgene Corp. | Skyhawk Therapeutics Inc. | $80.00 | 11/13/19 |
| Pfizer to use Centogene's data repository for discovery and validation of therapies against rare diseases | Centogene Gmbh | Pfizer Inc. | Payment unspecified | 11/13/19 |
| Pond's Chemical to commercialize CJ Heathcare's K-Cab for gastroesophageal reflux in Thailand | CJ Healthcare Corp. | Pond's Chemical Co. Ltd. | Payment unspecified | 11/20/19 |
| CNS Pharmaceuticals to grant Berubicin related patent rights to WPD Pharmaceuticals in Eastern Europe and Central Asia | CNS Pharmaceuticals Inc. | WPD Pharmaceuticals Sp. z o.o. | $2.00 | 11/26/19 |
| Iconovo and Crystecpharma to develop dry powder inhaler (DPI) products for pulmonary fibrosis, cystic fibrosis and pulmonary arterial hypertension | Crystecpharma Ltd. | Iconovo AB | Payment unspecified | 11/5/19 |
| CS Bio to manufacture Nervgen Pharma's NVG-291 for spinal cord injury and multiple sclerosis | CS Bio Co. | Nervgen Pharma Corp. | $1.50 | 11/18/19 |
| Transgene and CTI Biotechnology to develop 3D bioprinted preclinical models of liver metastases against liver cancer | CTI Biotechnology Co. Ltd. | Transgene SA | Payment unspecified | 11/6/19 |
| Cyclica and Enamine to identify novel molecules using Ligand Design and REAL Technologies | Cyclica | Enamine Ltd. | Payment unspecified | 11/5/19 |
| Atai Life Sciences and Cyclica to form joint venture, Entheogenix Biosciences to design and discover small molecule compounds against mental health disorders | Cyclica | Atai Life Sciences AG | Payment unspecified | 11/11/19 |
| Yuhan and Cyclica to develop lead-like molecules using Cyclica's ligand design and ligand express in two oncology research projects | Cyclica Inc. | Yuhan Pharmaceuticals Corp. | Payment unspecified | 11/7/19 |
| Daewoong to sell Merck’s Concor for cardiovascular disease treatment in Korea | Daewoong Pharmaceutical Co. Ltd. | Merck Biopharma Co. Ltd. | Payment unspecified | 11/5/19 |
| Dewpoint and Bayer to develop treatments for cardiovascular and gynecological diseases using compound library & biomolecular condensates | Dewpoint Therapeutics Inc. | Bayer AG | $100.00 | 11/14/19 |
| Dicerna and Novo Nordisk to discover, develop, commercialize RNAi therapies using Galxc RNAi technology with options for liver and cardio-metabolic diseases | Dicerna Pharmaceuticals Inc. | Novo Nordisk A/S | $657.50 | 11/15/19 |
| Dragonfly Therapeutics and Abbvie to develop novel natural killer cell engager-based immunotherapies for autoimmune and oncology indications | Dragonfly Therapeutics Inc. | Abbvie Inc. | Payment unspecified | 11/20/19 |
| Editas Medicine amended the collaboration with Celgene to research, develop and commercialize autologous and allogeneic alpha-beta T-cell medicines for the treatment of cancer and autoimmune diseases | Editas Medicine Inc. | Celgene Corp. | $70.00 | 11/12/19 |
| Royalty Pharma to purchase Eisai's royalties on worldwide sales of tazemetostat against cancer | Eisai Co. Ltd. | Royalty Pharma | $330.00 | 11/5/19 |
| Evotec and Vifor Pharma to launch joint venture to discover and develop new therapeutics for kidney diseases | Evotec SE | Vifor Pharma Group | $27.60 | 11/6/19 |
| Excelra and Maruho to discover and develop therapeutic hypotheses in Dermatology | Excelra | Maruho Co. Ltd. | Payment unspecified | 11/20/19 |
| Allergan to discover and develop spherical nucleic acid (SNA) based treatments for hair loss using Exicure's SNA technology | Exicure Inc. | Allergan plc | $770.00 | 11/13/19 |
| Eyepoint’s Dexycu to be available for Vizient’s member network for ophthalmic use in the US | Eyepoint Pharmaceuticals Inc. | Vizient Inc. | Payment unspecified | 11/1/19 |
| Finch Therapeutics and Takeda Pharmaceutical expanded the collaboration to develop microbiome-based therapeutics using Finch's Human-First Discovery platform to include Crohn's disease | Finch Therapeutics Group Inc. | Takeda Pharmaceutical Co. Ltd. | Payment unspecified | 11/13/19 |
| Fresenius to supply protamine, phenylephrine, oxytocin, thiamine and magnesium sulfate Vizient | Fresenius Kabi AG | Vizient Inc. | Payment Unspecified | 11/21/19 |
| Appili to develop and commercialize Fujiflim's T-2307 for drug-resistant fungal infections worldwide, ex-Japan | Fujiflim Toyama Chemical Co. Ltd. | Appili Therapeutics Inc. | Payment Unspecified | 11/21/19 |
| Siemens to use Galectin's data for regulatory filings of the ADVIA Centaur test against nonalcoholic steatohepatitis and liver fibrosis | Galectin Therapeutics Inc. | Siemens Healthineers Inc. | Payment unspecified | 11/11/19 |
| Twist Biopharma to use Genedata's Genedata Biologics software platform to advance antibody lead identification and optimization | Genedata AG | Twist Bioscience Corp. | Payment unspecified | 11/8/19 |
| Simcere to develop and commercialize GI Innovation's GI-101 against solid tumors in China, Hong Kong, Macau and Taiwan | GI Innovation Inc. | Simcere Pharmaceutical Co. Ltd. | $796.00 | 11/28/19 |
| Innovax and GSK Biologicals to develop and commercialize adjuvanted HPV vaccine against cervical cancer worldwide | Glaxosmithkline plc | Xiamen Innovax Biotech Co. Ltd. | Payment unspecified | 11/6/19 |
| Zelluna Immunotherapy and Glycostem Therapeutics to develop and manufacture allogeneic TCR guided NK cell therapies (TCR-NKs) for cancer | Glycostem Therapeutics BV | Zelluna Immunotherapy A/S | Payment unspecified | 11/19/19 |
| Gossamer and Merck to evaluate the combination of GB-1275 and keytruda for selected advanced solid tumors | Gossamer Bio Inc. | Merck & Co. Inc. | Payment unspecified | 11/12/19 |
| Enochian Biosciences to develop and commercialize G-Tech Bio's hepatitis B virus therapies | G-Tech Bio LLC | Enochian Biosciences Inc. | Payment unspecified | 11/25/19 |
| Haliodx to conduct translational investigation of immune biomarkers of phase III study of OSE Immunotherapeutics' Tedopi in non-small-cell lung cancer | Haliodx | OSE Immunotherapeutics SA | Payment unspecified | 11/27/19 |
| Abbvie to develop and commercialize Harpoon's HPN-217 for multiple myeloma worldwide | Harpoon Therapeutics Inc. | Abbvie Inc. | $510 | 11/20/19 |
| Health House to distribute Zelda's medicinal cannabis products in Australasia and the U.K. | Health House International Pty Ltd. | Zelda Therapeutics Pty Ltd. | Payment unspecified | 11/21/19 |
| Heidelberg and undisclosed French and German investors to form Emergence Therapeutics to develop antibody targeted amanitin conjugates | Heidelberg Pharma AG | Undisclosed French and German investors | Payment unspecified | 11/20/19 |
| Leo Pharma and Hitgen expanded their collaboration with a license to develop a novel class of drugs for a dermatology indication | Hitgen Inc. | Leo Pharma A/S | Payment unspecified | 11/12/19 |
| Altoida and Hope Biosciences to conduct phase I/II clinical trial on HB-adMSCs for Alzheimer’s disease | Hope Biosciences Inc. | Altoida AG | Payment unspecified | 11/20/19 |
| CNS Pharmaceuticals to acquire rights to develop Houston's Berubicin against brain cancer worldwide | Houston Pharmaceuticals Inc. | CNS Pharmaceuticals Inc. | Payment unspecified | 11/19/19 |
| CPI to develop heat-stable formulation for ImmunoBiology's Pnubiovax against pneumococcal diseases | Immunobiology Ltd. | Centre for Process Innovation | Payment unspecified | 11/28/19 |
| Avion and Immunpharma to jointly develop Lupuzor and Avion to gain exclusive rights to commercialize the drug for systemic lupus erythematosus in North America | Immupharma plc | Avion Pharmaceuticals LLC | $100.00 | 11/28/19 |
| Inceptua to supply Bendalis's generic oncology drugs for their use in clinical trials worldwide | Inceptua Group GmbH | Bendalis GmbH | Payment unspecified | 11/25/19 |
| Tris Pharma to market, sell and distribute Intellipharmaceutics International's Venlafaxine ER for depression, generalized anxiety, social anxiety and panic disorder in the U.S. | Intellipharmaceutics International Inc. | Tris Pharma Inc. | Payment unspecified | 11/25/19 |
| Iovance and Lytix to study LTX-315 in combination with TIL therapy for cancers | Iovance Biotherapeutics Inc. | Lytix Biopharma AS | Payment unspecified | 11/4/19 |
| Aspen Neuroscience to develop iPS Academia's iPS cell-derived dopamine neural progenitors worldwide | iPS Academia Japan Inc. | Aspen Neuroscience Inc. | Payment unspecified | 11/28/19 |
| Isotherapeutics to manufacture Q Biomed's Strontium-89 Chloride USP for cancer bone pain | Isotherapeutics Group LLC | Q Biomed Inc. | Payment unspecified | 11/20/19 |
| Vifor and Janssen to jointly commercialize Invokana for diabetic kidney disease in the U.S. | Janssen Pharmaceuticals Inc. | Vifor Pharma Group | Payment unspecified | 11/4/19 |
| Kadmon and Bio Nova to form BK Pharmaceuticals to develop and commercialize KD-025 for the treatment of graft-vs.-host disease in Republic of China | Kadmon Pharmaceuticals LLC | Bionova Pharmaceuticals Ltd. | $45.00 | 11/7/19 |
| Amneal to develop and commercialize Kashiv’s K-127 for myasthenia gravis in the U.S. | Kashiv Biosciences LLC | Amneal Pharmaceuticals Inc. | $18.00 | 11/6/19 |
| Jeil Pharmaceutical to develop and commercialize Kyorin’s vibegron for overactive bladder in Korea | Kyorin Pharmaceutical Co. Ltd. | Jeil Pharmaceutical Co. Ltd. | Payment unspecified | 11/7/19 |
| Talem Therapeutics to use Ligand's OmniAb platform to discover human antibodies worldwide | Ligand Pharmaceuticals Inc. | Talem Therapeutics | Payment unspecified | 11/5/19 |
| Navrogen and Lonza Pharma & Biotech to produce biotherapeutics using GS Xceed expression system | Lonza Pharma & Biotech AG | Navrogen Inc. | Payment unspecified | 11/20/19 |
| Shanghai Pharmaceutical to develop and commercialize Lumosa's LT-3001 for ischemic stroke in China | Lumosa Therapeutics Co. Ltd. | Shanghai Pharmaceutical Group Corp | $41.05 | 11/6/19 |
| Vor Biopharma to use Maxcyte's technologies to develop engineered hematopoietic stem cells for hematological cancers | Maxcyte Inc. | Vor Biopharma Inc. | Payment unspecified | 11/21/19 |
| Intellistem and Medimabs to develop platform for generation of monoclonal antibodies | Medimabs Inc. | Intellistem Technologies | Payment unspecified | 11/18/19 |
| Evotec SE to use and commercialize Milliporesigma's CRISPR genome-editing technology to create edited cell lines | Merck Millipore | Evotec SE | Payment unspecified | 11/12/19 |
| Shanghai Fosun to develop and commercialize Mimivax's SurvaxM for glioblastoma in China | Mimivax LLC | Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. | $148.00 | 11/18/19 |
| Vertex and Molecular Templates to discover and develop targeted conditioning regimens for hematopoietic stem cell transplants | Molecular Templates Inc. | Vertex Pharmaceuticals Inc. | $560.00 | 11/18/19 |
| Navidea and IMV to conduct preclinical study to evaluate the combination of macrophage targeting therapeutics with DPX-based immunotherapies against cancer | Navidea Biopharmaceuticals Inc. | IMV Inc. | Payment unspecified | 11/7/19 |
| Autolus to use Noile-Immune's proliferation-inducing and migration-enhancing technology to develop CAR T cell therapies for solid tumors | Noile-Immune Biotech Inc. | Autolus Therapeutics plc | Payment unspecified | 11/13/19 |
| Allogene and Notch to research and develop new induced pluripotent stem cell-based CAR T therapies products for initial application in non-Hodgkin lymphoma, leukemia and multiple myeloma worldwide | Notch Therapeutics Inc. | Allogene Therapeutics Inc. | $309.25 | 11/5/19 |
| Jiangsu to develop and market Novaliq's Cyclasol and NOV-03 for the treatment of dry eye disease in mainland China, Hong Kong, Macau, and Taiwan | Novaliq GmbH | Jiangsu Hengrui Medicine Co. Ltd. | $165.00 | 11/7/19 |
| Knight to commercialize Onconova's Rigosertib against myelodysplastic syndrome in Canada | Onconova Therapeutics Inc. | Knight Therapeutics Inc. | $25.81 | 11/20/19 |
| Tmunity Therapeutics to use Oncora Medical’s real-world data platform to support future trials with CAR T-cell therapy for cancer patients | Oncora Medical Inc. | Tmunity Therapeutics Inc. | Payment unspecified | 11/4/19 |
| CKD to develop and commercialize OSE's Tedopi against cancer, including non-small cell lung cancer in Korea | OSE Immunotherapeutics | Chong Kun Dang Pharmaceutical Corp. | $6.11 | 11/7/19 |
| OWC and Stenocare to sign memorandum of understanding for development and commercialization medical cannabis products in Denmark, Ireland and new territories | OWC Pharmaceutical Research Corp. | Stenocare | Payment unspecified | 11/13/19 |
| Parexel Biotech to conduct phase II to evaluate pharmacotherapeutics for posttraumatic stress disorder using Cohen Veterans' adaptive platform trial | Parexel Biotech | Cohen Veterans Bioscience | Payment unspecified | 11/11/19 |
| Sentinel to accelerate preclinical development and IND enabling studies of Phoremost's SOL-686 for glioma | Phoremost Ltd. | Sentinel Oncology Ltd. | Payment unspecified | 11/4/19 |
| Black Belt and Praxis to discover and develop small molecule therapeutics to undisclosed targets for the stress response in cancer | Praxis Biotech LLC | Black Belt Therapeutics Ltd. | Payment unspecified | 11/5/19 |
| Carina Biotech and Prescient Therapeutics to develop CAR-T cell combination therapies for solid and blood tumours | Prescient Therapeutics Ltd. | Carina Biotech Pty Ltd. | Payment unspecified | 11/18/19 |
| Proderm to conduct phase IIa clinical study for Follicum's FOL-005 for alopecia | Proderm GmbH | Follicum AB | Payment unspecified | 11/12/19 |
| Promega and Merck to develop microsatellite instability companion diagnostic for Keytruda against solid tumors worldwide | Promega Corp. | Merck & Co Inc. | Payment unspecified | 11/6/19 |
| Puma and Pierre Fabre extended their agreement to commercialize Nerlynx in additional countries including the Middle East, South Africa, Sudan and Turkey | Puma Biotechnology Inc. | Pierre Fabre SA | $7.00 | 11/25/19 |
| Labcorp to use Qiagen's Human Gene Mutation Database along with QCI platform for inherited disease mutations | Qiagen NV | Laboratory Corporation of America Holdings | Payment unspecified | 11/20/19 |
| Repertoire to provide access to new technologies to Qiagen for the development of T-cell/B-cell receptor assays for use in next-generation sequencing system | Repertoire Genesis Inc. | Qiagen NV | Payment unspecified | 11/5/19 |
| Oncology Pharma to use Ribera Solutions' clinical trials platform for human studies for drug development, clinical trials, personalized oncology and therapeutics worldwide | Ribera Solutions LLC | Oncology Pharma Inc. | Payment unspecified | 11/7/19 |
| Biogen to commercialize Samsung Bioepis' SB-11 and SB-15 against age-related macular degeneration worldwide, including the U.S., Canada, Europe, Japan, and Australia and with an option for three biosimilars in China | Samsung Bioepis Co. Ltd. | Biogen Inc. | $370.00 | 11/6/19 |
| Samsung Biologics to manufacture Ichnos’s ISB-830 for a phase III clinical trial | Samsung Biologics Co. Ltd. | Ichnos Sciences | Payment unspecified | 11/4/19 |
| Beigene to develop and commercialize Seattle Genetics' advanced preclinical antibody product for treating cancer worldwide except in the Americas, Europe and Japan | Seattle Genetics Inc. | Beigene Co. Ltd. | $160.00 | 11/5/19 |
| Scohia and Seedsupply to discover and develop drug candidates for unidentified diseases worldwide | Seedsupply Co. Ltd. | Scohia Pharma Inc. | Payment unspecified | 11/25/19 |
| Ascentage to conduct clinical study of APG-2575 in combination with Henlius' HLX-01 for chronic lymphocytic leukemia | Shanghai Henlius Biotech Co. Ltd. | Ascentage Pharma Group Corp. Ltd. | Payment unspecified | 11/4/19 |
| Artios Pharma to develop Shangpharma's small molecule ATR inhibitor against cancer worldwide | Shangpharma Innovation Inc. | Artios Pharma Ltd. | Payment unspecified | 11/6/19 |
| Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra related to amendment in asset purchase agreement | Sierra Oncology Inc. | Gilead Sciences Inc. | Payment unspecified | 11/8/19 |
| SQZ Biotechnologies and Askbio to develop tolerizing antigen carriers containing AAV components for treatment of patients' immune systems generating neutralizing antibodies toward therapeutic AAVs | SQZ Biotechnologies Inc. | Asklepios Biopharmaceutical Inc. | Payment unspecified | 11/7/19 |
| Qiagen to license novel mRNA gene expression signatures from Stratifyer Molecular Pathology for treatment decisions in bladder cancer and urothelial cancers | Stratifyer Molecular Pathology GmbH | Qiagen NV | Payment unspecified | 11/5/19 |
| Sarepta Therapeutics and Stridebio to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets worldwide | Stridebio LLC | Sarepta Therapeutics Inc. | $90.50 | 11/14/19 |
| Astrazeneca to distribute Sun Pharma’s cancer products in China | Sun Pharmaceutical Industries Ltd. | Astrazeneca plc | Payment unspecified | 11/6/19 |
| Stada Arzneimittel to acquire Takeda's over-the-counter and prescription pharmaceutical assets in Russia, Georgia and some countries from the Commonwealth of Independent States | Takeda Pharmaceutical Co. Ltd. | Stada Arzneimittel AG | $660.00 | 11/5/19 |
| Teijin Pharma and Veritas In Silico to discover small molecule products targeting nucleic acids | Teijin Pharma Ltd. | Veritas In Silico Inc. | Payment unspecified | 11/5/19 |
| Nanoviricides to develop Theracour Pharma's VZV-binding nanomicelle candidate against chickenpox | Theracour Pharma Inc. | Nanoviricides Inc. | $4.00 | 11/5/19 |
| Novo Nordisk to develop UBE Industries’ UD-014 for the treatment of non-alcoholic steatohepatitis worldwide | UBE Industries Ltd. | Novo Nordisk A/S | Payment unspecified | 11/7/19 |
| NEC and Vaximm to develop novel personalized neoantigen cancer vaccines worldwide, except for China and other Asian territories outside of Japan | Vaximm AG | NEC Corp. | Payment unspecified | 11/11/19 |
| Regeneron and Vyriad to develop vesicular stomatitis virus based oncolytic virus treatments against cancer | Vyriad Inc. | Regeneron Pharmaceuticals Inc. | Payment unspecified | 11/6/19 |
| Quest acquires sun recovery product brands from Welmedix | Welmedix Consumer Healthcare | Quest Products Inc. | Payment unspecified | 11/5/19 |
| Meiji Seika to develop and commercialize Zeria's Acofide for functional dyspepsia in Thailand and Indonesia | Zeria Pharmaceutical Co. Ltd. | Meiji Seika Pharma Co. Ltd. | Payment unspecified | 11/1/19 |
| Deal title | Principal company | Partner company | Value (US$M) | Start date |
| Tracon to develop and commercialize 3D Medicines' KN-035 against soft tissue sarcoma in North America | 3D Medicines Co. Ltd. | Tracon Pharmaceuticals Inc. | Payment unspecified | 12/20/19 |
| Alkem to acquire Abbvie's Dronabinol | Abbvie Inc. | Alkem Laboratories Ltd. | $10.00 | 12/30/19 |
| Abbvie to use Adaptive’s clonoseq assay to assess minimal residual disease response of venetoclax clinical trials against multiple myeloma | Adaptive Biotechnologies Corp. | Abbvie Inc. | Payment unspecified | 12/9/19 |
| Indivior to provide Addex Therapeutics with an additional $800,000 to accelerate research in their development of oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) compounds to treat addiction | Addex Therapeutics Ltd. | Indivior plc | $0.80 | 12/19/19 |
| GC and Addpharma to codevelop synthetic drugs like new chemical entities, incrementally modified and generic drugs | Addpharma Inc. | GC Pharma | Payment unspecified | 12/13/19 |
| GE Healthcare and ASLS to integrate IN Cell Analyzer with Bioassemblybot to develop tissue regeneration for bone, soft tissue, and organ replacements | Advanced Solutions Life Sciences LLC | GE Healthcare | Payment unspecified | 12/8/19 |
| Albertsons to dispense Dynavax Technologies' Heplisav-B against hepatitis B vaccine in the U.S. | Albertsons Companies | Dynavax Technologies Corp. | Payment unspecified | 12/5/19 |
| Altascience to conduct phase I clinical trial of Indivior's INDV-2000 for opioid use disorder and overdose | Altascience Ltd. | Indivior plc | Payment unspecified | 12/9/19 |
| An undisclosed company and Alteogen to develop and commercialize subcutaneous injection biologic product using ALT-B4 technology worldwide | Alteogen Inc. | Undisclosed top 10 global pharmaceutical company | $1,386.00 | 12/2/19 |
| Amyris and undisclosed company to develop therapeutic targets against cancer | Amyris Inc. | Undisclosed | Payment unspecified | 12/27/19 |
| Saptalis to commercialize Appili's ATI-1501 against bacterial infections in the U.S. | Appili Therapeutics Inc. | Saptalis Pharma Inc. | Payment unspecified | 12/3/19 |
| Arcus and Genentech to conduct combination clinical studies on AB-928 using morpheus phase Ib/II platform for third-line metastatic colorectal cancer and first-line metastatic pancreatic cancer | Arcus Biosciences Inc. | Genentech Inc. | Payment unspecified | 12/18/19 |
| Alvogen to acquire Assertio Therapeutics' Gralise for postherpetic neuralgia | Assertio Therapeutics Inc. | Alvogen Inc. | $127.50 | 12/11/19 |
| Astrazeneca expanded the partnership with Cheplapharm for the commercial rights to Seroquel and Seroquel XR in the U.S. and Canada | Astrazeneca plc | Cheplapharm Arzneimittel GmbH | $41.00 | 12/2/19 |
| Juvise Pharmaceuticals acquires commercial rights of Astrazeneca's oncology products Arimidex and Casodex in European, African and other countries | Astrazeneca plc | Juvise Pharmaceuticals | $198.00 | 12/20/19 |
| Baergic to develop Astrazeneca's AZD-7325 for central nervous system disorders worldwide | Astrazeneca plc | Baergic Bio Inc. | Payment unspecified | 12/23/19 |
| Guangzhou Xiangxue Pharmaceutical expanded its strategic partnership with Athenex’s to exclusively develop and commercialize oncology product candidates, oral paclitaxel (both the capsule and the tablet formulations), oral irinotecan and tirbanibulin ointment, including for the treatment of actinic keratosis in China, Hong Kong and Macau | Athenex Inc. | Guangzhou Xiangxue Pharmaceutical Co. Ltd. | $200.00 | 12/12/19 |
| Avitide to supply its affinity resins to support the development of one of the Gemini's therapeutic programs | Avitide Inc. | Gemini Therapeutics Inc. | Payment unspecified | 12/9/19 |
| Bioarctic and Eisai to further study the unique profile of BAN-2401 | Bioarctic AB | Eisai Co. Ltd. | $3.62 | 12/17/19 |
| Equillium to develop and commercialize Biocon's EQ-001 for asthma, autoimmune disease and graft versus host disease in Australia and New Zealand | Biocon Ltd. | Equillium Inc. | Payment unspecified | 12/12/19 |
| Indivumed to use Biognosys' proteomics solutions with its multi-omics cancer database to enable discoveries in cancer biology | Biognosys Ag | Indivumed GmbH | Payment unspecified | 12/2/19 |
| Bioinvent to evaluate BI-1206 in combination with Merck's Keytruda in advanced solid tumors | Bioinvent International AB | Merck & Co. Inc. | Payment unspecified | 12/18/19 |
| Merck to evaluate the phase II combination of Bioncotech Therapeutics’ BO-112 with Keytruda to treat solid tumors with liver metastases | Bioncotech Therapeutics SL | Merck & Co. Inc. | Payment unspecified | 12/10/19 |
| Medison Pharma to distribute, market, sell and commercialize Bridgebio Pharma's fosdenopterin for molybdenum cofactor deficiency type A in Israel | Bridgebio Pharma Inc. | Medison Pharma Ltd. | Payment unspecified | 12/18/19 |
| Genix Pharmaceuticals acquires 30 ophthalmic generic drug dossiers and letter of intent to acquire two additional nutraceutical products from Canagen | Canagen Pharmaceuticals Inc. | Genix Pharmaceuticals Corp. | $0.75 | 12/23/19 |
| Samyang to develop and commercialize Cancure's SYB-010 for cancer worldwide | Cancure LLC | Samyang Pharmaceuticals Corp. | Payment unspecified | 12/2/19 |
| Catalent and Ethicann to develop a combination of cannabidiol and tetrahydrocannabinol product using Zydis orally disintegrating tablet technology for the treatment of multiple sclerosis spasticity | Catalent Inc. | Ethicann Pharmaceuticals Inc. | Payment unspecified | 12/3/19 |
| Bridge Therapeutics to use Catalent's Zydis delivery technology for the development of formulation for BT-219 to treat opioid addiction | Catalent Inc. | Bridge Therapeutics Inc. | Payment unspecified | 12/10/19 |
| Biogen to develop and commercialize Catalyst's CB-2782-PEG for geographic atrophy associated dry age-related macular degeneration worldwide | Catalyst Biosciences Inc. | Biogen Inc. | $355.00 | 12/19/19 |
| Celonic to manufacture Chiome Bioscience's CBA-1535 | Celonic AG | Chiome Bioscience Inc. | Payment unspecified | 12/17/19 |
| Cerevance and Takeda to develop and commercialize therapeutic candidates against gastrointestinal disorders using Netsseq technology worldwide | Cerevance Inc. | Takeda Pharmaceutical Co. Ltd. | $170.00 | 12/17/19 |
| Genmab and Curevac to jointly conduct research, develop and commercialize mRNA-based antibodies by combining the mRNA technology with the antibody technologies and expertise against cancers | Curevac AG | Genmab A/S | $400.23 | 12/19/19 |
| Vyera to commercialize Cytodyn's leronlimab for HIV infection in the U.S. | Cytodyn Inc. | Vyera Pharmaceuticals LLC | $91.50 | 12/17/19 |
| Eagle to enter into a settlement with Eli Lilly's Pemfexy for non-small-cell lung carcinoma and mesothelioma | Eli Lilly and Co. | Eagle Pharmaceuticals Inc. | Payment unspecified | 12/13/19 |
| Engitix and Morphic to discover extracellular matrix-related targets and therapeutics for fibrostenotic inflammatory bowel disease | Engitix Ltd. | Morphic Therapeutic Inc. | Payment unspecified | 12/10/19 |
| Eyepoint Pharmaceuticals to distribute Dexycu to undisclosed company in the U.S. | Eyepoint Pharmaceuticals Inc. | Undisclosed | Payment unspecified | 12/4/19 |
| Fibriant expanded its recombinant fibrinogen license agreement with Bioceros BV for CHOBC expression technology to also include development and manufacturing of recombinant human (pro)thrombin | Fibriant BV | Bioceros BV | Payment unspecified | 12/5/19 |
| Forendo Pharma and Novartis to develop and commercialize new drugs for the treatment of chronic liver diseases worldwide | Forendo Pharma Ltd. | Novartis AG | Payment unspecified | 12/11/19 |
| Acceleron and Fulcrum to develop and commercialize small molecule therapeutics for pulmonary disease worldwide | Fulcrum Therapeutics Inc. | Acceleron Pharma Inc. | $448.50 | 12/20/19 |
| NHS to develop with an option to commercialize G3 Pharmaceuticals' galectin-3 inhibitors for nutritional solutions worldwide | G3 Pharmaceuticals Inc. | Nestle Health Science | Payment unspecified | 12/19/19 |
| Gatehouse and Astrazeneca to accelerate new drug discovery using artificial intelligence analytics targeting respiratory and cardiovascular diseases | Gatehouse Bio | Astrazeneca plc | Payment unspecified | 12/4/19 |
| Kishi Kasei to develop and commercialize GTS' Aflibercept biosimilars to treat ophthalmologic diseases | Gene Techno Science Co. Ltd. | Kishi Kasei Co. Ltd. | Payment unspecified | 12/2/19 |
| Editas to develop nanoparticle gene therapies using Genedit's Cpf1-based technologies worldwide with an option | Genedit Inc. | Editas Medicine Inc. | Payment unspecified | 12/11/19 |
| Genentech to evaluate Matinas Biopharma's lipid nanocrystal platform delivery technology for the development of oral formulations | Genentech Inc. | Matinas Biopharma Holdings Inc. | Payment unspecified | 12/12/19 |
| Gilead and Eisai to develop and copromote filgotinib in Japan for rheumatoid arthritis, ulcerative colitis, Crohn’s disease and psoriatic arthritis | Gilead Sciences Inc. | Eisai Co. Ltd. | Payment unspecified | 12/24/19 |
| Suzhou Erye to develop and commercialize Hainan's generic version of bivalirudin injection | Hainan Shuangcheng Pharmaceutical Co. Ltd. | Suzhou Erye Pharmaceutical Co. Ltd. | $7.13 | 12/3/19 |
| Shanghai Junshi to develop DAC Biotech's DAC-002 against solid tumors | Hangzhou DAC Biotech Co. Ltd. | Shanghai Junshi Biosciences Co. Ltd. | $43.08 | 12/3/19 |
| Boehringer Ingelheim to use Healx's Healnet to identify rare neurological indications for BI's assets | Healx Ltd. | Boehringer Ingelheim International GmbH | Payment unspecified | 12/9/19 |
| Hitgen and Mitsubishi Tanabe Pharma to develop small molecules for treating undisclosed targets | Hitgen Inc. | Mitsubishi Tanabe Pharma Corp. | Payment unspecified | 12/1/19 |
| Hitgen to design and develop DNA-encoded libraries to discover Janssen's small molecule therapies | Hitgen Ltd. | Janssen Biotech Inc. | Payment unspecified | 12/9/19 |
| Human Protein Atlas to use Horizon's CRISPR-edited knockout cell model to further expand Cell Atlas program | Horizon Discovery Group plc | Human Protein Atlas | Payment unspecified | 12/3/19 |
| Mochida to develop and commercialize Idorsia's daridorexant for the treatment of insomnia and related disorders in Japan | Idorsia Ltd. | Mochida Pharmaceutical Co. Ltd. | $9.32 | 12/5/19 |
| Almirall to develop therapeutics drug candidates using Iktos' generative modelling technology | Iktos | Almirall Ltd. | Payment unspecified | 12/12/19 |
| Screen Therapeutics and Immunaccel to discover and develop stromal interactions targeted cancer immunotherapies | Immunaccel | Screen Therapeutics LLC | Payment unspecified | 12/5/19 |
| Inceptua to provide Pre-approval Access Program services to Onconova' rigosertib against myelodysplastic syndrome in various countries, including Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal and South Africa | Inceptua SA | Onconova Therapeutics Inc. | Payment unspecified | 12/6/19 |
| Cereno acquires Inorbit Therapeutics' CS-036 for cardiovascular diseases | Inorbit Therapeutics AB | Cereno Scientific AB | Payment unspecified | 12/10/19 |
| Novartis agreed to pay Intec $1.5M following termination of its feasibility and option agreement to develop an Accordion Pill for a compound | Intec Pharma Inc. | Novartis AG | $1.50 | 12/10/19 |
| Adaptate to use Iontas' Mammalian Display technology to identify and optimize antibodies for immuno-oncology targets | Iontas Ltd. | Adaptate Biotherapeutics Ltd. | Payment unspecified | 12/3/19 |
| Accellta to use iPS Academia's iPS cell related technologies | Ips Academia Japan Inc. | Accellta | Payment unspecified | 12/2/19 |
| Celgenyx to use Ips Academia's patents on induced pluripotent stem cell related technologies | Ips Academia Japan Inc. | Celgenyx Inc. | Payment unspecified | 12/16/19 |
| Merck Sharp & Dohme to use Ips Academia's patents on induced pluripotent cell related technologies | Ips Academia Japan Inc. | Merck Sharp & Dohme Corp. | Payment unspecified | 12/18/19 |
| Fontacea Pharmaceutical to develop Janssen Biotech's anti-human IL-17A neutralizing monoclonal antibodies in China, Hong Kong, Macau, Taiwan and South Korea | Janssen Biotech Inc. | Shandong Fontacea Pharmaceutical Co. Ltd. | Payment unspecified | 12/17/19 |
| Kamada to commercialize Alvotech's six biosimilar products for autoimmunity, oncology and inflammatory conditions in Israel | Kamada Ltd. | Alvotech Ehf | Payment unspecified | 12/2/19 |
| Kite and Kiniksa to conduct phase II study for the combination of mavrilimumab and Yescarta in patients with relapsed or refractory large B-cell lymphoma | Kiniksa Pharmaceuticals Ltd. | Kite Pharma Inc. | Payment unspecified | 12/11/19 |
| Baker Bros. Advisors to acquire Kodiak Sciences' KSI-301 royalty rights | Kodiak Sciences Inc. | Baker Bros. Advisors LP | $225.00 | 12/2/19 |
| Landrace to supply hemp extracts for Abacus' Cbdmedic and Cbdclinic brands for pain management | Landrace Bioscience | Abacus Health Products Inc. | Payment unspecified | 12/10/19 |
| Karo Pharma to acquire LEO Pharma's hemorrhoid products (Sheriproct, Doloproct, Neriproct and Ultraproct) and dermatology, mainly over-the-counter products (Ultrabas, Ultralip, Ultraphil, Ultrasicc, Neribas and Ultralan) | LEO Pharma A/S | Karo Pharma AB | $100.04 | 12/23/19 |
| Sanofi to use Ligand's Omniab antibody discovery platform worldwide | Ligand Pharmaceuticals Inc. | Sanofi SA | Payment unspecified | 12/2/19 |
| Undisclosed company to use Lineage's cell therapy-related intellectual property and assets | Lineage Cell Therapeutics Inc. | Undisclosed three unnamed cell therapy companies | $1.00 | 12/24/19 |
| Cannassure and Lipidor to develop and commercialize sprayable medical cannabis products using drug delivery platform technology, Akvano worldwide | Lipidor AB | Cannassure | Payment unspecified | 12/11/19 |
| Lotus Pharmaceutical to distribute Orion's Stalevo and Comtan for Parkinson's disease in the Asia Pacific region | Lotus Pharmaceutical Co. Ltd. | Orion Corp. | Payment unspecified | 12/30/19 |
| Jemincare to development and commercialize Lumosa’s LT-1001 in China, Hong Kong and Macau | Lumosa Therapeutics Co. Ltd. | Jiangxi Jemincare Group | $18.53 | 12/2/19 |
| Lyphe Group to distribute Avicanna's cannabis based medicinal products in the U.K. | Lyphe Group | Avicanna Inc. | Payment unspecified | 12/3/19 |
| Horizon Discovery and Mammoth Biosciences to develop CRISPR tools for the next generation of engineered cell lines | Mammoth Biosciences | Horizon Discovery Group plc | Payment unspecified | 12/13/19 |
| Maxcyte to grant rights of flow electroporation technology and Expert to KSQ to develop treatment of PD-1 refractory solid tumors | Maxcyte Inc. | KSQ Therapeutics Inc. | Payment unspecified | 12/4/19 |
| Neoimmunetech to evaluate the combination of Hyleukin-7 with Merck's pembrolizumab in a phase Ib/IIa study in patients with relapsed/refractory advanced solid tumors | Merck & Co. Inc. | Neoimmunetech Inc. | Payment unspecified | 12/11/19 |
| Iteos Therapeutics to evaluate EOS-100850 with Merck's pembrolizumab in solid tumors | Merck & Co. Inc. | Iteos Therapeutics SA | Payment unspecified | 12/12/19 |
| Promega to use Merck’s CRISPR genome-editing technology and related IP to create research products | Merck & Co. Inc. | Promega Corp. | Payment unspecified | 12/19/19 |
| Promega to use Milliporesigma's Crispr genome-editing technology and related intellectual property to create research products | Merck Millipore | Promega Corp. | Payment unspecified | 12/19/19 |
| Ellipses to develop and commercialize Newlink’s NLG-207 and CRLX-301 for cancer worldwide | Newlink Genetics Corp. | Ellipses Pharma Ltd. | Payment unspecified | 12/17/19 |
| Samil to develop and commercialize Nicox’s Zerviate for ocular itching associated with allergic conjunctivitis in South Korea | Nicox SA | Samil Pharmaceutical Co. Ltd. | $0.25 | 12/6/19 |
| Bausch Health to develop Novaliq's Nov-03 for dry eye disease associated with Meibomian gland dysfunction in the U.S. and Canada | Novaliq GmbH | Bausch Health Companies Inc. | Payment unspecified | 12/20/19 |
| Eris acquires Zomelis trademark from Novartis for the treatment of type 2 diabetes | Novartis AG | Eris Lifesciences Pvt. Ltd. | 13 | 12/3/19 |
| Sunshine Guojian and Numab to develop multi-specific antibodies using Match technology for cancer therapy in China, Hong Kong, Macao and Taiwan | Numab Therapeutics AG | Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. | Payment unspecified | 12/12/19 |
| Ocean Grown Ventures to distribute Panaxia's tetrahydrocannabinol formulations in California and hemp-based cannabidiol formulations worldwide | Ocean Grown Ventures | Panaxia Pharmaceutical Industries Ltd. | Payment unspecified | 12/4/19 |
| STA to commercialize Onconova's rigosertib for myelodysplastic syndrome in Australia and New Zealand | Onconova Therapeutics Inc. | Specialised Therapeutics Asia Pte. Ltd. | Payment unspecified | 12/18/19 |
| Specialised Therapeutics to commercialize Onconova's rigosertib against solid tumors in Australia and New Zealand | Onconova Therapeutics Inc. | Specialised Therapeutics Asia Pte Ltd. | $30.45 | 12/18/19 |
| Nobelpharma to obtain option to develop and commercialize Oncotherapy’s peptide vaccines for cancer in Japan | Oncotherapy Science Inc. | Nobelpharma Co. Ltd. | Payment unspecified | 12/23/19 |
| Pantherx to distribute Alnylam's givosiran for acute hepatic porphyria | Pantherx Specialty Pharmacy | Alnylam Pharmaceuticals Inc. | Payment unspecified | 12/12/19 |
| Parexel to conduct phase I clinical study of Vivera's Tabmelt technology | Parexel International | Vivera Pharmaceuticals Inc. | Payment unspecified | 12/3/19 |
| Megapharm to commercialize Pharmamar's Yondelis in Israel | Pharmamar Inc. | Megapharm Ltd. | Payment unspecified | 12/13/19 |
| Jazz Pharmaceuticals to commercialize Pharmamar's lurbinectedin against small-cell lung cancer in the U.S. | Pharmamar SA | Jazz Pharmaceuticals plc | $1,000.00 | 12/19/19 |
| Leo Pharma to develop and commercialize Portal’s needle-free drug delivery device for biologic medicines against skin diseases worldwide | Portal Instruments Inc. | Leo Pharma A/S | Payment unspecified | 12/4/19 |
| Prasco to launch Merck's Nuvaring for contraception to prevent pregnancy in the U.S. | Prasco Laboratories | Merck & Co. Inc. | Payment unspecified | 12/17/19 |
| Biolab to develop and commercialize Quantum Genomics's firibastat for arterial hypertension in Latin America | Quantum Genomics Corp. | Biolab Farmaceutica | $21.20 | 12/9/19 |
| Quva to manufacture and distribute Hibernation's Adenocaine solution for cardioplegia | Quva Pharma Inc. | Hibernation Therapeutics Ltd. | Payment unspecified | 12/9/19 |
| Hanmi and Rapt to develop and commercialize FLX-475 for cancer including gastric cancer in Asia, South Korea and China, Taiwan and Hong Kong | Rapt Therapeutics Inc. | Hanmi Pharmaceutical Co. Ltd. | $118.00 | 12/3/19 |
| Recipharm to manufacture Aptahem's Apta-1 injectable formulation for phase I study against sepsis | Recipharm AB | Aptahem AB | Payment unspecified | 12/17/19 |
| Janssen and Resonant to discover and validate antibody tumor and immunological targets | Resonant Therapeutics Inc. | Janssen Research & Development LLC | Payment unspecified | 12/3/19 |
| Retrogenix to identify targets of Resonant's antibodies against the tumor using Impact tumor microenvironment models | Retrogenix Ltd. | Resonant Therapeutics Inc. | Payment unspecified | 12/10/19 |
| Rheos Medicines and Roche to discover, develop and commercialize therapeutic candidates for autoimmune and inflammatory disease worldwide | Rheos Medicines Inc. | Roche Holding AG | $792.50 | 12/19/19 |
| Baxter to acquire Sanofi's Seprafilm Adhesion Barrier and related assets | Sanofi SA | Baxter International Inc. | $350.00 | 12/2/19 |
| Roche to develop and commercialize Sarepta’s SRP-9001 outside the U.S. for Duchenne muscular dystrophy | Sarepta Therapeutics Inc. | Roche Holding AG | $2,850.00 | 12/23/19 |
| Neuro-Sys and Sciomics to study neuroprotective compounds for neurodegenerative diseases | Sciomics | Neuro-Sys | Payment unspecified | 12/18/19 |
| Seattle Genetics and Merck to conduct combination study of Keytruda with enfortumab vedotin against untreated metastatic urothelial cancer patients | Seattle Genetics Inc. | Merck & Co. Inc. | Payment unspecified | 12/2/19 |
| Askbio Biopharmaceutical exercised its option to exclusively license, develop and commercialize Selecta Biosciences’ immune tolerance platform for use in adeno-associated virus gene therapy for the treatment of Pompe disease | Selecta Biosciences Inc. | Askbio Biopharmaceutical Inc. | $240.00 | 12/18/19 |
| Seven and Eight Biopharmaceuticals and Merck to evaluate combination of BDB-001 with Keytruda against solid tumors | Seven and Eight Biopharmaceuticals Inc. | Merck & Co. Inc. | Payment unspecified | 12/9/19 |
| Farma de Colombia to commercialize Shanghai Henlius' HLX-01 in Colombia, Peru, Ecuador and Venezuela | Shanghai Henlius Biotech Co. Ltd. | Farma de Colombia | Payment unspecified | 12/5/19 |
| Signia and Cynbiose to develop therapeutic treatments for bronchiolitis and pneumovirus pneumopathy | Signia Therapeutics | Cynbiose | Payment unspecified | 12/9/19 |
| Gen1e to use Silcsbio's computational drug design technology to discover and develop UM-101 | Silcsbio LLC | Gen1e Lifesciences Inc. | Payment unspecified | 12/3/19 |
| Sisaf and Avellino Lab to co-develop topical non-viral gene therapies for corneal dystrophies | Sisaf Ltd. | Avellino Lab USA Inc. | Payment unspecified | 12/18/19 |
| Maruho to commercialize Solasia's SP-04 against chemotherapy induced peripheral neuropathy in Japan | Solasia Pharma K.K. | Maruho Co. Ltd. | $193.02 | 12/10/19 |
| Stemonix and Atomwise to establish joint venture to discover and develop small molecule therapies for Rett syndrome | Stemonix Inc. | Atomwise | Payment unspecified | 12/3/19 |
| Suda and Laboratorios Ordesa to develop consumer product using Oromist technology, with an option for full development of product | Suda Pharmaceuticals Ltd. | Laboratorios Ordesa SL | $0.10 | 12/5/19 |
| Suda and Sanofi to study Oromist Technology with Sanofi's selected active ingredient | Suda Pharmaceuticals Ltd. | Sanofi-aventis groupe | Payment unspecified | 12/9/19 |
| Denovo to develop, manufacture and commercialize Sunesis' Vosaroxin for cancers, including acute myeloid leukemia and solid tumors worldwide | Sunesis Pharmaceuticals Inc. | Denovo Biopharma LLC | Payment unspecified | 12/6/19 |
| GBT and Syros to discover, develop and commercialize drugs for sickle cell disease and beta thalassemia | Syros Pharmaceuticals Inc. | Global Blood Therapeutics Inc. | $375.00 | 12/17/19 |
| Samyang to develop and commercilize Talix' anti-CD96 antibody against cancers worldwide | Talix Therapeutics NV | Samyang Corp. | Payment unspecified | 12/9/19 |
| Eleison to develop and commercialize Targent's Dibromodulcitol for brain cancer and other cancers worldwide | Targent Inc. | Eleison Pharmaceuticals Inc. | Payment unspecified | 12/4/19 |
| Alternavida to develop, market and distribute Tetra Bio-Pharma's Caumz in Mexico along with the right of first refusal to commercialize in Colombia, Ecuador, Chile, Panama, Costa Rica, Honduras, Peru and the Dominican Republic | Tetra Bio-Pharma Inc. | Alternavida SA de CV | $0.09 | 12/2/19 |
| Azevedos Indústria Farmacêutica SA to market and distribute Tetra’s cannabinoid Caumz (PPP-011) in Portugal | Tetra Bio-Pharma Inc. | Azevedos Industria Farmaceutica SA | Payment unspecified | 12/16/19 |
| Wcte to sign letter of intent to develop Therapeutic Solutions' adult stem cell therapy for treatment ofchronic traumatic encephalopathy and traumatic brain injury within the field of sports and athletics | Therapeutic Solutions International Inc. | Wcte Inc. | Payment unspecified | 12/16/19 |
| Pfizer to develop and commercialize Theravance's preclinical JAK inhibitors for skin diseases worldwide | Theravance Biopharma Ireland Ltd. | Pfizer Inc. | $250.00 | 12/23/19 |
| Takeda to use Turnstone's vaccinia virus platform to codevelop and cocommercialize multiple products including RIVAL-01 against cancers worldwide | Turnstone Biologics Inc. | Takeda Pharmaceutical Co. Ltd. | $1,020.00 | 12/19/19 |
| Ultragenyx to sell royalty rights of Crysvita due on the net sales in the EU, the U.K. and Switzerland to Royalty Pharma | Ultragenyx Pharmaceutical Inc. | Royalty Pharma | $320.00 | 12/18/19 |
| An undisclosed company to enter into a binding term sheet to manufacture Kamada's immune globulin product for orphan indications | Undisclosed | Kamada Ltd. | Payment unspecified | 12/9/19 |
| An undisclosed Chinese company to evaluate Scancell's monoclonal antibodies targeting tumor-associated glycans | Undisclosed Chinese company | Scancell Ltd. | Payment unspecified | 12/16/19 |
| Janssen to acquire Xbiotech's bermekimab for the treatment of atopic dermatitis and hidradenitis suppurativa | Xbiotech Inc. | Janssen Biotech Inc. | $1,350.00 | 12/7/19 |
| Xenon Pharmaceuticals and Neurocrine to develop selective sodium channel inhibitor for epileptic encephalopathy worldwide | Xenon Pharmaceuticals Inc. | Neurocrine Biosciences Inc. | $1,767.50 | 12/2/19 |
| Advance Biomedics to develop Zelira Therapeutics' Hope products against autism spectrum disorder in the U.S. | Zelira Therapeutics Ltd. | Advanced Biomedics LLC | Payment unspecified | 12/3/19 |